

References

Chapter 1 Circulatory Blood Flow

References

General Texts

Berne R, Levy M. Cardiovascular physiology, 8th ed. St. Louis: Mosby, 2001.

Guyton AC, Jones CE, Coleman TG. Circulatory physiology: cardiac output and its regulation, 2nd ed. Philadelphia: WB Saunders, 1973.

Nichols WW, O'Rourke M. McDonald's blood flow in arteries, 3rd ed. Baltimore: Williams & Wilkins, 1990.

Vogel S. Vital circuits. New York: Oxford University Press, 1992.

Wartier DC. Ventricular function. Baltimore: Williams & Wilkins, 1995.

Cardiac Output

1. Vogel S. Vital circuits. New York: Oxford University Press, 1992:1-17.

2. Vogel S. Life in moving fluids. Princeton: Princeton University Press, 1981: 25-28.

3. Opie LH. Mechanisms of cardiac contraction and relaxation. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia: WB Saunders, 2001:443-478.

4. Parmley WM, Talbot L. The heart as a pump. In: Berne RM, ed. Handbook of physiology: the cardiovascular system. Bethesda: American Physiological Society, 1979:429-460.

5. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. *Circ Res* 1989;64:827-852.

6. Zile M, Baicu C, Gaasch W. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004;350: 1953-1959.

7. Pinsky MR. Cardiopulmonary interactions: the effects of negative and positive changes in pleural pressures on cardiac output. In: Dantzger DR, ed. Cardiopulmonary critical care, 2nd ed. Philadelphia: WB Saunders, 1991: 87-120.

8. Hausnecht N, Brin K, Weisfeldt M, et al. Effects of left ventricular loading by negative intrathoracic pressure in dogs. *Circ Res* 1988;62:620-631.

9. Magder S. Clinical usefulness of respiratory variations in blood pressure. *Am J Respir Crit Care Med* 2004;169:151-155.

10. Peters J. Mechanical ventilation with PEEP: a unique therapy for failing hearts. *Intens Care Med* 1999;25:778-780.

11. Nichols WW, O'Rourke MF. Input impedance as ventricular load. In: McDonald's blood flow in arteries, 3rd ed. Philadelphia: Lea & Febiger, 1990: 330-342.

12. Finkelstein SM, Collins R. Vascular impedance measurement. *Progr Cardio-vasc Dis* 1982;24:401-418.

13. Laskey WK, Parker G, Ferrari VA, et al. Estimation of total systemic arterial compliance in humans. *J Appl Physiol* 1990;69:112-119.

14. Lang RM, Borrow KM, Neumann A, et al. Systemic vascular resistance: an unreliable index of left ventricular afterload. *Circulation* 1986;74:1114-1123.

15. Pinsky MR. Hemodynamic monitoring in the intensive care unit. *Clin Chest Med* 2003;24:549-560.

16. Bargiggia GS, Bertucci C, Recusani F, et al. A new method for estimating left ventricular dP/dt by continuous wave Doppler echocardiography: validation studies at cardiac catheterization. *Circulation* 1989;80:1287-1292.

17. Broka S, Dubois P, Jamart J, et al. Effects of acute decrease in afterload on accuracy of Doppler-derived left ventricular rate of pressure rise measurement in anesthetized patients. *J Am Soc Echocardiogr* 2001;14:1161-1165.

Peripheral Blood Flow

18. Chien S, Usami S, Skalak R. Blood flow in small tubes. In: Renkin EM, Michel CC, eds. *Handbook of physiology, Section 2: the cardiovascular system. Vol IV: The microcirculation.* Bethesda: American Physiological Society, 1984:217-249.

19. Little RC, Little WC. *Physiology of the heart and circulation*, 4th ed. Chicago: Year Book Publishers, 1989:219-236.

20. Gorback MS. Problems associated with the determination of pulmonary vascular resistance. *J Clin Monit* 1990;6:118-127.

21. Vogel S. *Life in moving fluids*. Princeton: Princeton University Press, 1981: 11-24.

22. Merrill EW. Rheology of blood. *Physiol Rev* 1969;49:863-888.

23. Lowe GOD. Blood rheology in vitro and in vivo. *Baillieres Clin Hematol* 1987;1:597.

24. Berne RM, Levy MN. *Cardiovascular physiology*, 8th ed. Philadelphia: Mosby, 1992:127-133.

Chapter 2

Oxygen and Carbon Dioxide Transport

References

General Works

Halliwell B, Gutteridge JMC. *Free radicals in biology and medicine*, 3rd ed. New York: Oxford University Press, 1999.

Edwards JD, Shoemaker WC, Vincent J-L, eds. *Oxygen transport: principles and practice*. London: WB Saunders, 1993.

Zander R, Mertzlufft F, eds. *The oxygen status of arterial blood*. Basel: Karger, 1991.

Oxygen Content in Blood

1. Pauling L. *General chemistry*, 3rd ed. Mineola, NY: Dover Publications, 1988:215.

2. Little RA, Edwards JD. Applied physiology. In: Edwards JD, Shoemaker WC, Vincent JL, eds. *Oxygen transport: principles and practice*. London: WB Saunders, 1993:21-40.

3. Zander R. Calculation of oxygen concentration. In: Zander R, Mertzlufft F, eds. *The oxygen status of arterial blood*. Basel: Karger, 1991:203-209.

4. Christoforides C, Laasberg L, Hedley-Whyte J. Effect of temperature on solubility of O₂ in plasma. *J Appl Physiol* 1969;26:56-60.

Oxygen Delivery and Oxygen Uptake

5. Hameed SM, Aird WC, Cohn SM. Oxygen delivery. *Crit Care Med* 2003; 31(suppl):S658-S667.

6. Little RA, Edwards JD. Applied physiology. In: Edwards JD, Shoemaker WC, Vincent J-L, eds. *Oxygen transport: principles and practice*. London, WB Saunders, 1993:21-40.

7. Bartlett RH. Oxygen kinetics: integrating hemodynamic, respiratory, and metabolic physiology. In: *Critical care physiology*. Boston: Little, Brown, 1996:1-23.

8. Ledingham IM, Naguib M. Overview: evolution of the concept from Fick to the present day. In: Edwards JD, Shoemaker WC, Vincent J-L, eds. *Oxygen transport: principles and practice*. London: WB Saunders, 1993:3-20.

9. Nunn JF. Nonrespiratory functions of the lung. In: Nunn JF, ed. *Applied respiratory physiology*. London: Butterworths 1993:306-317.

10. Jolliet P, Thorens JB, Nicod L, et al. Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury. *Intens Care Med* 1996;22:277-285.

11. Leach RM, Treacher DF. The relationship between oxygen delivery and consumption. *Dis Mon* 1994;30:301-368.

12. Connett RJ, Honig CR, Gayeski TEJ, et al. Defining hypoxia: a systems view of VO₂, glycolysis, energetics, and intracellular PO₂. *J Appl Physiol* 1990;68: 833–842.

13. Shoemaker WC. Oxygen transport and oxygen metabolism in shock and critical illness. *Crit Care Clin* 1996;12:939–969.

14. Ronco J, Fenwick J, Tweedale M, et al. Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. *JAMA* 1993;270:1724–1730.

15. Lebarsky DA, Smith LR, Sladen RN, et al. Defining the relationship of oxygen delivery and consumption: use of biological system models. *J Surg Res* 1995;58:503–508.

Carbon Dioxide Transport

16. Lambertson CJ. Carbon dioxide and respiration in acid–base homeostasis. *Anesthesiology* 1960;21:642–651.

17. Henneberg S, Soderberg D, Groth T, et al. Carbon dioxide production during mechanical ventilation. *Crit Care Med* 1987;15:8–13.

18. Brahm J. The red cell anion–transport system: kinetics and physiologic implications. In: Gunn R, Parker C, eds. *Cell physiology of blood*. New York: Rockefeller Press, 1988:142–150.

19. Nunn RF. *Nunn's applied respiratory physiology*, 4th ed. Oxford: Butterworth–Heinemann, 1993:220.

20. Forster RE II, DuBois A, Briscoe WA, et al. *The lung*, 3rd ed. Chicago: Yearbook Medical Publishers, 1986:223–247.

21. Comroe JH Jr. *Physiology of respiration*, 2nd ed. Chicago: Year Book, 1974: 201–210.

Chapter 3

Infection Control in the ICU

References

Clinical Practice Guidelines

1. Centers for Disease Control and Prevention. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health–care settings. *MMWR* 1988;37:377–388.

2. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Am J Infect Control* 1996; 24:24–52. (Available at <http://www.cdc.gov/ncidod/hip/ISOLAT/Isolat.htm>) Updated guidelines available at <http://www.cdc.gov/ncidod/hip/ISOLAT/isopart2.htm>

3. Larson EL, Rackoff WR, Weiman M, et al. APIC guideline for hand antisepsis in health–care settings. *Am J Infect Control* 1995;23:251–269. (Available in pdf format at <http://www.apic.org/pdf/gdhandws.pdf>)

4. Centers for Disease Control and Prevention. Guidelines for hand hygiene in health–care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *MMWR* 2002;51(No. RR–16):1–45. (Available in pdf format at <http://www.cdc.gov/mmwr/PDF/RR/RR5116.pdf>)

5. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. *MMWR* 2001;50(No. RR–11):1–52. (Available at <http://www.cdc.gov/NIOSH/bbpgg.html>)

6. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter–related infections. *MMWR* 2002;51(No. RR–10):1–29. (Available in pdf format at <http://www.cdc.gov/mmwr/pdf/RR/RR5110.pdf>)

7. Centers for Disease Control and Prevention. Immunization of health–care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 1997;46(RR–18):1–42. (Available at <http://www.cdc.gov/hip/publications/ACIP-list.htm>)

Skin Hygiene

8. Katz JD. Hand washing and hand disinfection: more than your mother taught you. *Anesthesiol Clin North Am* 2004;22:457-471.
9. Larson EL, Aiello AE, Bastyr J, et al. Assessment of two hand hygiene regimens for intensive care unit personnel. *Crit Care Med* 2001;29:944-951.
10. Parienti J-J, du Cheyron D, Ramakers M, et al. Alcoholic povidone-iodine to prevent central venous catheter colonization: a randomized unit-crossover study. *Crit Care Med* 2004;32:708-713.
11. Laestadius JG, Dimberg L. Hot water for handwashing—where is the proof? *J Occup Environ Med* 2005;47:434-435.
12. Gustafson DR, Vetter EA, Larson DR, et al. Effects of 4 hand-drying methods for removing bacteria from washed hands: a randomized trial. *Mayo Clin Proc* 2000;75:705-708.
- Protective Barriers
13. Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Standard precautions: excerpted from guideline for isolation precautions in hospitals. Accessed at http://www.cdc.gov/ncidod/hip/ISOLAT/std_prec_excerpt.htm
14. Rossoff LJ, Borenstein M, Isenberg HD. Is handwashing really needed in an intensive care unit? *Crit Care Med* 1995;25:1211-1216.
15. Nakamura CT, Ferdman RM, Keens TG, et al. Latex allergy in children on home mechanical ventilation. *Chest* 2003;118:1000-1003.
16. Charous L, Charous MA. Is occupational latex allergy causing your patient's asthma? *J Respir Dis* 2002;23:250-256.
17. Guin JD. Clinical presentation of patients sensitive to natural rubber latex. *Dermatitis* 2004;4:192-196.
18. Food and Drug Administration. Allergic reactions to latex-containing medical devices. Publication #MDA91-1, March 29, 1991. Bethesda: FDA, 1991.
19. Hamilton RG, Peterson EL, Ownby DR. Clinical and laboratory-based methods in the diagnosis of natural rubber latex allergy. *J Allergy Clin Immunol* 2002;110(suppl 2):S47-S56.
20. Smith JW, Nichols RL. Barrier efficiency of surgical gowns. *Arch Surg* 1991; 126:756-763.
21. Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Droplet precautions: excerpted from guideline for isolation precautions in hospitals. Accessed at http://www.cdc.gov/ncidod/hip/ISOLAT/droplet_prec_excerpt.htm
22. Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Airborne precautions: excerpted from guideline for isolation precautions in hospitals. Accessed at http://www.cdc.gov/ncidod/hip/ISOLAT/airborne_prec_excerpt.htm
23. Fennelly KP. Personal respiratory protection against *Mycobacterium tuberculosis*. *Clin Chest Med* 1997;18:1-17.

Blood-Borne Pathogens

24. National Institute for Occupational Safety and Health. Preventing needlestick injuries in health care settings. DHHS (NIOSH) Publication No. 2000-108, 1999. Bethesda: NIOSH, 1999. (Available at <http://www.cdc.gov/niosh/pdfs/2000-108.pdf>)
25. Radechi S, Abbott A, Eloi L. Occupational human immunodeficiency virus exposure among residents and medical students. *Arch Intern Med* 2000;160: 3107-3100.
26. Berguer R, Heller PJ. Preventing sharps injuries in the operating room. *J Am Coll Surg* 2004;199:462-467.

27. Berry AJ, Greene ES. The risk of needlestick injuries and needlestick-transmitted diseases in the practice of anesthesiology. *Anesthesiology* 1992;77:1007-1021.
28. Moran GJ. Emergency department management of blood and body fluid exposures. *Ann Emerg Med* 2000;35:47-62.
29. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. *N Engl J Med* 1997;337:1485-1490.

Chapter 4

Alimentary Prophylaxis

References

Microbial Invasion from the Bowel

1. Simon GL, Gorbach SL. Intestinal microflora. *Med Clin North Am* 1982;66: 557-574.
2. Borriello SP. Microbial flora of the gastrointestinal tract. In: *Microbial metabolism in the digestive tract*. Boca Raton, FL: CRC Press, 1989:2-19.
3. Bengmark S. Gut microbial ecology in critical illness: is there a role for prebiotics, probiotics, and synbiotics? *Curr Opin Crit Care* 2002;8:145-151.
4. Langkamp-Henken B, Glezer JA, Kudsk KA. Immunologic structure and function of the gastrointestinal tract. *Nutr Clin Pract* 1992;7:100-108.
5. Howden CW, Hunt RH. Relationship between gastric secretion and infection. *Gut* 1987;28:96-107.
6. Wingate DL. Acid reduction and recurrent enteritis. *Lancet* 1990;335:222.
7. Cook GC. Infective gastroenteritis and its relationship to reduced acidity. *Scand J Gastroenterol* 1985;20(suppl 111):17-21.
8. Alexander JW, Boyce ST, Babcock GF, et al. The process of microbial translocation. *Ann Surg* 1990;212:496-510.
9. Cook DJ, Laine LA, Guyatt GH, et al. Nosocomial pneumonia and the role of gastric pH. *Chest* 1991;100:7-13.
10. Laheij R, Sturkenboom M, Hassing R-J, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004;292:1955-1960.
11. Garvey BM, McCambley JA, Tuxen DV. Effects of gastric alkalization on bacterial colonization in critically ill patients. *Crit Care Med* 1989;17:211-216.

Stress-related Mucosal Injury

12. Steinberg KP. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. *Crit Care Med* 2002;30(suppl):S362-S364.
13. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. *Crit Care Med* 2002;30(suppl):S351-S355.
14. Muthu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. *Chest* 2001;119:1222-1241.

15. Cook DJ, Fuller MB, Guyatt GH. Risk factors for gastrointestinal bleeding in critically ill patients. *N Engl J Med* 1994;330:377-381.
16. Marik PE. Sublingual capnography. a clinical validation study. *Chest* 2001; 120:923-927.
17. Kompan L, Kremzar B, Gadzije V, et al. Effects of enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. *Intensive Care Med* 1999;25:157-161.
18. Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. *Burns* 1997; 23:313-318.
19. Pingleton SK, Hadzima SK. Enteral alimentation and gastrointestinal bleeding in mechanically ventilated patients. *Crit Care Med* 1983;11:13-16.
20. McCarthy DM. Sucralfate. *N Engl J Med* 1990;325:1016-1025.
21. Cook DJ, Reeve BK, Guyatt GH. Stress ulcer prophylaxis in critically ill patients. *JAMA* 1996;275:308-314.
22. McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health System Pharmacists, 1995:2021-2065.
23. Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. *Nutr Clin Pract* 1991;6: 199-201.
24. Tryba M, Kurz-Muller K, Donner B. Plasma aluminum concentrations in long-term mechanically ventilated patients receiving stress ulcer prophylaxis with sucralfate. *Crit Care Med* 1994;22:1769-1773.
25. Daley RJ, Rebuck JA, Welage LS, et al. Prevention of stress ulceration: current trends in critical care. *Crit Care Med* 2004;32:2008-2013.
26. Morris DL, Markham SJ, Beechey A, et al. Ranitidine-bolus or infusion prophylaxis for stress ulcer. *Crit Care Med* 1988;16:229-232.
27. Famotidine. Mosby's Drug Consult. Mosby, 2005. Accessed at <http://www.mdconsult.com> on June 26, 2005.
28. Ranitidine. Mosby's Drug Consult. Mosby, 2005. Accessed at <http://www.mdconsult.com>. on June 26, 2005.
29. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. *N Engl J Med* 1998;338:791-797.
30. Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. *Br Med J* 2000;321:1-7.
31. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. *Crit Care Med* 2002;30(suppl):S356-S361.
32. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension: a liquid formulation of lansoprazole effectively suppresses intragastric acidity when administered through a gastrostomy. *Am J Gastroenterol* 1999;94: 1813-1817.
33. Morgan D. Intravenous proton pump inhibitors in the critical care setting. *Crit Care Med* 2002; 30(suppl):S369-S372.

34. Maier RV, Mitchell D, Gentiello L. Optimal therapy for stress gastritis. *Ann Surg* 1994;220:353-363.

35. Rosenthal P, Thompson J, Singh M. Detection of occult blood in gastric juice. *J Clin Gastroenterol* 1984;6:119.

Decontamination of the Alimentary Tract

36. Higuchi JH, Johanson WG. Colonization and bronchopulmonary infection. *Clin Chest Med* 1982;3:133-142.

37. Estes RJ, Meduri GU. The pathogenesis of ventilator-associated pneumonia, I: mechanisms of bacterial transcolonization and airway inoculation. *Intensive Care Med* 1995;21:365-383.

38. Rendell PM, Seger A, Rodrigues J, et al. Glycodendriproteins: a synthetic glycoprotein mimic enzyme with branched sugar-display potentially inhibits bacterial aggregation. *J Am Chem Soc* 2004. Web-based journal accessed on June 26, 2005 at pubs.acs.org/cen/news/8215/8215notw1.html

39. Bergmans C, Bonten M, Gaillard C, et al. Prevention of ventilator-associated pneumonia by oral decontamination. *Am J Respir Crit Care Med* 2001;164:382-388.

40. van Nieuwenhoven CA, Buskens E, Bergmans DC, et al. Oral decontamination is cost-saving in the prevention of ventilator associated pneumonia in intensive care units. *Crit Care Med* 2004;32:126-130.

41. Centers for Disease Control and Prevention. Guidelines for preventing healthcare-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. *MMWR* 2004;53:1-40. Also available at <http://www.cdc.gov/mmwr/PDF/rr/rr5303.pdf> (Accessed June 19, 2005).

42. Stoutenbeek CP, van Saene HKF, Miranda DR, et al. The effect of selective decontamination of the digestive tract on colonization and infection rate in multiple trauma patients. *Intensive Care Med* 1984;10:185-192.

43. D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: a systematic review of randomised controlled trials. *Br Med J* 1998;316:1275-1285.

44. de Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomized controlled trial. *Lancet* 2003;362:1011-1016.

45. Krueger WA, Unertl KE. Selective decontamination of the digestive tract. *Curr Opin Crit Care* 2002;8:139-144.

Chapter 5

Venous Thromboembolism

References

Reviews

1. Rocha AT, Tapson VF. Venous thromboembolism in the intensive care unit. *Clin Chest Med* 2003;24:103-122.

2. Heit JA. Risk factors for venous thromboembolism. *Clin Chest Med* 2003;24: 1-12.

3. Bick RL, Haas S. Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. *Hematol Oncol Clin North Am* 2003;17:217-258.
 4. Bick RL, Frenkel EP, Walenga J, et al. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology and clinical use. *Hematol Oncol Clin North Am* 2005;19:1-51.
- Clinical Practice Guidelines
5. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(suppl):338S-400S (794 citations!)
 6. Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(suppl):188S-203S.
 7. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(suppl):401S-428S.
- Thromboprophylaxis
8. Shojania KG, Duncan BW, McDonald KM, et al., eds. Making health care safer: a critical analysis of patient safety practices. Evidence report/technology assessment No. 43. AHRQ Publication No. 01-E058. Rockville, MD: Agency for Healthcare Research and Quality, July, 2001.
 9. Linblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. *Br J Surg* 1991;78:849-852.
 10. Ageno W, Turpie AGG. What's new for DVT prophylaxis for the medically ill. *Dis Mon* 2005;51:194-199.
 11. Cook DJ, Crowther M, Meade M, et al. Deep vein thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. *Crit Care Med* 2005;33:1565-1571.
 12. Ibrahim E, Iregui M, Prentice D, et al. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. *Crit Care Med* 2002;30:771-774.
 13. Goldhaber SZ, Marpurgo M, for the WHO/ISFC Task Force on Pulmonary Embolism. Diagnosis, treatment and prevention of pulmonary embolism. *JAMA* 1992;268:1727-1733.
 14. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism: a meta-analysis. *Arch Intern Med* 1994;154:67-72.
 15. Turpie AG, Hirsch J, Gent M, et al. Prevention of deep vein thrombosis in potential neurosurgical patients. *Arch Intern Med* 1989;149:679-681.
 16. Heparin. Mosby Drug Consult 2005. Accessed at <http://www.mdconsult.com> on July 4, 2005.
 17. Enoxaparin. Mosby Drug Consult 2005. Accessed at <http://www.mdconsult.com> on July 4, 2005.
 18. Dalteparin. Mosby Drug Consult 2005. Accessed at <http://www.mdconsult.com> on July 4, 2005.
 19. Raskob G, Hirsch J. Controversies in timing of first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. *Chest* 2003;124(suppl):379S-385S.
 20. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(suppl):204S-233S.
 21. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. *Chest* 2003;124(suppl):364S-370S.
 22. Fondaparinux. Mosby's Drug Consult 2005. Accessed at <http://www.mdconsult.com> on July 6, 2005.
- Diagnostic Approach
23. Hoellerich VL, Wigton RS. Diagnosing pulmonary embolism using clinical findings. *Arch Intern Med* 1986;146:1699-1704.
 24. Stein PD, Goldhaber SZ, Henry JW. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. *Chest* 1995;107:139-143.
 25. Kelly J, Rudd A, Lewis RR, et al. Plasma D-dimers in the diagnosis of venous thromboembolism. *Arch Intern Med* 2002;162:747-756.
 26. Kollef MH, Zahid M, Eisenberg PR. Predictive value of a rapid semiquantitative D-dimer assay in critically ill patients with suspected thromboembolism. *Crit Care Med* 2000;28:414-420.
 27. Kline JA, Israel EG, Michelson EA, et al. Diagnostic accuracy of a bedside D-dimer assay and alveolar dead space measurement for rapid exclusion of pulmonary embolism. *JAMA* 2001;285:761-768.
 28. Moser KM. Is embolic risk conditioned by location of deep vein thrombosis? *Ann Intern Med* 1981;94:439-444.

29. Tracey JA, Edlow JA. Ultrasound diagnosis of deep venous thrombosis. *Emerg Med Clin North Am* 2004;22:775-796.
 30. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion scans. *Ann Intern Med* 1983;98:891-899.
 31. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). *JAMA* 1990;263:2753-2759.
 32. Remy-Jardin M, Remy J, Wattinine L, et al. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold technique: comparison with pulmonary angiography. *Radiology* 1992;185:381-387.
 33. Kaplan AE, Frankenthaler ML, Schneider RF, et al. A strategy to avoid respiratory motion artifact in mechanically ventilated patients undergoing helical chest computed tomography angiography. *Crit Care Med* 2001;29:1292.
 34. Mullins MD, Becker DM, Hagspiel KD, et al. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. *Arch Intern Med* 2000;160:293-298.
 35. Quiroz R, Kucher N, Zou KH, et al. Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism. *JAMA* 2005;293:2012-2017.
 36. Wolfe TR, Hartsell SC. Pulmonary embolism: making sense of the diagnostic evaluation. *Ann Emerg Med* 2001;37:504-514.
- Antithrombotic Therapy**
37. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. *Ann Intern Med* 1993;119:874-881.
 38. Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient. *Ann Pharmacother* 1994;28:1110-1111.
 39. Le DT, Weibert RT, Sevilla BK, et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. *Ann Intern Med* 1994;120:552-558.
- Thrombolytic Therapy**
40. Wood KE. Major pulmonary embolism. *Chest* 2002;121:877-905.
 41. Comeraota AJ. The role of fibrinolytic therapy in the treatment of venous thromboembolism. *Dis Mon* 2005;51:124-134.
 42. Bailen MR, Cuarda JAR, de Hoyos EA. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: a review. *Crit Care Med* 2001;29:2211-2219.
 43. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial: the Bolus Alteplase Pulmonary Embolism Group. *Chest* 1994;106:718-724.
 44. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. *Am Heart J* 1999;138:39-44.
- Vena Cava Filters**
45. Stein PD, Kayali F, Olson RE. Twenty-one year trends in the use of inferior vena cava filters. *Arch Intern Med* 2004;164:1541-1545.
 46. Sing RF, Cicci CK, Smith CH, et al. Bedside insertion of inferior vena cava filters in the intensive care unit. *J Trauma* 1999;47:1104-1107.
 47. Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena cava filters: review of 26-year single-center clinical experience. *Radiology* 2000;216:54-66.

Chapter 6

Establishing Venous Access

References

General Texts

Latto IP, Ng WS, Jones PL, et al. *Percutaneous central venous and arterial catheterization*, 3rd ed. Philadelphia: WB Saunders, 2000.

Wilson SE. *Vascular access: principles and practice*, 3rd ed. St. Louis: Mosby, 1996.

Preparing for Vascular Cannulation

1. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. *MMWR* 2002;51(No.RR-10):1-30. Also available in pdf format at <http://www.cdc.gov/mmwr/PDF/RR/RR5110.pdf> (Accessed June 26, 2005).

2. Centers for Disease Control and Prevention. Guidelines for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and

the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR 2002;51 (No.RR-16):1-45. Also available in pdf format at <http://www.cdc.gov/mmwr/PDF/RR/RR5116.pdf> (Accessed April 10, 2005).

Vascular Catheters

3. de la Roche MRP, Gauthier L. Rapid transfusion of packed red blood cells: effects of dilution, pressure, and catheter size. *Ann Emerg Med* 1993;22:1551-1555.

4. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003;348:1123-1133.

5. Jacobs BR. Central venous catheter occlusion and thrombosis. *Crit Care Clin* 2003;19:489-514.

6. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. *Crit Care Med* 2000;28:3332-3338.

7. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. *Arch Intern Med* 1989;149:2285-2287.

8. Darouche RO, Raad II, Heard SO, et al. A comparison of antimicrobial-impregnated central venous catheters. *N Engl J Med* 1999;340:1-8.

9. Hanna H, Darouche R, Raad I. New approaches for prevention of intravascular catheter-related infections. *Infect Med* 2001;18:38-48.

10. Ng P, Ault M, Ellrodt AG, et al. Peripherally inserted central catheters in general medicine. *Mayo Clin Proc* 1997;72:225-233.

11. Heffner JE. A guide to the management of peripherally inserted central catheters. *J Crit Illness* 2000;15:165-169.

Vascular Access Sites

12. Merrer J, DeJonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients. *JAMA* 2001;286:700-707.

13. Ruesch S, Walder B, Tramer M. Complications of central venous catheters: internal jugular versus subclavian access: a systematic review. *Crit Care Med* 2002;30:454-460.

14. Deshpande K, Hatem C, Ulrich H, et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. *Crit Care Med* 2005;33: 13-20.

15. Foster PF, Moore LR, Sankary HN, et al. Central venous catheterization in patients with coagulopathy. *Arch Surg* 1992;127:273-275.

16. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy: a prospective audit. *Intensive Care Med* 1999;25:481-485.

17. Doerfler M, Kaufman B, Goldenberg A. Central venous catheter placement in patients with disorders of hemostasis. *Chest* 1996;110:185-188.

18. McGee WT, Ackerman BL, Rouben LR, et al. Accurate placement of central venous catheters: a prospective, randomized, multicenter trial. *Crit Care Med* 1993;21:1118-1123.

19. Seneff MG. Central venous catheterization. A comprehensive review. *Intensive Care Med* 1987;2:163-175, 218-232.

20. Joynt GM, Kew J, Gomersall CD, et al. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. *Chest* 2000;117:178-183.

21. Getzen LC, Pollack EW. Short-term femoral vein catheterization. *Am J Surg* 1979;138:875-877.

22. Hilty WM, Hudson PA, Levitt MA, et al. Real-time ultrasound-guided femoral vein catheterization during cardiopulmonary resuscitation. *Ann Emerg Med* 1997;29:311-316.

23. Cummins RO, ed. ACLS provider manual. Dallas, TX: American Heart Association, 2001:38-39. Ultrasound Guidance

24. Abboud PAC, Kendall JL. Ultrasound guidance for vascular access. *Emerg Med Clin North Am* 2004;22:749-773.

25. Hind D, Calvert N, McWilliams R, et al. Ultrasonic locating devices for central venous cannulation: a meta-analysis. *Br Med J* 2003;327:361-367.

26. Keyes LA, Frazee BW, Snoey ER, et al. Ultrasound-guided brachial and basilic vein cannulation in emergency department patients with difficult venous access. *Ann Emerg Med* 1999;34:711-714.

27. Bo-Lin GW, Andersen DJ, Andersen KC, et al. Percutaneous central venous catheterization performed by medical house officers: a prospective study. *Cathet Cardiovasc Diagn* 1982;8:23-29.

28. Emerman CI, Bellon EM, Lukens TW, et al. A prospective study of femoral versus subclavian vein catheterization during cardiac arrest. *Ann Emerg Med* 1990;19:26-30.

Immediate Concerns

29. Muth CM, Shank ES. Gas embolism. *N Engl J Med* 2000;342:476-482.

30. Sladen A. Complications of invasive hemodynamic monitoring in the intensive care unit. *Curr Probl Surg* 1988;25:69-145.

31. FDA Task Force. Precautions necessary with central venous catheters. *FDA Drug Bull* 1989;15-16.

32. Marino PL. Delayed pneumothorax: a complication of subclavian vein catheterization. *J Parenter Enteral Nutr* 1985;9:232.

33. Tocino IM, Miller MH, Fairfax WR. Distribution of pneumothorax in the supine and semirecumbent critically ill adult. *Am J Radiol* 1985;144:901-905.

34. Collin GR, Clarke LE. Delayed pneumothorax: a complication of central venous catheterization. *Surg Rounds* 1994;17:589-594.

35. McGee WT, Ackerman BL, Rouben LR, et al. Accurate placement of central venous catheters: a prospective, randomized, multicenter trial. *Crit Care Med* 1993;21:1118-1123.

Chapter 7

The Indwelling Vascular Catheter

References

Practice Guidelines

1. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. *MMWR* 2002;51(no. RR-10):1-30. Also available at <http://www.cdc.gov/mmwr/PDF/RR/RR5110.pdf> (Accessed on June 26, 2005).

2. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis* 2001;32:1249-1272. Also available at http://www.sccm.org/professional_resources/guidelines/table_of_contents/index.asp (accessed on June 26, 2005).

Reviews

3. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003;348:1123-1133.

4. Jacobs BR. Central venous catheter occlusion and thrombosis. *Crit Care Clin* 2003;19:489-514.

Protective Dressings

5. Hoffman KK, Weber DJ, Samsa GP, et al. Transparent polyurethane film as intravenous catheter dressing: a meta-analysis of infection risks. *JAMA* 1992;267:2072-2076.

6. Maki DG, Stolz SS, Wheeler S, et al. A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. *Crit Care Med* 1994;22:1729-1737.

7. Marshall DA, Mertz PA, Eaglestein WH. Occlusive dressings. *Arch Surg* 1990;125:1136-1139. Antimicrobial Ointments

8. Zakrzewska-Bode A, Muyltjens HL, Liem KD, et al. Muciproc resistance in coagulase-negative staphylococci after topical prophylaxis for the reduction of colonization of central venous catheters. *J Hosp Infect* 1995;31:189-193.

Replacing Catheters

9. Lai KK. Safety of prolonging peripheral cannula and IV tubing use from 72 hours to 96 hours. *Am J Infect Control* 1998;26:66-70.

10. Ullman RF, Guerivich I, Schoch PE, et al. Colonization and bacteremia related to duration of triple-lumen intravascular catheter placement. *Am J Infect Control* 1990;18:201-207.

11. Cook D, Randolph A, Kernerman P, et al. Central venous replacement strategies: a systematic review of the literature. *Crit Care Med* 1997;25:1417-1424.

12. Cobb DK, High KP, Sawyer RP, et al. A controlled trial of scheduled replacement of central venous and pulmonary artery catheters. *N Engl J Med* 1992;327:1062-1068.

13. Safdar N, Maki D. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. *Crit Care Med* 2002;30:2632-2635.

Catheter Flushes

14. Walsh DA, Mellor JA. Why flush peripheral intravenous cannulae used for intermittent intravenous injection? *Br J Clin Pract* 1991;45:31-32.

15. Peterson FY, Kirchhoff KT. Analysis of research about heparinized versus non-heparinized intravascular lines. *Heart Lung* 1991;20:631-642.

16. American Association of Critical Care Nurses. Evaluation of the effects of heparinized and nonheparinized flush solutions on the patency of arterial pressure monitoring lines: the AACN Thunder Project. *Am J Crit Care* 1993;2:3-15.

17. Branson PK, McCoy RA, Phillips BA, et al. Efficacy of 1.4% sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. *Chest* 1993;103:882-885.

Mechanical Complications

18. Trissel LA. Drug stability and compatibility issues in drug delivery. *Cancer Bull* 1990;42:393-398.

19. Calis KA, ed. Pharmacy update: Drug Information Service, National Institutes of Health. Bethesda, MD:1999 (Accessed at <http://www.cc.nih.gov/phar/updates/.99nov-dec.html> on August 5, 2005).

20. Davis SN, Vermeulen L, Banton J, et al. Activity and dosage of alteplase dilution for clearing occlusions of vascular-access devices. *Am J Health Syst Pharm* 2000;57:1039-1045.

21. Zacharias JM. Alteplase versus urokinase for occluded hemodialysis catheters. *Ann Pharmacother* 2003;37:27-33.
22. Shulman RJ, Reed T, Pitre D, et al. Use of hydrochloric acid to clear obstructed central venous catheters. *J Parent Enteral Nutr* 1988;12:509-510.
23. Mustafa S, Stein P, Patel K, et al. Upper extremity deep venous thrombosis. *Chest* 2003;123:1953-1956.
24. Hingorani A, Ascher E, Hanson J, et al. Upper extremity versus lower extremity deep venous thrombosis. *Am J Surg* 1997;174:214-217.
25. Otten TR, Stein PD, Patel KC, et al. Thromboembolus disease involving the superior vena cava and brachiocephalic veins. *Chest* 2003;123:809-812.
26. Mustafa BO, Rathbun SW, Whitsett TL, et al. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep venous thrombosis: a systematic review. *Arch Intern Med* 2002;162:401-404.
27. Heffner JE. A 49-year-old man with tachypnea and a rapidly enlarging pleural effusion. *J Crit Illness* 1994;9:101-109.
28. Armstrong CW, Mayhall CG. Contralateral hydrothorax following subclavian catheter replacement using a guidewire. *Chest* 1983;84:231-233.
29. Long R, Kassum D, Donen N, et al. Cardiac tamponade complicating central venous catheterization for total parenteral nutrition: a review. *J Crit Care* 1987;2:39-44.
- Infectious Complications
30. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. *JAMA* 1994;271:1598-1601.
31. Edgeworth J, Treacher D, Eykyn S. A 25-year study of nosocomial bacteremia in an adult intensive care unit. *Crit Care Med* 1999;27:1421-1428.
32. Laupland KB, Zygun DA, Davies D, et al. Population-based assessment of intensive care unit-acquired bloodstream infection in adults: incidence, risk factors, and associated mortality rate. *Crit Care Med* 2002;30:2462-2467.
33. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. *Annu Rev Microbiol* 2000;54:49-79.
34. Chenoweth CE. Biofilms and catheter-associated urinary tract infections. *Infect Dis Clin North Am* 2003;17:411-432.
35. von Eiff C, Peters G, Heilman C. Pathogenesis of infections due to coagulase-negative staphylococci. *Lancet Infect Dis* 2002;2:677-685.
36. Biofilm: Disinfecting biofilms using hydrogen peroxide/silver based biocide. Available at http://www.accepta.com/Industry_Water_Treatment/Biofilm_biocide.asp (Accessed 8/07/2005).
37. Richards M, Edwards J, Culver D, et al. Nosocomial infections in medical intensive care units in the United States. *Crit Care Med* 1999;27:887-892.
38. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34:730-751.

39. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161–189.
40. Raad I, Davis S, Khan A, et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. *Infect Control Hosp Epidemiol* 1992;154:808–816.
41. Verghese A, Widrich WC, Arbeit RD. Central venous septic thrombophlebitis: the role of antimicrobial therapy. *Medicine* 1985;64:394–400.
42. Ostrosky-Zeichner L, Rex JH, Bennett J, et al. Deeply invasive candidiasis. *Infect Dis Clin North Am* 2002;16:821–835.
43. Calandra T. Candida infections in the intensive care unit. *Curr Opin Crit Care* 1997;3:335–341.
44. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. *Intensive Care Med* 1994;20:522–528.
45. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of capsosungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002;347:2020–2029.

Chapter 8

Arterial Blood Pressure

References

Indirect Measurements

1. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the AHA Council on HBP. *Circulation* 2005;111:697–716.
2. Ellestad MH. Reliability of blood pressure recordings. *Am J Cardiol* 1989;63: 983–985.
3. Cohn JN. Blood pressure measurement in shock. *JAMA* 1967;199:118–122.
4. Davis RF. Clinical comparison of automated auscultatory and oscillometric and catheter-transducer measurements of arterial pressure. *J Clin Monit* 1985;1:114–119.
5. Ramsey M. Blood pressure monitoring: automated oscillometric devices. *J Clin Monit* 1991;7:56–67.
6. Bur A, Hirschl M, Herkner H, et al. Accuracy of oscillometric blood pressure measurement according to the relation between cuff size and upper-arm circumference in critically ill patients. *Crit Care Med* 2000;28:371–376.
7. Bur A, Herkner H, Vleck M, et al. Factors influencing the accuracy of oscillometric blood pressure measurements in critically ill patients. *Crit Care Med* 2003;31:793–799.

Direct Measurements

8. Darovic GO, Vanriper S. Arterial pressure recording. In: Darovic GO, ed. *Hemodynamic monitoring*, 2nd ed. Philadelphia: WB Saunders, 1995:177–210.
9. Nichols WW, O'Rourke MF. *McDonald's blood flow in arteries*, 3rd ed. Philadelphia: Lea & Febiger, 1990:251–269.
10. Gardner RM. Direct blood pressure measurement dynamic response requirements. *Anesthesiology* 1981;54:227–236.

11. Darovic GO, Vanriper S, Vanriper J. Fluid-filled monitoring systems. In: Darovic GO, ed. Hemodynamic monitoring, 2nd ed. Philadelphia: WB Saunders, 1995:149-175.
12. Rothe CF, Kim KC. Measuring systolic arterial blood pressure. Crit Care Med 1980;8:683-689.
13. Kleinman B, Powell S, Kumar P, et al. The fast flush test measures the dynamic response of the entire blood pressure monitoring system. Anesthesiology 1992;77:1215-1220.
14. Bruner JMR, Krewis LJ, Kunsman JM, et al. Comparison of direct and indirect methods of measuring arterial blood pressure. Med Instr 1981;15:11-21.
15. Rich GF, Lubanski RE Jr, McLoughlin TM. Differences between aortic and radial artery pressure associated with cardiopulmonary bypass. Anesthesiology 1992;77:63-66.
16. Pauca AL, Wallenhaupt SL, Kon ND. Reliability of the radial arterial pressure during anesthesia. Chest 1994;105:69-75.
17. World Almanac and Book of Facts, 2005. New York: World Almanac Education Group, 2005:87.

Chapter 9

The Pulmonary Artery Catheter

References

Reviews

1. Swan HJ. The pulmonary artery catheter. Dis Mon 1991;37:473-543.
2. Pinsky MR. Hemodynamic monitoring in the intensive care unit. Clin Chest Med 2003;24:549-560.
3. American Society of Anesthesiologists Task Force on Pulmonary Artery Catheterization. Practice guidelines for pulmonary artery catheterization: an updated report by the American Society of Anesthesiologists Task Force on Pulmonary Artery Catheterization. Anesthesiology 2003;99:988-1014.
4. Silvestry FE. Swan-Ganz catheterization: interpretation of tracings. UpToDate Online, Version 13.2. (Accessed on August 28, 2005).
5. Cruz K, Franklin C. The pulmonary artery catheter: uses and controversies. Crit Care Clin 2001;17:271-291.

Selected References

6. Iberti TJ, Fischer EP, Liebowitz AB, et al. A multicenter study of physicians' knowledge of the pulmonary artery catheter. JAMA 1990;264:2928-2932.
7. Gnaegi A, Feihl F, Perret C. Intensive care physicians' insufficient knowledge of right heart catheterization at the bedside: time to act? Crit Care Med 1997;25:213-220.
8. Halpern N, Feld H, Oropello JM, et al. The technique of inserting an RV port PA catheter and pacing probe. J Crit Illn 1991;6:1153-1159.
9. Armaganidis A, Dhainaut JF, Billard JL, et al. Accuracy assessment for three fiberoptic pulmonary artery catheters for SvO₂ monitoring. Intensive Care Med 1994;20:484-488.
10. Vincent JL, Thirion M, Brimiouille S, et al. Thermodilution measurement of right ventricular ejection fraction with a modified pulmonary artery catheter. Intensive Care Med 1986;12:33-38.
11. Yelderman M, Ramsay MA, Quinn MD, et al. Continuous thermodilution cardiac output measurement in intensive care unit patients. J Cardiothorac Vasc Anesth 1992;6:270-274.
12. Venus B, Mathru M. A maneuver for bedside pulmonary artery catheterization in patients with right heart failure. Chest 1982;82:803-804.
13. Jacobson B. Medicine and clinical engineering. Englewood Cliffs, NJ: Prentice Hall, 1977:388.
14. Gardner PE. Cardiac output: theory, technique, and troubleshooting. Crit Care Nurs Clin North Am 1989;1:577-587.
15. Daily EK, Schroeder JS. Cardiac output measurements. In: Techniques in bedside hemodynamic monitoring, 5th ed. St. Louis: CV Mosby, 1994:173-194.
16. Renner LE, Morton MJ, Sakuma GY. Indicator amount, temperature, and intrinsic cardiac output affect thermodilution cardiac output accuracy and reproducibility. Crit Care Med 1993;21:586-597.
17. Nelson LD, Anderson HB. Patient selection for iced versus room temperature injectate for thermodilution cardiac output determinations. Crit Care Med 1985;13:182-184.
18. Pearl RG, Rosenthal MH, Nielson L, et al. Effect of injectate volume and temperature on thermodilution cardiac output determinations. Anesthesiology 1986;64:798-801.

19. Nadeau S, Noble WH. Limitations of cardiac output measurement by thermodilution. *Can J Anesth* 1986;33:780-784.
20. Sasse SA, Chen PA, Berry RB, et al. Variability of cardiac output over time in medical intensive care unit patients. *Chest* 1994;22:225-232.
21. Konishi T, Nakamura Y, Morii I, et al. Comparison of thermodilution and Fick methods for measurement of cardiac output in tricuspid regurgitation. *Am J Cardiol* 1992;70:538-540.
22. Yelderman M, Ramsay MA, Quinn MD, et al. Continuous thermodilution cardiac output measurement in intensive care unit patients. *J Cardiothorac Vasc Anesth* 1992;6:270-274.
23. Boldt J, Menges T, Wollbruck M, et al. Is continuous cardiac output measurement using thermodilution reliable in the critically ill patient? *Crit Care Med* 1994;22:1913-1918.
24. Mihaljevic T, von Segesser LK, Tonz M, et al. Continuous versus bolus thermodilution cardiac output measurements: a comparative study. *Crit Care Med* 1995;23:944-949.
25. Mattar JA. A simple calculation to estimate body surface area in adults and its correlation with the Dubois formula. *Crit Care Med* 1989;17:846-847.
26. Yu DT, Platt R, Lamken PN, et al. Relationship of pulmonary artery catheter use to mortality and resource utilization in patients with severe sepsis. *Crit Care Med* 2003;31:2734-2741.
27. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. *JAMA* 1996;276:889-897.
28. Pinsky MR, Vincent J-L. Let us use the pulmonary artery catheter correctly and only when we need it. *Crit Care Med* 2005;33:1119-1122.

Chapter 10

Central Venous Pressure and Wedge Pressure

References

Reviews

1. Leatherman JW, Marini JJ. Pulmonary artery catheterization: interpretation of pressure recordings. In: Tobin MJ, ed. *Principles and practice of intensive care monitoring*. New York: McGraw-Hill, 1998:821-837.
 2. Pinsky MR. Hemodynamic monitoring in the intensive care unit. *Clin Chest Med* 2003;24:549-560.

 3. O'Quin R, Marini JJ. Pulmonary artery occlusion pressure: clinical physiology, measurement, and interpretation. *Am Rev Respir Dis* 1983;128:319-326.
- #### **Selected References**
4. Kumar A, Anel R, Bunnell E, et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. *Crit Care Med* 2004;32:691-699.

 5. Jacka MJ, Cohen MM, To T, et al. Pulmonary artery occlusion pressure estimation: how confident are anesthesiologists? *Crit Care Med* 2002;30:1197-1203.
 6. Nadeau S, Noble WH. Misinterpretation of pressure measurements from the pulmonary artery catheter. *Can Anesth Soc J* 1986;33:352-363.
 7. Komandina KH, Schenk DA, LaVeau P, et al. Interobserver variability in the interpretation of pulmonary artery catheter pressure tracings. *Chest* 1991;100:1647-1654.
 8. Kee LL, Simonson JS, Stotts NA, et al. Echocardiographic determination of valid zero reference levels in supine and lateral positions. *Am J Crit Care* 1993;2:72-80.

 9. Schmitt EA, Brantigen CO. Common artifacts of pulmonary artery and pulmonary artery wedge pressures: recognition and management. *J Clin Monit* 1986;2:44-52.

 10. Pinsky M, Vincent J-L, De Smet J-M. Estimating left ventricular filling pressure during positive end-expiratory pressure in humans. *Am Rev Respir Dis* 1991;143:25-31.
 11. Teboul J-L, Pinsky MR, Mercat A, et al. Estimating cardiac filling pressure in mechanically ventilated patients with hyperinflation. *Crit Care Med* 2000;28:3631-3636.

12. Dobbin K, Wallace S, Ahlberg J, et al. Pulmonary artery pressure measurement in patients with elevated pressures: effect of backrest elevation and method of measurement. *Am J Crit Care* 1992;2:61-69.
13. Halck S, Walther-Larsen S, Sanchez R. Reliability of central venous pressure measured by water column. *Crit Care Med* 1990;18:461-462.
14. Nemens EJ, Woods SL. Normal fluctuations in pulmonary artery and pulmonary capillary wedge pressures in acutely ill patients. *Heart Lung* 1982;11:393-398.
15. Morris AH, Chapman RH, Gardner RM. Frequency of wedge pressure errors in the ICU. *Crit Care Med* 1985;13:705-708.
16. Diebel LN, Wilson RF, Tagett MG, et al. End-diastolic volume: a better indicator of preload in the critically ill. *Arch Surg* 1992;127:817-822.
17. Morris AH, Chapman RH. Wedge pressure confirmation by aspiration of pulmonary capillary blood. *Crit Care Med* 1985;13:756-759.
18. Tracey WR, Hamilton JT, Craig ID, et al. Effect of endothelial injury on the responses of isolated guinea pig pulmonary venules to reduced oxygen tension. *J Appl Physiol* 1989;67:2147-2153.
19. Michel RP, Hakim TS, Chang HK. Pulmonary arterial and venous pressures measured with small catheters. *J Appl Physiol* 1984;57:309-314.
20. Kloess T, Birkenhauer U, Kottler B. Pulmonary pressure-flow relationship and peripheral oxygen supply in ARDS due to bacterial sepsis. *Second Vienna Shock Forum*, 1989:175-180.
21. Cope DK, Grimbert F, Downey JM, et al. Pulmonary capillary pressure: a review. *Crit Care Med* 1992;20:1043-1056.
22. Gilbert E, Hakim TS. Derivation of pulmonary capillary pressure from arterial occlusion in intact conditions. *Crit Care Med* 1994;22:986-993.
23. Leibowitz AB. More reliable determination of central venous and pulmonary artery occlusion pressures: does it matter? *Crit Care Med* 2005;33:243-244.

Chapter 11

Tissue Oxygenation

References

Tissue Oxygen Balance

1. Connett RJ, Honig CR, Gayeski TEJ, et al. Defining hypoxia: a systems view of VO₂, glycolysis, energetics, and intracellular PO₂. *J Appl Physiol* 1990;68: 833-842.
 2. Shoemaker WC, Kram HB, Appel PL. Therapy of shock based on pathophysiology, monitoring, and outcome prediction. *Crit Care Med* 1990;18(suppl): S19-S25.
- #### **Oxygen Uptake**
3. Nunn JF. Nonrespiratory functions of the lung. In: Nunn JF, ed. *Applied respiratory physiology*. London: Butterworth, 1993:306-317.
 4. Jolliet P, Thorens JB, Nicod L, et al. Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury. *Intensive Care Med* 1996;22:277-285.
 5. Sasse SA, Chen PA, Berry RB, et al. Variability of cardiac output over time in medical intensive care unit patients. *Chest* 1994;22:225-232.
 6. Bartlett RH, Dechert RE. Oxygen kinetics: pitfalls in clinical research. *J Crit Care* 1990;5:77-80.
 7. Schneeweiss B, Druml W, Graninger W, et al. Assessment of oxygen-consumption by use of reverse Fick-principle and indirect calorimetry in critically ill patients. *Clin Nutr* 1989;8:89-93.
 8. Dunham CM, Seigel JH, Weireter L, et al. Oxygen debt and metabolic acidemia as quantitative predictors of mortality and the severity of the ischemic insult in hemorrhagic shock. *Crit Care Med* 1991;19:231-243.
 9. Shoemaker WC, Appel PL, Krom HB. Role of oxygen debt in the development of organ failure, sepsis, and death in high-risk surgical patients. *Chest* 1992;102:208-215.

10. Hurst JK, Barrette WC, Jr. Leukocyte activation and microbicidal oxidative toxins. *Crit Rev Biochem Mol Biol* 1989;24:271-328.
 11. Jolliet P, Thorens JB, Nicod L, et al. Relationship between pulmonary oxygen consumption, lung inflammation, and calculated venous admixture in patients with acute lung injury. *Intensive Care Med* 1996;22:277-285.
 12. Sair M, Etherington PJ, Winlove CP, et al. Tissue oxygenation and perfusion in patients with systemic sepsis. *Crit Care Med* 2001;29:1343-1349.
 13. VanderMeer TJ, Wang H, Fink MP. Endotoxemia causes ileal mucosal acidosis in the absence of mucosal hypoxia in a normodynamic porcine model of septic shock. *Crit Care Med* 1995;23:1217-1226.
 14. Fink MP. Impaired cellular use of oxygen in critically ill patients. *J Crit Illness* 2001;16(suppl):S28-S32.
 15. Kern JW, Shoemaker WC. Meta-analysis of hemodynamic optimization in high-risk patients. *Crit Care Med* 2002;30:1686-1692.
 16. Alia I, Esteban A, Gordo F, et al. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis and septic shock. *Chest* 1999;115:453-461.
- Venous O₂ Saturation
17. Noll ML, Fountain RL, Duncan CA, et al. Fluctuations in mixed venous oxygen saturation in critically ill medical patients: a pilot study. *Am J Crit Care* 1992;3:102-106.
 18. Krafft P, Stelzer H, Heismay M, et al. Mixed venous oxygen saturation in critically ill septic shock patients. *Chest* 1993;103:900-906.
 19. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32:858-873.
 20. Dueck MH, Kilmek M, Appenrodt S, et al. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. *Anesthesiology* 2005;103: 249-257.
- Lactate Levels in Blood
21. Duke T. Dysoxia and lactate. *Arch Dis Child* 1999;81:343-350.
 22. Aduen J, Bernstein WK, Khastgir T, et al. The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. *JAMA* 1994;272:1678-1685.
 23. Bakker J, Coffernils M, Leon M, et al. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in septic shock. *Chest* 1991;99: 956-962.
 24. Mizock BA, Falk JL. Lactic acidosis in critical illness. *Crit Care Med* 1992;20: 80-93.
 25. Curtis SE, Cain SM. Regional and systemic oxygen delivery/uptake relations and lactate flux in hyperdynamic, endotoxin-treated dogs. *Am Rev Respir Dis* 1992;145:348-354.
 26. Brooks GA. Lactate production under fully aerobic conditions: the lactate shuttle during rest and exercise. *Fed Proc* 1986;45:2924-2929.
 27. Maran A, Cranston I, Lomas J, et al. Protection by lactate of cerebral function during hypoglycemia. *Lancet* 1994;343:16-20.
- Tissue PCO₂
28. Sato Y, Weil MH, Tang W. Tissue hypercarbic acidosis as a marker of acute circulatory failure (shock). *Chest* 1998;114:263-274.
 29. Tang W, Weil MH, Sun S, et al. Gastric intramural PCO₂ as a monitor of perfusion failure during hemorrhagic and anaphylactic shock. *J Appl Physiol* 1994;76:572-577.
 30. Fiddian-Green RG. Studies in splanchnic ischemia and multiple organ failure. In: Marston A, Bulkley GB, Fiddian-Green RG, et al., eds. *Splanchnic ischemia and multiple organ failure*. St. Louis: CV Mosby, 1989:349-364.
 31. Hameed SM, Cohn SM. Gastric tonometry: the role of mucosal pH measurement in the management of trauma. *Chest* 2003;123(suppl):475S-481S.
 32. Weil MH, Nakagawa Y, Tang W, et al. Sublingual capnometry: a new noninvasive measurement for diagnosis and quantitation of severity of circulatory shock. *Crit Care Med* 1999;27:1225-1229.

Chapter 12

Hemorrhage and Hypovolemia

References

Clinical Practice Guidelines

1. Tisherman SA, Barie P, Bokhari F, et al. Clinical practice guideline: endpoints of resuscitation. Winston-Salem, NC: Eastern Association for Surgery of Trauma, 2003. Available at <http://www.east.org/tpg/endpoints.pdf> (accessed 10/1/05)
2. Martel M-J, the Clinical Practice Obstetrics Committee. Hemorrhagic shock. *J Obstet Gynaecol Can* 2002;24:504-511. Also available at <http://www.sogc.org> (accessed 10/1/05)
3. Walker RH, ed. Technical manual of the American Association of Blood Banks, 10th ed. Arlington, VA: American Association of Blood Banks, 1990:650.
4. Moore FD. Effects of hemorrhage on body composition. *N Engl J Med* 1965; 273:567-577.
5. Shires GT, Coln D, Carrico J, et al. Fluid therapy in hemorrhagic shock. *Arch Surg* 1964;88:688-693.
6. Committee on Trauma. Advanced trauma life support student manual. Chicago: American College of Surgeons, 1989:47-59.
7. Schadt JC, Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious animals. *Am J Physiol* 1991;260:H305-H318.
8. Fiddian-Green RG. Studies in splanchnic ischemia and multiple organ failure. In: Marston A, Bulkley GB, Fiddian-Green RG, et al., eds. *Splanchnic ischemia and multiple organ failure*. St. Louis: CV Mosby, 1989:349-364.
9. McGee S, Abernathy WB, Simel DL. Is this patient hypovolemic? *JAMA* 1999; 281:1022-1029.
10. Cordts PR, LaMorte WW, Fisher JB, et al. Poor predictive value of hematocrit and hemodynamic parameters for erythrocyte deficits after extensive vascular operations. *Surg Gynecol Obstet* 1992;175:243-248.
11. Stamler KD. Effect of crystalloid infusion on hematocrit in nonbleeding patients, with applications to clinical traumatology. *Ann Emerg Med* 1989;18: 747-749.
12. Shippy CR, Appel PL, Shoemaker WC. Reliability of clinical monitoring to assess blood volume in critically ill patients. *Crit Care Med* 1984;12:107-112.
13. Kumar A, Anel R, Bunnell E, et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volumes, cardiac performance, or the response to volume infusion in normal subjects. *Crit Care Med* 2004;32:691-699.
14. Michard F, Teboud J-L. Predicting fluid responsiveness in ICU patients. *Chest* 2002;121:2000-2008.
15. Walley KR, Cooper DJ. Diastolic stiffness impairs left ventricular function during hypovolemic shock in pigs. *Am J Physiol* 1991;260:H702-H712.
16. Severinghaus JW. Case for standard-base excess as the measure of non-respiratory acid-base imbalance. *J Clin Monit* 1991;7:276-277.
17. Kincaid EH, Miller PR, Meredith JW, et al. Elevated arterial base deficit in trauma patients: a marker of impaired oxygen utilization. *J Am Coll Surg* 1998;187:384-392.
18. Landow L. Letter to the editor. *J Trauma* 1994;37:870-871.
19. Davis JW, Shackford SR, Mackersie RC, et al. Base deficit as a guide to volume resuscitation. *J Trauma* 1998;28:1464-1467.
20. Moomey CB Jr, Melton SM, Croce MA, et al. Prognostic value of blood lactate, base deficit, and oxygen-derived variables in an LD50 model of penetrating trauma. *Crit Care Med* 1999;27:154-161.

21. Husain FA, Martin MJ, Mullenix PS, et al. Serum lactate and base deficit as predictors of mortality and morbidity. *Am J Surg* 2003;185:485-491.

Basics of Volume Resuscitation

22. Falk JL, O'Brien JF, Kerr R. Fluid resuscitation in traumatic hemorrhagic shock. *Crit Care Clin* 1992;8:323-340.

23. Trendelenburg F. The elevated pelvic position for operations within the abdominal cavity. *Med Classics* 1940;4:964-968. [Translation of original manuscript.]

24. Sing R, O'Hara D, Sawyer MJ, et al. Trendelenburg position and oxygen transport in hypovolemic adults. *Ann Emerg Med* 1994;23:564-568.

25. Taylor J, Weil MH. Failure of Trendelenburg position to improve circulation during clinical shock. *Surg Gynecol Obstet* 1967;122:1005-1010.

26. Bivins HG, Knopp R, dos Santos PAL. Blood volume distribution in the Trendelenburg position. *Ann Emerg Med* 1985;14:641-643.

27. Gaffney FA, Bastian BC, Thal ER, et al. Passive leg raising does not produce a significant auto transfusion effect. *J Trauma* 1982;22:190-193.

28. Mateer JR, Thompson BM, Aprahamian C, et al. Rapid fluid resuscitation with central venous catheters. *Ann Emerg Med* 1983;12:149-152.

29. Buchman TG, Menker JB, Lipsett PA. Strategies for trauma resuscitation. *Surg Gynecol Obstet* 1991;172:8-12.

30. Hyman SA, Smith DW, England R, et al. Pulmonary artery catheter introducers: do the component parts affect flow rate? *Anesth Analg* 1991;73: 573-575.

31. Dula DJ, Muller A, Donovan JW. Flow rate of commonly used IV techniques. *J Trauma* 1981;21:480-482.

Resuscitation Strategies

32. Shoemaker WC. Relationship of oxygen transport patterns to the pathophysiology and therapy of shock states. *Intensive Care Med* 1987;213:230-243.

33. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. *JAMA* 1993;269:3024-3029.

34. Imm A, Carlson RW. Fluid resuscitation in circulatory shock. *Crit Care Clin* 1993;9:313-333.

35. Domskey MF, Wilson RF. Hemodynamic resuscitation. *Crit Care Clin* 1993;9: 715-726.

36. Whinney RR, Cohn SM, Zacur SJ. Fluid resuscitation for trauma patients in the 21st century. *Curr Opin Crit Care* 2000;6:395-400.

37. Velmahos GC, Demetriades D, Shoemaker WC, et al. Endpoints of resuscitation of critically injured patients: normal or supranormal? *Ann Surg* 2000; 232:409-418.

38. Shoemaker WC, Fleming AW. Resuscitation of the trauma patient: restoration of hemodynamic functions using clinical algorithms. *Ann Emerg Med* 1986; 12:1437-1444.

39. Abramson D, Scalea TM, Hitchcock R, et al. Lactate clearance and survival following injury. *J Trauma* 1993;35:584-589.

40. American College of Physicians. Practice strategies for elective red blood cell transfusion. *Ann Intern Med* 1992;116:403-406.

41. Levy PS, Chavez RP, Crystal GJ, et al. Oxygen extraction ratio: a valid indicator of transfusion need in limited coronary vascular reserve. *J Trauma* 1992; 32:769-774.

42. Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. *Circulation* 1999; 100:226-229.

43. Patel B, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002;96:576-582.

44. Marik PE. Assessment of intravascular volume: a comedy of errors. *Crit Care Med* 2001;29:1635.

Chapter 13

Colloid and Crystalloid Resuscitation

References

Reviews

01. Alderson P, Schierhout G, Roberts I, et al. Colloid versus crystalloids for fluid resuscitation in critically ill patients: a systematic review of randomized trials. *Cochrane Database Syst Rev* 2000; Issue 3, Art. No. CD000567.

02. Choi PT, Yip G, Quinonez LG, et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. *Crit Care Med* 1999;27:200-210.

03. Whinney RR, Cohn SM, Zacur SJ. Fluid resuscitation for trauma patients in the 21st century. *Curr Opin Crit Care* 2000;6:396-400.

04. Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation. *Cochrane Database Syst Rev* 2001;:CD001319.

Crystalloid Fluids

1. Imm A, Carlson RW. Fluid resuscitation in circulatory shock. *Crit Care Clin* 1993;9:313-333.

2. Scheingraber S, Rehm M, Schmisch C, et al. Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery. *Anesthesiology* 1999;90:1265-1270.

3. Prough DS, Bidani A. Hyperchloremic metabolic acidosis is a predictable consequence of intraoperative infusion of 0.9% saline. *Anesthesiology* 1999;90:1247-1249.

4. Griffith CA. The family of Ringer's solutions. *J Natl Intravenous Ther Assoc* 1986;9:480-483.

5. American Association of Blood Banks. Technical manual, 10th ed. Arlington, VA: American Association of Blood Banks, 1990:368.

6. King WH, Patten ED, Bee DE. An in vitro evaluation of ionized calcium levels and clotting in red blood cells diluted with lactated Ringer's solution. *Anesthesiology* 1988;68:115-121.

7. Didwania A, Miller J, Kassel D, et al. Effect of intravenous lactated Ringer's solution infusion on the circulating lactate concentration, part 3: result of a prospective, randomized, double-blind, placebo-controlled trial. *Crit Care Med* 1997;25:1851-1854.

8. Jackson EV Jr, Wiese J, Sigal B, et al. Effects of crystalloid solutions on circulating lactate concentrations, part 1: implications for the proper handling of blood specimens obtained from critically ill patients. *Crit Care Med* 1997;25: 1840-1846.

9. Halpern NA, Alicea M, Seabrook B, et al. [Q]olyte S, a physiologic multielectrolyte solution, is preferable to normal saline to wash cell saver salvaged blood: conclusions from a prospective, randomized study in a canine model. *Crit Care Med* 1997;12:2031-2038.

Dextrose Solutions

10. Gunther B, Jauch W, Hartl W, et al. Low-dose glucose infusion in patients who have undergone surgery. *Arch Surg* 1987;122:765-771.

11. DeGoute CS, Ray MJ, Manchon M, et al. Intraoperative glucose infusion and blood lactate: endocrine and metabolic relationships during abdominal aortic surgery. *Anesthesiology* 1989;71:355-361.

12. Turina M, Fry D, Polk HC Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. *Crit Care Med* 2005;33:1624-1633.

13. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359-1367.

14. Sieber FE, Traystman RJ. Special issues: glucose and the brain. *Crit Care Med* 1992;20:104-114.

15. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. *JAMA* 2003;290:2041-2047.

Colloid Fluids

16. Jacob G, Raj S, Ketch T, et al. Postural pseudoanemia: posture-dependent changes in hematocrit. *Mayo Clin Proc* 2005;80:611-614.

17. Griffel MI, Kaufman BS. Pharmacology of colloids and crystalloids. *Crit Care Clin* 1992;8:235-254.

18. Kaminski MV, Haase TJ. Albumin and colloid osmotic pressure: implications for fluid resuscitation. *Crit Care Clin* 1992;8:311-322.

19. Sutin KM, Ruskin KJ, Kaufman BS. Intravenous fluid therapy in neurologic injury. *Crit Care Clin* 1992;8:367-408.

20. Imm A, Carlson RW. Fluid resuscitation in circulatory shock. *Crit Care Clin* 1993;9:313-333.

21. Soni N, Margaron M. Albumin, where are we now? *Curr Anesth Crit Care* 2004;15:61-68.

22. Halliwell B. Albumin: an important extracellular antioxidant? *Biochem Pharmacol* 1988;37:569-571.

23. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized, controlled trials. *Br Med J* 1998;317:235-240.

24. Choi PT-L, Yip G, Quinonez LG, et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. *Crit Care Med* 1999;27:200-210.

25. Wilkes MN, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. *Ann Intern Med* 2001;135: 149-164.

26. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004;350:2247-2256.

27. Vincent J-L, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human serum albumin: a meta-analysis of randomized, controlled trials. *Crit Care Med* 2004;32:2029-2038.

28. Treib J, Baron JF, Grauer MT, et al. An international view of hydroxyethyl starches, *Intensive Care Med* 1999;25:258-268.

29. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. *Crit Care Med* 2001;29:1261-1267.

30. Haynes GR, Havidich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. *Anesthesiology* 2004;101:560-561.

31. Nearman HS, Herman ML. Toxic effects of colloids in the intensive care unit. *Crit Care Clin* 1991;7:713-723.

32. Gan TJ. Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. *Anesth Analg* 1999;88:992-998.

33. Drumi W, Polzleitner D, Laggner AN, et al. Dextran-40, acute renal failure, and elevated plasma oncotic pressure. *N Engl J Med* 1988;318:252-254.

Colloid-Crystalloid Wars

34. Moore FD. The effects of hemorrhage on body composition. *N Engl J Med* 1965;273:567-577.

35. Shires T, Carrico J, Lightfoot S. Fluid therapy in hemorrhagic shock. *Arch Surg* 1964;88:688-693.

36. Weil MH, Tang W. Albumin versus crystalloid solutions for the critically ill and injured [Editorial]. *Crit Care Med* 2004;32:2154-2155.

Hypertonic Resuscitation

37. Chiara O, Pelosi P, Brazzi L, et al. Resuscitation from hemorrhagic shock: experimental model comparing normal saline, dextran, and hypertonic saline solutions. *Crit Care Med* 2003;31:1915-1922.

38. Cooper DJ, Myles PS, McDermott FT, et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury. *JAMA* 2004;291:1350-1357.

Chapter 14

Acute Heart Failure Syndromes

References

Reviews

1. American Heart Association. Heart Disease and Stroke Statistics – 2005 Update. Dallas, TX: American Heart Association, 2005.

2. Nieminen MS, Harjola V-P. Definition and etiology of acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl):5G-10G.

3. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl):32G-40G.

4. The Task Force on Acute Heart Failure of the European Society of Cardiology. Guidelines on the diagnosis and treatment of heart failure. European Society of Cardiology Web Site. Available at <http://www.escardio.org>.

5. Jain P, Massie BM, Gattis WA, et al. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. *Am Heart J* 2003;145:S3-S17.

Diastolic Heart Failure

6. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure – Abnormalities in active relaxation and passive stiffness of the left ventricle. *New Engl J Med* 2004;350:1953-1959.

7. Aurigemma GP, Gaasch WH. Diastolic heart failure. *New Engl J Med* 2004;351:1097-1015.

8. Numi Y, Haki M, Ishiguro Y, et al. Determination of right ventricular function by transesophageal echocardiography: impact of proximal right coronary artery stenosis. *J Clin Anesthesia* 2004;16:104-110.

Right Heart Failure

9. Hurford WE, Zapol WM. The right ventricle and critical illness: a review of anatomy, physiology, and clinical evaluation of its function. *Intensive Care Med* 1988;14:448-457.

10. Isner JM. Right ventricular myocardial infarction. *JAMA* 1988;259:712-718.

11. Vincent JL, Thirion M, Brimiouille S, et al. Thermodilution measurement of right ventricular ejection fraction with a modified pulmonary artery catheter. *Intensive Care Med* 1986;12:33-38.

12. Robotham JL, Takala M, Berman M, et al. Ejection fraction revisited. *Anesthesiology* 1991;74:172-183.

13. Boldt J, Kling D, Moosdorf R, Hempelmann G. Influence of acute volume loading on right ventricular function after cardiopulmonary bypass. *Crit Care Med* 1989;17:518-521.

B-Type Natriuretic Peptide

14. Maisel AS, Wanner EC. Measuring BNP levels in the diagnosis and treatment of CHF. *J Crit Illness* 2002;17:434-442.

15. Maisel AS, Krishnaswamy P, Nomak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *New Engl J Med* 2002;347:161-167.

16. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. *J Am Coll Cardiol* 2001;37:379-385.

17. Takami Y, Horio T, Iwashima Y, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. *Am J Kidney Dis* 2004;44:420-428.

18. Charpentier J, Luyt C-E, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. *Crit Care Med* 2004;32:660-665.

Management Strategies

19. Bayram M, De Luca L, Massie B, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl):47G-58G.

20. Stough WG, O'Connor CM, Gheorghiade M. Overview of current noninodilator therapies for acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl): 41G-46G.

21. Chatterjee K, De Marco T. Role of nonglycosidic inotropic agents: indications, ethics, and limitations. *Med Clin N Am* 2003;87:391-418.

22. Flaherty JT, Magee PA, Gardner TL, et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertension developing after coronary artery bypass surgery. *Circulation* 1982;65:1072-1077.

23. Robin ED, McCauley R. Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions. *Chest* 1992;102:1842-1845.

24. Franciosa JA. Optimal left heart filling pressure during nitroprusside infusion for congestive heart failure. *Am J Med* 1983;74:457-464.

25. Samuels LE, Darze ES. Management of acute cardiogenic shock. *Cardiol Clin* 2003;21:43-49.

26. Davidson RM. Hemodynamic effects of furosemide in acute myocardial infarction. *Circulation* 1971;54(Suppl II):156.

27. Kiely J, Kelly DT, Taylor DR, Pitt B. The role of furosemide in the treatment of left ventricular dysfunction associated with acute myocardial infarction. *Circulation* 1973;58:581-587.

28. Mond H, Hunt D, Sloman G. Haemodynamic effects of frusemide in patients suspected of having acute myocardial infarction. *Br Heart J* 1974;36:44-53.
29. Nelson GIC, Ahuja RC, Silke B, et al. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart failure following myocardial infarction. *Lancet* 1983a;i:730-733.
30. Nelson GIC, Ahuja RC, Silke B, et al. Haemodynamic effects of frusemide and its influence on repetitive volume loading in acute myocardial infarction. *Eur Heart J* 1983b;4:706-711.
31. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. *Ann Intern Med* 1986;103:1-6.
32. Brater DC. Resistance to loop diuretics: why it happens and what to do about it. *Drugs* 1985;30:427-443.
33. van Meyel JJM, Smits P, Russell FGM, et al. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. *Clin Pharmacol Ther* 1992;51:440-444.
34. Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. *Chest* 2001;119:807-810.
35. Aurigemma GP, Gaasch WH. Diastolic heart failure. *New Engl J Med* 2004; 351:1097-1105.
36. Vasodilation in the Management of Acute CHF (VMAC) Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. *JAMA* 2002;287:1531-1540.
37. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure. *JAMA* 2005;293:1900-1905.
38. Tamborini G, Pepi M, Susini G, et al. Reversal of cardiogenic shock and severe mitral regurgitation through verapamil in hypertensive hypertrophic cardiomyopathy. *Chest* 1993;104:319-324.
39. Nishimura R, Schwartz RS, Holmes DR, Tajik J. Failure of calcium channel blockers to improve ventricular relaxation in humans. *J Am Coll Cardiol* 1993;21:182-188.
40. Reuse C, Vinvcent JL, Pinsky MR. Measurement of right ventricular volumes during fluid challenge. *Chest* 1990;98:1450-1454.
41. Vincent RL, Reuse C, Kahn RJ. Effects on right ventricular function of a change from dopamine to dobutamine in critically ill patients. *Crit Care Med* 1988;16:659-662.
42. Dell'Italia LJ, Starling MR, Blumhardt R, et al. Comparative effects of volume loading, dobutamine and nitroprusside in patients with predominant right ventricular infarction. *Circulation* 1986;72:1327-1335.
- Mechanical Cardiac Support**
43. Kantrowitz A, Tjonneland S, Freed PS, et al. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. *JAMA* 1968;203:113-118.
44. Williams DO, Korr KS, Gewirtz H, Most AS. The effect of intra-aortic balloon counterpulsation on regional myocardial blood flow and oxygen consumption in the presence of coronary artery stenosis with unstable angina. *Circulation* 1982;3:593-597.
45. Stevenson LW, Kormos RL. Mechanical cardiac support 2000: current applications and future trial design. *J Am Coll Cardiol* 2000;37:340-370.
46. Kantrowitz A, Cordona RR, Freed PS. Percutaneous intra-aortic balloon counterpulsation. *Crit Care Clin* 1992;8:819-837.
47. Baldyga AP. Complications of intra-aortic balloon pump therapy. In Maccioli GA, ed. *Intra-aortic balloon pump therapy*. Philadelphia: Williams & Wilkins, 1997, 127-162.

48. Mackenzie DJ, Wagner WH, Kulber DA, et al. Vascular complications of the intra-aortic balloon pump. *Am J Surg* 1992;164:517-521.

49. Bolno PB, Kresh Y. Physiologic and hemodynamic basis of ventricular assist devices. *Cardiol Clin* 2003;21:15-27.

50. Killen DA, Piehler JM, Borkon AM, et al. Bio-Medicus ventricular assist device for salvage of cardiac surgical patients. *Ann Thorac Surg* 1991;52:230-235.

51. Lee WA, Gillinov AM, Cameron DE, et al. Centrifugal ventricular assist device for support of the failing heart after cardiac surgery. *Crit Care Med* 1993;21:1186-1191.

The Future

52. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl):26G-31G.

53. Gheorghiade M, Teerlionk JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. *Am J Cardiol* 2005;96(Suppl):68G-73G.

54. Kersten JR, Montgomery MW, Pagel PL, Waltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. *Anesth Analg* 2000;90:5-11.

Chapter 15

Cardiac Arrest

References

Introduction

1. Kouwenhoven WB, Ing Jude JR, Knickerbocker GG. Closed chest cardiac massage. *JAMA* 1960;173:1064-1067.

2. Nadkarni VM, Laarkin GL, Peberdy MA, et al., for the National Registry of Cardiopulmonary Resuscitation Investigators. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. *JAMA* 2006;295:50-57.

Guidelines

3. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2005;112(suppl 112). (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)

Basic Life Support

4. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, Part 4: adult basic life support. *Circulation* 2005;112(suppl 1):IV19-IV34. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)

5. Aufderheide TP, Lurie KG. Death by hyperventilation: a common and life-threatening problem during cardiopulmonary resuscitation. *Crit Care Med* 2004;32(suppl):S345-S351.

6. Abella BS, Alvarado JP, Mykelbust H, et al. Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest. *JAMA* 2005;293:305-310.

7. Cummins RO, ed. ACLS provider manual. Dallas, TX: American Heart Association, 2001:25.

8. Aufderheide TP, Pirallo RG, Provo TA, et al. Clinical evaluation of an inspiratory impedance threshold device during standard cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest. *Crit Care Med* 2005;33:734-740.

Advanced Life Support

9. 2005 International consensus on cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC) science with treatment recommendations, Part 4: advanced life support. *Circulation* 2005;112(suppl I):III-25-III-54. (Available online @ http://www.circ.ahajournals.org/content/vol112/22_suppl/)
10. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care: Part 7.2, management of cardiac arrest. *Circulation* 2005;112(suppl I):IV58-IV66. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)
11. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, Part 5: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing. *Circulation* 2005;112(suppl I):IV17-IV24. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)
12. Larsen MP, Eisenberg M, Cummins RO, et al. Predicting survival from out of hospital cardiac arrest: a graphic model. *Ann Emerg Med* 1993;22:1652-1658.
13. Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and meta-analysis. *Arch Intern Med* 2005;165:17-24.

14. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for out-of-hospital cardiac arrest due to ventricular fibrillation. *N Engl J Med* 1999;341:871-878.
15. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared to lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med* 2002;346:884-890.

Monitoring During CPR

16. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, Part 7.4: monitoring and medications. *Circulation* 2005;112(suppl I):IV78-IV83. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)
17. Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. *JAMA* 1990;263:1106-1113.
18. Falk JL, Rackow EC, Weil MH. End-tidal carbon dioxide concentration during cardiopulmonary resuscitation. *N Engl J Med* 1988;318:607-611.
19. Sanders AB, Kern KB, Otto CW, et al. End-tidal carbon dioxide monitoring during cardiopulmonary resuscitation. *JAMA* 1989;262:1347-1351.
20. Wayne MA, Levine RL, Miller CC. Use of end-tidal carbon dioxide to predict outcome in prehospital cardiac arrest. *Ann Emerg Med* 1995;25:762-767.
21. Weil MH, Rackow EC, Trevino R. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. *N Engl J Med* 1986;315:153-156.
22. Steedman DJ, Robertson CE. Acid-base changes in arterial and central venous blood during cardiopulmonary resuscitation. *Arch Emerg Med* 1992; 9:169-176.
23. Abramson NS, Safar P, Detre KM, et al. Neurologic recovery after cardiac arrest: effect of duration of ischemia. *Crit Care Med* 1985;13:930-931.

Postresuscitation Management

24. Hickey RW, Kochanek PM, Ferimer H, et al. Induced hyperthermia exacerbates neurologic neuronal histologic damage after asphyxial cardiac arrest in rats. *Crit Care Med* 2003;31:531-535.
25. Zeiner A, Holzer M, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. *Arch Intern Med* 2001;161: 2007-2012.
26. Nobel EG, Gang P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries cause by the cold pressor test. *Circulation* 1987;77:43-52.
27. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med* 2002;346:549-556.

28. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med* 2002; 346:557-563.
29. Calle PA, Buylaert WA, Vanhaute OA. Glycemia in the post-resuscitation period: The Cerebral Resuscitation Study Group. *Resuscitation* 1989;17(suppl): S181-188.
30. 2005 American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, Part 7.5: postresuscitation support. *Circulation* 2005;112(suppl I):IV84-IV88. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)
31. van der Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359-1367.
32. Levy DE, Caronna JJ, Singer BH, et al. Predicting outcome from hypoxic-ischemic coma. *JAMA* 1985;253:1420-1426.
33. Edgren E, Hedstrand U, Kelsey S, et al. Assessment of neurologic prognosis in comatose survivors of cardiac arrest. *Lancet* 1994;343:1055-1059.
34. Booth CM, Boone RH, Tomlinson G, et al. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. *JAMA* 2004;291:870-879.

Chapter 16

Hemodynamic Drug Infusions

References

Dobutamine

1. Dobutamine monograph. Mosby's Drug Consult, 2006. Accessed on the MD Consult website (<http://www.MDconsult.com>) on Feb 3, 2006.
2. Bayram M, De Luca L, Massie B, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. *Am J Cardiol* 2005;96(suppl):47G-58G.
3. Romson JL, Leung JM, Bellows WH, et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. *Anesthesiology* 1999;91:1318-1327.
4. Hayes MA, Yau EHS, Timmins AC, et al. Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption: relationship to outcome. *Chest* 1993;103:886-895.
5. Klem C, Dasta JF, Reilley TE, et al. Variability in dobutamine pharmacokinetics in unstable critically ill surgical patients. *Crit Care Med* 1994;22:1926-1932.
6. Rich MW, Imburgia M. Inotropic response to dobutamine in elderly patients with decompensated congestive heart failure. *Am J Cardiol* 1990;65:519-521.

Dopamine

7. Dopamine monograph. Mosby's Drug Consult, 2006. Accessed on the MD Consult website (<http://www.MDconsult.com>) on Feb 3, 2006.
8. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001;29:1526-1531.
9. Brath PC, MacGregor DA, Ford JG, Prielipp RC. Dopamine and intraocular pressure in critically ill patients. *Anesthesiology* 2000;93:1398-1400.
10. Johnson AG. Source of infection in nosocomial pneumonia [Letter]. *Lancet* 1993;341:1368.

Nitroglycerin

11. Anderson TJ, Meredith IT, Ganz P, et al. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. *J Am Coll Cardiol* 1994;24: 555-566.
12. Nitroglycerin. In: McEvoy GK, ed. *AHFS Drug Information*, 2001. Bethesda, MD: American Society of Health System Pharmacists, 2001:1832-1835.
13. Elkayam U. Nitrates in heart failure. *Cardiol Clin* 1994;12:73-85.
14. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. *J Am Coll Cardiol* 1991;18:1529-1536.
15. Curry SC, Arnold-Cappell P. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors. In: *Toxic effects of drugs used in the ICU*. *Crit Care Clin* 1991;7:555-582.

16. Radermacher P, Santak B, Becker H, et al. Prostaglandin FI and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distribution in patients with adult respiratory distress syndrome. *Anesthesiology* 1989;70:601-606.
17. Korn SH, Comer JB. Intravenous nitroglycerin and ethanol intoxication. *Ann Intern Med* 1985;102:274.
18. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. *Intensive Care Med* 1988;14:221-226.
19. Daiber A, Mulsch A, Hink U, et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. *Am J Cardiol* 2005; 96(suppl):25i-36i.
20. Gogia A, Mehra A, Parikh S, et al. Prevention of tolerance to the hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. *J Am Coll Cardiol* 1995;26:1575-1580.
- Nitroprusside
21. Nitroprusside. In: McEvoy GK, ed. *AHFS Drug Information*, 2001. Bethesda, MD: American Society of Health System Pharmacists, 2001:1816-1820.
22. Guha NH, Cohn JN, Mikulic E, et al. Treatment of refractory heart failure with infusion of nitroprusside. *N Engl J Med* 1974;291:587-592.
23. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. *N Engl J Med* 2003;348:1756-1763.
24. Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. *Am J Crit Care* 1992;2: 19-27.
25. Robin ED, McCauley R. Nitroprusside-related cyanide poisoning: time (long past due) for urgent, effective interventions. *Chest* 1992;102:1842-1845.
26. Arieff AI. Is measurement of venous oxygen saturation useful in the diagnosis of cyanide poisoning? *Am J Med* 1992;93:582-583.
27. Kirk MA, Gerace R, Kulig KW. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the Cyanide Antidote Kit. *Ann Emerg Med* 1993;22:1413-1418.
28. Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. *Ann Emerg Med* 1994;24:65-67.
- Norepinephrine
29. Norepinephrine bitartrate. In: McEvoy GK, ed. *AHFS Drug Information*, 2001. Bethesda, MD: American Society of Health System Pharmacists, 2001: 1258-1261.
30. Beale RJ, Hollenberg SM, Vincent J-L, et al. Vasopressor and inotropic support in septic shock: an evidence-based review. *Crit Care Med* 2004;32(suppl): S455-S465.
31. Desairs P, Pinaud M, Bugnon D, et al. Norepinephrine therapy has no deleterious renal effects in human septic shock. *Crit Care Med* 1989;17:426-429.

Chapter 17

Early Management of Acute Coronary Syndromes

References

Clinical Practice Guidelines

1. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: Stabilization of the patient with acute coronary syndromes. *Circulation* 2005;112(suppl I):IV89-IV110. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/I)
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). *Circulation* 2004;110:588-636. (Available at <http://www.acc.org/clinical/guidelines/stemi/Guideline1/index.htm>)
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-1374.

Acute Coronary Syndromes

4. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction. *Br Heart J* 1985;53:363-373.

5. Van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation* 1994;89:36-44.
6. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. *JAMA* 1999;282:2035-2042.

Routine Measures

7. Patrono C, Collier B, Fitzgerald G, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. *Chest* 2004;126:234S-264S.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988;2:349-360.
9. Roux S, Christellar S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. *J Am Coll Cardiol* 1992;19:671-677.
10. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502.
11. Kloner RA, Hale S. Unraveling the complex effects of cocaine on the heart. *Circulation* 1993;87:1046-1047.
12. AHFS. Metoprolol succinate and metoprolol tartrate. In McEvoy GK, ed. AHFS drug information, 2001. Bethesda, MD: American Society for Health System Pharmacists, 2001:1622-1629.
13. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation* 1998;97:2202-2212.
14. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (GISSI). GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. *Lancet* 1994;343:1115-1122.
15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893-1906.

Thrombolytic Therapy

16. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. *N Engl J Med* 1993;329:703-725.
17. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. *Lancet* 1986;1:397-401.
18. Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. *Lancet* 1994;343:311-322.
19. Boden WE, Kleiger RE, Gibson RS, et al. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression. *Am J Cardiol* 1987;59:782-787.
20. Guidry JR, Raschke R, Morkunas AR. Anticoagulants and thrombolytics. In: Blumer JL, Bond GR, eds. Toxic effects of drugs in the ICU: critical care clinics. Vol. 7. Philadelphia: WB Saunders, 1991:533-554.
21. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993;329:673-682.
22. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. *JAMA* 2001;286:442-449.

23. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. *Circulation* 1995;91:2725-2732.

24. GUSTO-III Investigators. An international, multicenter, randomized comparison of reteplase with alteplase for acute myocardial infarction. *N Engl J Med* 1997;337:1118-1123.

25. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. *Lancet* 1999;354:716-722.

26. Young GP, Hoffman JR. Thrombolytic therapy. *Emerg Med Clin* 1995;13:735-759.

27. Topol EJ. Acute myocardial infarction: thrombolysis. *Heart* 2000;83:122-126.

Coronary Angioplasty

28. The GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. *N Engl J Med* 1997;336:1621-1628.

29. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. *Lancet* 2003;361:13-20.

30. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. *Circulation* 2001;104:636-641.

31. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom onset to balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000;283:2941-2947.

32. Meyer MC. Reperfusion strategies for ST-segment elevation myocardial infarction: an overview of current therapeutic options. Part II: Mechanical reperfusion. *Emergency Medicine Reports*, Vol 25, April 2004 (Accessed on 1/2/2005 at http://www.emronline.com/articles/Issues_Abstracts/2004/emr04052004a.html)

33. Andersen HR, Nielsen TT, Rasmussen K, et al. for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003;349:733-742.

Adjuncts to Reperfusion Therapy

34. Wong GC, Gugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary syndromes and percutaneous coronary intervention. *JAMA* 2003;289:331-342.

35. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. *JAMA* 2004;292:89-96.

36. Theroux P, Welsh RC. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. *Am J Cardiol* 2003;91:860-864.

37. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. *Lancet* 2001;358:605-613.

38. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *JAMA* 2000;284:1549-1558.

Early Complications

39. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. *J Am Coll Cardiol* 2000;36:1104-1109.

40. Samuels LF, Darze ES. Management of acute cardiogenic shock. *Cardiol Clin* 2003;21:43-49.

Aortic Dissection

41. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. *Chest* 2002;122:311-328.

42. Knaut AL, Cleveland JC. Aortic emergencies. *Emerg Med Clin N Am* 2003; 21:817-845.

43. Zegel HG, Chmielewski S, Freiman DB. The imaging evaluation of thoracic aortic dissection. *Appl Radiol* 1995;(June):15-25.

Chapter 18

Tachyarrhythmias

References

Clinical Practice Guidelines

1. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.3: Management of symptomatic bradycardia and tachycardia. *Circulation* 2005;112(suppl):IV67-IV77. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)

2. Blomstrom-Lundqvist C, Scheinmann MM, Haliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee on Practice Guidelines, 2003. American College of Cardiology Web Site. Available at http://www.acc.org/clinical/guidelines/arrhythmias/sva_index.pdf

3. Fuster V, Ryden LE, Ansinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee on Practice Guidelines and Policy Conferences. *J Am Coll Cardiol* 2001;38:1266i-lxx. (Available @ http://www.acc.org/clinical/guidelines/atrial.fib/as_index.htm)

Atrial Flutter and Fibrillation

4. Guyton AC. The relationship of cardiac output and arterial pressure control. *Circulation* 1981;64:1079-1088.

5. Siebers MJ, Drinka PJ, Vergauwen C. Hyperthyroidism as a cause of atrial fibrillation in long-term care. *Arch Intern Med* 1992;152:2063-2064.

6. Hogue CW, Creswell LL, Gutterman DD, et al. American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery: epidemiology, mechanisms, and risks. *Chest* 2005;128(suppl):9S-16S.

7. Martinez EA, Epstein AE, Bass EB. American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Pharmacological control of ventricular rate. *Chest* 2005;128(suppl):56S-60S.

8. Blackshear JL, Kopecky SL, Litin SC, et al. Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. *Mayo Clin Proc* 1996;71:150-160.

9. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake, chronically instrumented goats. *Circulation* 1995;92:1954-1968.

10. Danias PG, Caulfield TA, Weigner MJ, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. *J Am Coll Cardiol* 1998;31:588-592.

11. VerNooy RA, Mounsey P. Antiarrhythmic drug therapy in atrial fibrillation. *Cardiol Clin* 2004;22:21-34.

12. Trohman RG. Supraventricular tachycardia: implications for the intensivist. *Crit Care Med* 2000;28(suppl): N129-N135.

13. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. *J Am Coll Cardiol* 1991;18:891-897.
14. Diltiazem injectable monograph. Mosby's Drug Consult, 2006. Accessed from MD Consult Web Site on 3/1/06.
15. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. *Am J Cardiol* 1994;74:884-889.
16. Gray RJ. Managing critically ill patients with esmolol: an ultra-short-acting β -adrenergic blocker. *Chest* 1988;93:398-404.
17. Karth GD, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. *Crit Care Med* 2001;29:1149-1153.
18. Chow MSS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. *Ann Pharmacother* 1996;30:637-643.
19. Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. *Mayo Clin Proc* 2004;79: 904-913.
20. Marcus FI, Opie LH. Antiarrhythmic drugs. In: Opie LH, ed. *Drugs for the heart*. 4th ed. Philadelphia: WB Saunders, 1995:207-246.
- Multifocal Atrial Tachycardia
21. Kastor J. Multifocal atrial tachycardia. *N Engl J Med* 1990;322:1713-1720.
22. Levine J, Michael J, Guanieri T. Multifocal atrial tachycardia: a toxic effect of theophylline. *Lancet* 1985;1:1-16.
23. Iseri LT, Fairshier RD, Hardeman JL, et al. Magnesium and potassium therapy in multifocal atrial tachycardia. *Am Heart J* 1985;312:21-26.
- Paroxysmal Supraventricular Tachycardias
24. Shen W-K, Kurachi Y. Mechanisms of adenosine-mediated actions on cellular and clinical cardiac electrophysiology. *Mayo Clin Proc* 1995;70:274-291.
25. Rankin AC, Brooks R, Ruskin JM, et al. Adenosine and the treatment of supraventricular tachycardia. *Am J Med* 1992;92:655-664.
26. Chronister C. Clinical management of supraventricular tachycardia with adenosine. *Am J Crit Care* 1993;2:41-47.
27. McCollam PL, Uber W, Van Bakel AB. Adenosine-related ventricular asystole. *Ann Intern Med* 1993;118:315-316.
28. Cushley MJ, Tattersfield AE, Holgate ST. Adenosine-induced bronchoconstriction in asthma. *Am Rev Respir Dis* 1984;129:380-384.
29. Bjorck T, Gustafsson LE, Dahlen S-E. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. *Am Rev Respir Dis* 1992;145:1087-1091.
- Ventricular Tachycardia
30. Gupta AK, Thakur RK. Wide QRS complex tachycardias. *Med Clin North Am* 2001;85:245-266.
31. Akhtar M, Shenasa M, Jazayeri M, et al. Wide QRS complex tachycardia. *Ann Intern Med* 1988;109:905-912.
32. Sharma AD, Purves P, Yee R, et al. Hemodynamic effects of intravenous procainamide during ventricular tachycardia. *Am Heart J* 1990;119:1034-1041.
33. Vukmir RB. Torsades de pointes: a review. *Am J Emerg Med* 1991;9:250-262.
34. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. *Pharmacotherapy* 2001;21:1468-1472.

35. Roden DM. Drug-induced prolongation of the QT interval. *N Engl J Med* 2004;350:1013–1022.
36. Garson A Jr. How to measure the QT interval: what is normal? *Am J Cardiol* 1993;72:14B–16B.

Chapter 19

Hypoxemia and Hypercapnia

References

Introduction

1. Dale JC, Pruett SK. Phlebotomy: a minimalist approach. *Mayo Clin Proc* 1993;68:249–255.
2. Raffin TA. Indications for blood gas analysis. *Ann Intern Med* 1986;105:390–398.
3. Dantzger DR. Pulmonary gas exchange. In: Dantzger DR, ed. *Cardiopulmonary critical care*. 2nd ed. Philadelphia: WB Saunders, 1991:25–43.
4. Lanken PN. Ventilation–perfusion relationships. In: Grippi MA, ed. *Pulmonary pathophysiology*. Philadelphia: JB Lippincott, 1995:195–210.
5. Buohuys A. Respiratory dead space. In: Fenn WO, Rahn H, eds. *Handbook of physiology: respiration*. Bethesda: American Physiological Society, 1964:699–714.
6. D'Alonzo GE, Dantzger DR. Mechanisms of abnormal gas exchange. *Med Clin North Am* 1983;67:557–571.

Quantitative Measures

7. Gammon RB, Jefferson LS. Interpretation of arterial oxygen tension. UpToDate Web Site, 2006. (Accessed 3/11/2006)
8. Harris EA, Kenyon AM, Nisbet HD, et al. The normal alveolar–arterial oxygen tension gradient in man. *Clin Sci* 1974;46:89–104.
9. Gilbert R, Kreighley JF. The arterial/alveolar oxygen tension ratio: an index of gas exchange applicable to varying inspired oxygen concentrations. *Am Rev Respir Dis* 1974;109:142–145.
10. Carroll GC. Misapplication of the alveolar gas equation. *N Engl J Med* 1985;312:586.
11. Covelli HD, Nesson VJ, Tuttle WK. Oxygen derived variables in acute respiratory failure. *Crit Care Med* 1983;11:646–649.

Blood–Gas Variability

12. Hess D, Agarwal NN. Variability of blood gases, pulse oximeter saturation, and end-tidal carbon dioxide pressure in stable, mechanically ventilated trauma patients. *J Clin Monit* 1992;8:111–115.
13. Sasse SA, Chen P, Mahutte CK. Variability of arterial blood gas values over time in stable medical ICU patients. *Chest* 1994;106:187–193.

Hypoxemia

14. Duarte A, Bidani A. Evaluating hypoxemia in the critically ill. *J Crit Illness* 2005;20:91–93.
15. White AC. The evaluation and management of hypoxemia in the chronic critically ill patient. *Clin Chest Med* 2001;22:123–134.
16. Nowbar S, Burkhart KM, Gonzalez R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. *Am J Med* 2004;116:1–7.
17. Rich MM, Raps EC, Bird SJ. Distinction between acute myopathy syndrome and critical illness polyneuropathy. *Mayo Clin Proc* 1995;70:198–199.
18. Bruschi C, Cerveri I, Zoia MC, et al. Reference values for maximum respiratory mouth pressures: a population-based study. *Am Rev Respir Dis* 1992; 146:790–793.
19. Baydur A. Respiratory muscle strength and control of ventilation in patients with neuromuscular disease. *Chest* 1991;99:330–338.
20. Rossaint R, Hahn S–M, Pappert D, et al. Influence of mixed venous PO₂ and inspired oxygen fraction on intrapulmonary shunt in patients with severe ARDS. *J Appl Physiol* 1995;78:1531–1536.
21. Lele A, Mirski MA, Stevens RD. Spurious hypoxemia. *Crit Care Med* 2005;33: 1854–1856.

22. Fox MJ, Brody JS, Weintraub LR. Leukocyte larceny: a cause of spurious hypoxemia. *Am J Med* 1979;67:742-746.

Hypercapnia

23. Weinberger SE, Schwartzstein RM, Weiss JW. Hypercapnia. *N Engl J Med* 1989;321:1223-1230.

24. Talpers SS, Romberger DJ, Bunce SB, et al. Nutritionally associated increased carbon dioxide production. *Chest* 1992;102:551-555.

25. Gray BA, Blalock JM. Interpretation of the alveolar-arterial oxygen difference in patients with hypercapnia. *Am Rev Respir Dis* 1991;143:4-8.

Chapter 20

Oximetry and Capnography

References

General Reviews

1. Jubran A, Tobin MJ. Monitoring during mechanical ventilation. *Clin Chest Med* 1996;17:453-473.

2. Soubani AO. Noninvasive monitoring of oxygen and carbon dioxide. *Am J Emerg Med* 2001;19:141-146.

Pulse Oximetry

3. Stoneham MD, Saville GM, Wilson IH. Knowledge about pulse oximetry among medical and nursing staff. *Lancet* 1994;344:1339-1342.

4. Wahr JA, Tremper KK. Noninvasive oxygen monitoring techniques. *Crit Care Clin* 1995;11:199-217.

5. Severinghaus JW, Kelleher JF. Recent developments in pulse oximetry. *Anesthesiology* 1992;76:1018-1038.

6. Hess D, Agarwal NN. Variability of blood gases, pulse oximeter saturation, and end-tidal carbon dioxide pressure in stable, mechanically ventilated trauma patients. *J Clin Monit* 1992;8:111-115.

7. Bozeman WP, Myers RAM, Barish RA. Confirmation of the pulse oximetry gap in carbon monoxide poisoning. *Ann Emerg Med* 1997;30:608-611.

8. Barker SJ, Kemper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. *Anesthesiology* 1989;70:112-117.

9. Severinghaus JW, Spellman MJ. Pulse oximeter failure thresholds in hypotension and vasoconstriction. *Anesthesiology* 1990;73:532-537.

10. Morris RW, Nairn M, Beaudoin M. Does the radial arterial line degrade the performance of a pulse oximeter? *Anesth Intensive Care* 1990;18:107-109.

11. Bebout DE, Mannheim PD, Wun CC. Site-dependent differences in the time to detect changes in saturation during low perfusion. *Crit Care Med* 2001;29:A115.

12. Jay GD, Hughes L, Renzi FP. Pulse oximetry is accurate in acute anemia from hemorrhage. *Ann Emerg Med* 1994;24:32-35.

13. Ries AL, Prewitt LM, Johnson JJ. Skin color and ear oximetry. *Chest* 1989;96: 287-290.

14. Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturations. *Anesthesiology* 2005;102:715-719.

15. Chan ED. What is the effect of fingernail polish on pulse oximetry? *Chest* 2003;123:2163-2164.

16. Fu ES, Downs JB, Schweiger JW, et al. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. *Chest* 2004;126:1552-1558.

Venous Oximetry

17. Rivers EP, Ander DS, Powell D. Central venous oxygen saturation monitoring in the critically ill patient. *Curr Opin Crit Care* 2001;7:204-211.

18. Armaganidis A, Dhinaut JF, Billard JL, et al. Accuracy assessment for three fiberoptic pulmonary artery catheters for SvO₂ monitoring. *Intensive Care Med* 1994;20:484-488.

19. Noll ML, Fountain RL, Duncan CA, et al. Fluctuation in mixed venous oxygen saturation in critically ill medical patients: a pilot study. *Am J Crit Care* 1992;3:102-106.

20. Krafft P, Steltzer H, Heismay M, et al. Mixed venous oxygen saturation in critically ill septic shock patients. *Chest* 1993;103:900-906.

21. Dueck MH, Kilmek M, Appenrodt S, et al. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. *Anesthesiology* 2005;103: 249-257.

22. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004;32:858-873.
23. Bongard FS, Leighton TA. Continuous dual oximetry in surgical critical care. *Ann Surg* 1992;216:60-68.
- Colorimetric CO₂ Detection
24. Ornato JP, Shipley JB, Racht EM, et al. Multicenter study of a portable, hand-size, colorimetric end-tidal carbon dioxide detection device. *Ann Emerg Med* 1992;21:518-523.
25. Deem S, Bishop MJ. Evaluation and management of the difficult airway. *Crit Care Clin* 1995;11:1-27.
26. Mizutani AR, Ozake G, Benumoff JL, et al. Auscultation cannot distinguish esophageal from tracheal passage of tube. *J Clin Monit* 1991;7:232-236.
27. Preza-Araujo CE, Melhado ME, Guitierrez FJ, et al. Use of capnometry to verify feeding tube placement. *Crit Care Med* 2002;30:2255-2259.
- Infrared Capnography
28. Stock MC. Capnography for adults. *Crit Care Clin* 1995;11:219-232.
29. Gravenstein JS, Paulus DA, Hayes TJ. Capnography in clinical practice. Boston: Butterworth-Heinemann, 1989:11.
30. Moorthy SS, Losasso AM, Wilcox J. End-tidal PCO₂ greater than PaCO₂. *Crit Care Med* 1984;12:534-535.
31. Roy J, McNulty SE, Torjman MC. An improved nasal prong apparatus for end-tidal carbon dioxide monitoring in awake, sedated patients. *J Clin Monit* 1991;7:249-252.
32. Hoffman RA, Kreiger PB, Kramer MR, et al. End-tidal carbon dioxide in critically ill patients during changes in mechanical ventilation. *Am Rev Respir Dis* 1989;140:1265-1268.
33. Shibutani K, Shirasaki S, Braatz T, et al. Changes in cardiac output affect PETCO₂, CO₂ transport, and O₂ uptake during unsteady state in humans. *J Clin Monit* 1992;8:175-176.
34. Gandhi SK, Munshi CA, Bardeen-Henschel A. Capnography for detection of endobronchial migration of an endotracheal tube. *J Clin Monit* 1991;7: 35-38.
35. Rodger MA, Gwynne J, Rasuli P. Steady-state end-tidal alveolar dead space fraction and D-dimer: Bedside tests to exclude pulmonary embolism. *Chest* 2001;120:115-119.
36. Healey CJ, Fedullo AJ, Swinburne AJ, et al. Comparison of noninvasive measurements of carbon dioxide tension during weaning from mechanical ventilation. *Crit Care Med* 1987;15:764-767.
- Transcutaneous PCO₂
37. Bendjelid K, Schutz N, Stotz M, et al. Transcutaneous PCO₂ monitoring in critically ill adults: clinical evaluation of a new sensor. *Crit Care Med* 2005; 33:2203-2206.

Chapter 21

Oxygen Inhalation Therapy

References

The Need for Supplemental Oxygen

1. Small D, Duha A, Wiskopf B, et al. Uses and misuses of oxygen in hospitalized patients. *Am J Med* 1992;92:591-595.
2. Whalen WJ, Riley J. A microelectrode for measurement of intracellular PO₂. *J Appl Physiol* 1967;23:798-801.
3. Sair M, Etherington PJ, Winlove CP, Evans TW. Tissue oxygenation and perfusion in patients with systemic sepsis. *Crit Care Med* 2001;29:1343-1349.
4. Kallstrom TJ. AARC Clinical Practice Guideline: oxygen therapy for adults in the acute care facility: 2002 revision & update. *Respir Care* 2002;47:717-720.
5. Eldridge FE. Blood lactate and pyruvate in pulmonary insufficiency. *N Engl J Med* 1966;274:878-883.
6. Lundt T, Koller M, Kofstad J. Severe hypoxemia without evidence of tissue hypoxia in the adult respiratory distress syndrome. *Crit Care Med* 1984;12: 75-76.
7. Abdelsalam M. Permissive hypoxemia: Is it time to change our approach? *Chest* 2006;129:210-211.

The End-Point of Oxygen Inhalation

8. Corriveau ML, Rosen BJ, Dolan GF. Oxygen transport and oxygen consumption during supplemental oxygen administration in patients with chronic obstructive pulmonary disease. *Am J Med* 1989;87:633-636.

9. Lejeune P, Mols P, Naeije R, et al. Acute hemodynamic effects of controlled oxygen therapy in decompensated chronic obstructive pulmonary disease. *Crit Care Med* 1984;12:1032-1035.

10. Kavanaugh PB, Cheng DCH, Sandler AN, et al. Supplemental oxygen does not reduce myocardial ischemia in premedicated patients with critical coronary artery disease. *Anesth Analg* 1993;76:950-956.

11. Packer M, Lee WH, Medina N, Yushak M. Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. *Am J Cardiol* 1986;57:853-858.

12. Bongard O, Bounameaux H, Fagrell B. Effects of oxygen on skin microcirculation in patients with peripheral arterial occlusive disease. *Circulation* 1992; 86:878-886.

13. Daly WJ, Bondurant S. Effects of oxygen breathing on the heart rate, blood pressure and cardiac index of normal men—resting, with reactive hyperemia, and after atropine. *J Clin Invest* 1962;41:126-132.

Methods of Oxygen Inhalation

14. Vines DL, Shelledy DC, Peters J. Current respiratory care: Oxygen therapy, oximetry, bronchial hygiene. *J Crit Illness* 2000;15:507-515.

15. Shapiro BA, Kacmarek RM, Cane RD, et al. Clinical application of respiratory care. 4th ed. St. Louis: CV Mosby, 1991:123-134.

16. O'Connor BS, Vender JS. Oxygen therapy. *Crit Care Clin* 1995;11:67-78.

17. Scacci R. Air entrainment masks: jet mixing is how they work. The Bernoulli and Venturi principles is how they don't. *Respir Care* 1979;24:928-931.

The Dark Side of Oxygen

18. Halliwell B, Gutteridge JMC. Oxygen is a toxic gas: an introduction to oxygen toxicity and reactive oxygen species. In: *Free radicals in biology and medicine*. 3rd ed. Oxford: Oxford University Press, 1999:1-104.

19. Anderson BO, Brown JM, Harken A. Mechanisms of neutrophil-mediated tissue injury. *J Surg Res* 1991;51:170-179.

20. Fink M. Role of reactive oxygen and nitrogen species in acute respiratory distress syndrome. *Curr Opin Crit Care* 2002;8:6-11.

21. Alonso de Vega JM, Diaz J, Serrano E, Carbonell LF. Oxidative stress in critically ill patients with systemic inflammatory response syndrome. *Crit Care Med* 2002;30:1782-1788.

22. Halliwell B, Gutteridge JMC. Antioxidant defenses. In: *Free radicals in biology and medicine*. 3rd ed. Oxford: Oxford University Press, 1999:105-245.

23. Liochev SI, Fridovich I. The role of O₂• in the production of HO• in vitro and in vivo. *Free Radic Biol Med* 1994;16:29-33.

24. Michiels C, Raes M, Toussant O, et al. Importance of Se-glutathione, peroxidase, catalase, and CU/ZN-SOD for cell survival against oxidative stress. *Free Rad Biol Med* 1994;17:235-248.

25. Suttrop N, Toepfer W, Roka L. Antioxidant defense mechanisms of endothelial cells: glutathione redox cycle versus catalase. *Am J Physiol* 1986;251:C671-C680.

26. National Research Council. Subcommittee. On the tenth edition of the RDAs. 10th ed. Washington, DC: Academic Press, 1989:220.
27. Sando K, Hoki M, Nezu R, et al. Platelet glutathione peroxidase activity in long-term total parenteral nutrition with and without selenium supplementation. *J Parent Enteral Nutr* 1992;16:54-58.
28. World Health Organization. Selenium. Environmental Health Criteria 58. Geneva, Switzerland, 1987.
29. Meister A. On the antioxidant effects of ascorbic acid and glutathione. *Biochem Pharmacol* 1992;44:1905-1915.
30. Cantin AM, Begin R. Glutathione and inflammatory disorders of the lung. *Lung* 1991;169:123-138.
31. Robinson M, Ahn MS, Rounds JD, et al. Parenteral glutathione monoester enhances tissue antioxidant stores. *J Parent Enteral Nutr* 1992;16:413-418.
32. Meydani M. Vitamin E. *Lancet* 1995;345:170-176.
33. Pincemail J, Bertrand Y, Hanique G, et al. Evaluation of vitamin E deficiency in patients with adult respiratory distress syndrome. *Ann N Y Acad Sci* 1989; 570:498-500.
34. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease. *Methods Enzymol* 1990;186:1-85.
35. Herbert V, Shaw S, Jayatilleke E, et al. Most free-radical injury is iron-related: it is promoted by iron, hemin, haloferitin and vitamin C, and inhibited by desferrioxamine and apoferritin. *Stem Cells* 1994;12:289-303.
36. Fanburg BL. Oxygen toxicity: why can't a human be more like a turtle? *Intensive Care Med* 1988;3:134-136.
37. Lodato RF. Oxygen toxicity. *Crit Care Clin* 1990;6:749-765.
38. Barber RE, Hamilton WK. Oxygen toxicity in man. *N Engl J Med* 1970;283: 1478-1483.
39. Winter PM, Smith G. The toxicity of oxygen. *Anesthesiology* 1972;37:210-212.
40. Hawker FH, Stewart PM, Switch PJ. Effects of acute illness on selenium homeostasis. *Crit Care Med* 1990;18:442-446.
41. Pincemail J, Bertrand Y, Hanique G, et al. Evaluation of vitamin E deficiency in patients with adult respiratory distress syndrome. *Ann N Y Acad Sci* 1989; 570:498-500.

Chapter 22

Acute Respiratory Distress Syndrome

References

Reviews

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000;342:1334-1349.
2. Abraham E, Matthay MA, Dinarello C, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury and acute respiratory distress syndrome: time for a reevaluation. *Crit Care Med* 2000;28:232-235.
3. The Fourth Margaux Conference on Critical Illness. Acute lung injury: understanding mechanisms of injury and repair. *Crit Care Med* 2003;31(suppl):S183-S337.
- Pathogenesis
4. Petty TL. The acute respiratory distress syndrome: historical perspective. *Chest* 1994;105(suppl):44S-46S.
5. Abraham E. Neutrophils and acute lung injury. *Crit Care Med* 2003;31(suppl):S195-S199.

6. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. *Crit Care Med* 2003;31(suppl):S213-S220.

7. Hudson LD, Milberg JA, Anardi D, et al. Clinical risks for development of the acute respiratory distress syndrome. *Am Rev Respir Crit Care Med* 1995; 151:293-301.

Clinical Features

8. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am Rev Respir Crit Care Med* 1994;149:818-824.

9. Aberle DR, Brown K. Radiologic considerations in the adult respiratory distress syndrome. *Clin Chest Med* 1990;11:737-754.

10. Weiner-Kronish JP, Matthay MA. Pleural effusions associated with hydrostatic and increased permeability pulmonary edema. *Chest* 1988;93:852-858.

11. Idell S, Cohen AB. Bronchoalveolar lavage in patients with the adult respiratory distress syndrome. *Clin Chest Med* 1985;6:459-471.

12. Sprung CL, Long WM, Marcial EH, et al. Distribution of proteins in pulmonary edema: the value of fractional concentrations. *Am Rev Respir Dis* 1987;136:957-963.

Lung-Protective Ventilation

13. Rouby J-J, Puybasset L, Nieszkowska A, Lu Q. Acute respiratory distress syndrome: lessons from computed tomography of the whole lung. *Crit Care Med* 2003;31(suppl):S285-S295.

14. Dreyfuss D, Saumon G. Ventilator-induced lung injury. *Am J Respir Crit Care Med* 1998;157:294-323.

15. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 1999;282:54-61.

16. Ranieri VM, Giunta F, Suter P, et al. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. *JAMA* 2000;284:43-44.

17. Fan E, Needham DM, Stewart TE. Ventilator management of acute lung injury and acute respiratory distress syndrome. *JAMA* 2005;294:2889-2896.

18. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342: 1301-1308.

19. Bidani A, Tzouanakis AE, Cardenas VJ, et al. Permissive hypercapnia in acute respiratory failure. *JAMA* 1994;272:957-962.

20. Potkin RT, Swenson ER. Resuscitation from severe acute hypercapnia: determinants of tolerance and survival. *Chest* 1992;102:1742-1745.

21. Hickling KG, Walsh J, Henderson S, et al. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. *Crit Care Med* 1994;22:1568-1578.

22. Muscedere JG, Mullen JBM, Gan K, et al. Tidal ventilation at low airway pressures can augment lung injury. *Am J Respir Crit Care Med* 1994;149: 1327-1334.

23. The National Heart, Lung, and Blood Institute ARDS Clinical Network. Higher versus lower positive end-expiratory pressures in patients with acute respiratory distress syndrome. *N Engl J Med* 2004;351:327-336.

Fluid Management

24. Brower RG, Ware LB, Berthiaume Y, et al. Treatment of ARDS. *Chest* 2001; 120:1347-1367.

25. McIntyre RC Jr, Pulido EJ, Bensard DD, et al. Thirty years of clinical trials in acute respiratory distress syndrome. *Crit Care Med* 2000;28:3314–3331.

Promoting Oxygen Transport

26. Broaddus VC, Berthiaume Y, Biondi JW, et al. Hemodynamic management of the adult respiratory distress syndrome. *J Intensive Care Med* 1987;2:190–213.
27. Hebert PC, Blajchman MA, Cook DJ, et al. Do blood transfusions improve outcomes related to mechanical ventilation? *Chest* 2001;119:1850–1857.
28. Goodnough LT. Risks of blood transfusion. *Crit Care Med* 2003;31(suppl):S678–S686.

Pharmacotherapy

29. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with adult respiratory distress syndrome. *N Engl J Med* 1987;317:1565–1570.
30. Bone RC, Fischer CJ Jr, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. *Chest* 1987;92:1032–1036.
31. Meduri GU, Chinn A. Fibrinoproliferation in late adult respiratory distress syndrome. *Chest* 1994;105(suppl):127S–129S.
- A Case of Misdirection?
32. Montgomery AB, Stager MA, Carrico J, et al. Causes of mortality in patients with the adult respiratory distress syndrome. *Am Rev Respir Dis* 1985;132: 485–489.
33. Bartlett RH, Morris AH, Fairley B, et al. A prospective study of acute hypoxic respiratory failure. *Chest* 1986;89:684–689.
34. Gillespie DJ, Marsh HMM, Divertie MB, et al. Clinical outcome of respiratory failure in patients requiring prolonged (> 24 hours) mechanical ventilation. *Chest* 1986;90:364–369.
35. Suchyta MR, Clemmer TP, Elliott CG, et al. The adult respiratory distress syndrome: a report of survival and modifying factors. *Chest* 1992;101:1074–1079.
36. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005;353:1685–1693.

Chapter 23

Severe Airflow Obstruction

References

Clinical Practice Guidelines

1. National Asthma Education and Prevention Program Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication No. 97–4051, July, 1997. (Available at <http://www.nhlbi.nih.gov/guidelines/asthma>)
2. National Asthma Education and Prevention Program Expert Panel Report. Guidelines for the diagnosis and management of asthma. Update on selected topics, 2002. NIH Publication No. 02–5074, June, 2003. (Available at <http://www.nhlbi.nih.gov/guidelines/asthma>)

Bedside Monitoring

3. Shim CS, Williams MH. Evaluation of the severity of asthma: patients versus physicians. *Am J Med* 1980;68:11–13.
4. Tantucci C. The best peak expiratory flow is flow-limited and effort-independent in normal subjects. *Am J Respir Crit Care Med* 2002;165:1304–1308.
5. Leiner GC. Expiratory peak flow rate: Standard values from normal subjects. *Am Rev Respir Dis* 1963;88:644.
6. Hankinson J, Odencrantz J, Ferdan K. Spirometric reference values from a sample of the general U.S. population. *Am Rev Respir Crit Care Med* 1999; 159:179–187.
7. Quackenboss JJ, Lebowitz MD, Kryzhanowski M. The normal range of diurnal changes in peak expiratory flow rate. *Am Rev Respir Dis* 1991;143: 323–330.
8. Jain P, Kavuru MS, Emerman CL, et al. Utility of peak expiratory flow monitoring. *Chest* 1998;114:861–876.

9. Gay PC, Rodarte JR, Tayyab M, et al. Evaluation of bronchodilator responsiveness in mechanically ventilated patients. *Am Rev Respir Dis* 1987;136:880-885.
- Aerosol Drug Therapy
10. Kacmarek RM. Humidity and aerosol therapy. In: Pierson DJ, Kacmarek RM, eds. *Foundations of respiratory care*. New York: Churchill Livingstone, 1992: 793-824.
11. Clarke SW, Newman SP. Differences between pressurized aerosol and stable dust particles. *Chest* 1981;80(suppl):907-908.
12. Dutta EJ, Li JTC. β -agonists. *Med Clin North Am* 2002;86:991-1008.
13. Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma: metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. *Chest* 1993;103:665-672.
14. Dhand R, Tobin MJ. Pulmonary perspective: inhaled bronchodilator therapy in mechanically ventilated patients. *Am J Respir Crit Care Med* 1997;156: 3-10.
15. AARC Clinical Practice Guideline. Selection of device, administration of bronchodilator, and evaluation of response to therapy in mechanically ventilated patients. *Respir Care* 1999;44:105-113.
16. Mantous CA, Hall JB. Update on using therapeutic aerosols in mechanically ventilated patients. *J Crit Illness* 1996;11:457-468.
17. Smalldone GC. Aerosolized bronchodilators in the intensive care unit. *Am Rev Respir Crit Care Med* 1999;159:1029-1030.

Management of Acute Asthma

18. Shim C, Williams MH. Bronchial response to oral versus aerosol metaproterenol in asthma. *Ann Intern Med* 1980;93:428-431.
19. Salmeron S, Brochard L, Mal H, et al. Nebulized versus intravenous albuterol in hypercapnic acute asthma. *Am J Respir Crit Care Med* 1994;149:1466-1470.
20. Rubenfeld JMF, Georgas SN. The treatment of acute severe asthma in the adult: an overview. *Formulary* 2003;38:538-544.
21. Emerman CL, Cydulka RK, McFadden ER. Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. *Chest* 1999;115:92-96.
22. Rodrigo GJ, Rodrigo C. Continuous vs. intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analyses. *Chest* 2002;122:1982-1987.
23. Travers AH, Rowe BH, Barker S, et al. The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. *Chest* 2002;122:1200-1207.
24. Truwit JD. Toxic effect of bronchodilators. *Crit Care Clin* 1991;7:639-657.
25. Bodenhamer J, Bergstrom R, Brown D, et al. Frequently nebulized beta agonists for asthma: effects on serum electrolytes. *Ann Emerg Med* 1992;21:1337-1342.
26. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. *Ann Intern Med* 1989;110:426-429.
27. Rodrigo G, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. *Chest* 2002;121:1977-1987.
28. Kay AB. Asthma and inflammation. *J Allergy Clin Immunol* 1991;87:893-945.
29. Rodrigo G, Rodrigo C. Corticosteroids in the emergency department therapy of acute adult asthma: an evidence-based evaluation. *Chest* 1999;116:285-295.
30. Cydulka RK, Emerman CL. A pilot study of steroid therapy after emergency department treatment of acute asthma: is a taper needed? *J Emerg Med* 1998; 16:15-19.
31. Stein LM, Cole RP. Early administration of corticosteroids in emergency room treatment of asthma. *Ann Intern Med* 1990;112:822-827.
32. Bowler SD, Mitchell CA, Armstrong JG. Corticosteroids in acute severe asthma: effectiveness of low doses. *Thorax* 1992;47:584-587.
33. Morrell F, Orriols R, de Gracia J, et al. Controlled trial of intravenous corticosteroids in severe acute asthma. *Thorax* 1992;47:588-591.

34. Griffin D, Fairman N, Coursin D, et al. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. *Chest* 1992;102:510-514.
- Chronic Obstructive Pulmonary Disease
35. Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002;346:988-994.
36. Snow V, Lascher S, Mottur-Pilson C, for the Joint Expert Panel on COPD of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. The evidence base for management of acute exacerbations of COPD. *Chest* 2001;119:1185-1189.
37. McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. *Chest* 2001; 119:1190-1209.
38. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1999;340:1941-1947.
39. Sethi S. Acute exacerbations of COPD: a "multipronged" approach. *J Respir Dis* 2002;23:217-225.
40. Campbell EJM. The J. Burns Amberson Lecture: The management of acute respiratory failure in chronic bronchitis and emphysema. *Am Rev Respir Dis* 1967; 96:626-639.
41. Aubier M, Murciano D, Fournier M, et al. Central respiratory drive in acute respiratory failure or patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1980;122:191-199.

Chapter 24

Principles of Mechanical Ventilation

References

Reviews

1. Tobin MJ. Advances in mechanical ventilation. *N Engl J Med* 2001;344:1986-1996.
2. Fan E, Needham DM, Stewart TE. Ventilatory management of acute lung injury and acute respiratory distress syndrome. *JAMA* 2005;294:2889-2896.
3. Dreyfuss D, Saumon G. Ventilator-induced lung injury. *Am Rev Respir Crit Care Med* 1998;157:294-323.
- Cardiac Performance
4. Pinsky MR. Cardiovascular issues in respiratory care. *Chest* 2005;128:592S-597S.
5. Versprille A. The pulmonary circulation during mechanical ventilation. *Acta Anesthesiol Scand* 1990;34(suppl):51-62.
6. Venus B, Cohen LE, Smith RA. Hemodynamics and intrathoracic pressure transmission during controlled mechanical ventilation and positive end-expiratory pressure in normal and low compliant lungs. *Crit Care Med* 1988; 16:686-690.
7. Kiiski R, Takala J, Kari A, et al. Effect of tidal volume on gas exchange and oxygen transport in the adult respiratory distress syndrome. *Am Rev Respir Dis* 1992;146:1131-1135.
- Strategies for Mechanical Ventilation
8. Bendixen HH, Egbert LD, Hedley-White J, et al. *Respiratory care*. St. Louis: Mosby, 1965:137-153.
9. Ranieri VM, Giunta F, Suter P, et al. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. *JAMA* 2000;284:43-44.
10. Gattinoni L, Caironi P, Pelosi P, et al. What has computed tomography taught us about the acute respiratory distress syndrome? *Am J Respir Crit Care Med* 2001;164:1701-1711.
11. Costello ML, Mathieu-Costello OA, West JB. Stress failure of alveolar epithelial cells studied by scanning electron microscopy. *Am Rev Respir Dis* 1992;145:1446-1455.

12. Hotchkiss JR, Simonson DA, Marek DJ, et al. Pulmonary microvascular fracture in a patient with acute respiratory distress syndrome. *Crit Care Med* 2002;30:2368-2370.

13. Bray JC, Cane RD. Mechanical ventilatory support and pulmonary parenchymal injury: positive airway pressure or alveolar hyperinflation? *Intensive Crit Care Digest* 1993;12:33-36.

14. Timby J, Reed C, Zeilander S, et al. "Mechanical" causes of pulmonary edema. *Chest* 1990;98:973-979.

15. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342: 1301-1308.

16. Gajic O, Dara S, Mendez JL, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. *Crit Care Med* 2004;32:1817-1824.

17. Muscedere JG, Mullen JBM, Gan K, et al. Tidal ventilation at low airway pressures can augment lung injury. *Am J Respir Crit Care Med* 1994;149: 1327-1334.

18. O'Croinin D, Ni Chonghaile M, Higgins B, et al. Bench-to-bedside review: permissive hypercapnia. *Crit Care* 2005;9:51-59.

Monitoring Lung Mechanics

19. Tobin MJ. Respiratory monitoring. *JAMA* 1990;264:244-251.

20. Marini JJ. Lung mechanics determinations at the bedside: instrumentation and clinical application. *Respir Care* 1990;35:669-696.

21. Katz JA, Zinn SE, Ozanne GM, et al. Pulmonary, chest wall, and lung-thorax elastances in acute respiratory failure. *Chest* 1981;80:304-311.

22. Marini JJ. Strategies to minimize breathing effort during mechanical ventilation. *Crit Care Clin* 1990;6:635-662.

Chapter 25

Modes of Assisted Ventilation

References

Reviews

1. Tobin MJ. Advances in mechanical ventilation. *N Engl J Med* 2001;344:1986-1996.

2. Tobin MJ. Patient-ventilator interaction. *Am J Respir Crit Care Med* 2001; 163:1059-1063.

3. Branson RD. Functional principles of positive pressure ventilators: implications for patient-ventilator interaction. *Respir Care Clin North Am* 2005; 11:119-145.

Assist-Control Ventilation

4. Marini JJ, Capps JS, Culver BH. The inspiratory work of breathing during assisted mechanical ventilation. *Chest* 1985;87:612-618.

5. Fernandez R, Blanch L, Antigas A. Respiratory center activity during mechanical ventilation. *J Crit Care* 1991;6:102-111.

6. Izurieta R, Rabatin J. Sedation during mechanical ventilation: a systematic review. *Crit Care Med* 2002;30:2644-2648.

7. Leung P, Jubran A, Tobin MJ. Comparison of assisted ventilator modes on triggering, patients' effort, and dyspnea. *Am J Respir Crit Care Med* 1997;155:1940-1948.

8. Laureen H, Pearl R. Flow triggering, pressure triggering, and autotriggering during mechanical ventilation. *Crit Care Med* 2000;28:579-581.

Ventilator-Induced Lung Injury

9. Dreyfuss D, Saumon G. Ventilator-induced lung injury. *Am Rev Respir Crit Care Med* 1998;157:294-323.
10. Ranieri VM, Giunta F, Suter P, Slutsky AS. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. *JAMA* 2000;284:43-44.
11. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342: 1301-1308.
12. Gajic O, Dara S, Mendez JL, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. *Crit Care Med* 2004;32:1817-1824.

Intermittent Mandatory Ventilation

13. Sassoon CSH, Del Rosario N, Fei R, et al. Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work. *Crit Care Med* 1994;22:1933-1941.
14. Pinsky MR. Cardiovascular issues in respiratory care. *Chest* 2005;128(suppl):592S-597S.
15. Mathru M, et al. Hemodynamic responses to changes in ventilatory patterns in patients with normal and poor left ventricular reserve. *Crit Care Med* 1982; 10:423-426.

Pressure-Controlled Ventilation

16. Shelledy DC, Rau JL, Thomas-Goodfellow L. A comparison of the effects of assist-control, SIMV, and SIMV with pressure-support on ventilation, oxygen consumption, and ventilatory equivalent. *Heart Lung* 1995;24:67-75.
17. Rappaport SH, Shipner R, Yoshihara G, et al. Randomized, prospective trial of pressure-limited versus volume controlled ventilation in severe respiratory failure. *Crit Care Med* 1994;22:22-32.
18. Yang SC, Yang SP. Effects of inspiratory waveform on lung mechanics, gas exchange, and respiratory metabolism in COPD patients during mechanical ventilation. *Chest* 2002;122:2096-2104.

Inverse Ratio Ventilation

19. Marcy TW, Marini JJ. Inverse ratio ventilation in ARDS: rationale and implementation. *Chest* 1991;100:494-504.
20. Malarkkan N, Snook NJ, Lumb AB. New aspects of ventilation in acute lung injury. *Anesthesia* 2003;58:647-667.
21. Yanos J, Watling SM, Verhey J. The physiologic effects of inverse ratio ventilation. *Chest* 1998;114:834-838.
22. Wang SH, Wei TS. The outcome of early pressure-controlled inverse ratio ventilation on patients with severe acute respiratory distress syndrome in surgical intensive care unit. *Am J Surg* 2002;183:151-155.

Pressure-Support Ventilation

23. Hess DR. Ventilator waveforms and the physiology of pressure support ventilation. *Respir Care* 2005;50:166-186.
24. Hess DR. The evidence for noninvasive positive-pressure ventilation in the care of patients in acute respiratory failure: a systematic review of the literature. *Respir Care* 2004;49:810-829.

25. Caples SM, Gay PC. Noninvasive positive pressure ventilation in the intensive care unit: a concise review. *Crit Care Med* 2005;33:2651-2658.

Positive End-Expiratory Pressure

26. Barbas CSV, Lung recruitment maneuvers in acute respiratory distress syndrome and facilitating resolution. *Crit Care Med* 2003;31(suppl):S265-S271.

27. Gattinoni L, Cairon M, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006;354:1775-1786.

28. Schmitt J-M, Viellard-Baron A, Augarde R, et al. Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements. *Crit Care Med* 2001;29:1154-1158.

29. Takata M, Robotham JL. Ventricular external constraint by the lung and pericardium during positive end-expiratory pressure. *Am Rev Respir Dis* 1991; 43:872-875.

30. Gainnier M, Michelet P, Thirion X, et al. Prone position and positive end-expiratory pressure in acute respiratory distress syndrome. *Crit Care Med* 2003; 31:2719-2726.

31. Hawker FH, Torzillo PJ, Southee AE. PEEP and "reverse mismatch": a case where less PEEP is best. *Chest* 1991;99:1034-1036.

32. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med* 2004;351:327-336.

33. Petty TL. The use, abuse, and mystique of positive end-expiratory pressure. *Am Rev Respir Dis* 1988;138:475-478.

34. Saul GM, Freeley TW, Mihm FG. Effect of graded PEEP on lung water in noncardiogenic pulmonary edema. *Crit Care Med* 1982;10:667-669.

Continuous Positive Airway Pressure

35. Hess DR. Noninvasive positive-pressure ventilation and ventilator-associated pneumonia. *Respir Care* 2005;50:924-931.

36. Brochard L, Mancebo J, Elliott MW. Noninvasive ventilation for acute respiratory failure. *Eur Respir J* 2002;19:712-721.

37. Pack AI. Advances in sleep-disordered breathing. *Am J Respir Crit Care Med* 2006;173:7-15.

38. de Lucas P, Tarancon C, Puente L, et al. Nasal continuous positive airway pressure in patients with COPD in acute respiratory failure. *Chest* 1993;104:1694-1697.

39. Majid A, Hill NS. Noninvasive ventilation for acute respiratory failure. *Curr Opin Crit Care* 2005;11:77-81.

Chapter 26

The Ventilator-Dependent Patient

References

Reviews

1. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.1: Adjuncts for airway control and ventilation. *Circulation* 2005; 112 (Suppl I):IV51-IV57. (Available online @ http://www.circ.ahajournals.org/content/vol112/24_suppl/)
 2. Gray AW. Endotracheal tubes. *Crit Care Clin* 2003;24:379-387.
 3. Sue RD, Susanto I. Long-term complications of artificial airways. *Clin Chest Med* 2003;24:457-471.
 4. Heffner JE, Hess D. Tracheostomy management in the chronically ventilated patient. *Clin Chest Med* 2001;22:561-568.
- Endotracheal Intubation
5. Habib MP. Physiologic implications of artificial airways. *Chest* 1989;96:180-184.
 6. Goodman LR. Pulmonary support and monitoring apparatus. In: Goodman LR, Putman CE, eds. *Critical care imaging*. 3rd ed. Philadelphia: WB Saunders, 1992:35-59.
 7. Owen RL, Cheney FW. Endotracheal intubation: a preventable complication. *Anesthesiology* 1987;67:255-257.
 8. Rouby J-J, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. *Am J Respir Crit Care Med* 1994;150:776-783.
 9. van Zanten AR, Dixon JM, Nipshagen MD, et al. Hospital-acquired sinusitis is a common cause of fever of unknown origin in orotracheally intubated critically ill patients. *Crit Care* 2005;9:R583-R590.
 10. Gallagher TJ. Endotracheal intubation. *Crit Care Clin* 1992;8:665-676.
 11. Colice GL. Resolution of laryngeal injury following translaryngeal intubation. *Am Rev Respir Dis* 1992;145:361-364.
- Tracheostomy
12. Tracheotomy: application and timing. *Clin Chest Med* 2003;24:389-398.
 13. Estenssoro E, Dubin A, Laffaire E, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. *Crit Care Med* 2002;30:2450-2456.
 14. Ciaglia P. Technique, complications, and improvements in percutaneous dilatational tracheostomy. *Chest* 1999;115:1229-1230.
 15. Freeman BD, Isabella K, Lin N, et al. A meta-analysis of prospective trials comparing percutaneous and surgical tracheostomy in critically ill patients. *Chest* 2000;118:1412-1418.
 16. Elpern EH, Scott MG, Petro L, et al. Pulmonary aspiration in mechanically ventilated patients with tracheostomies. *Chest* 1994;105:563-566.
 17. Estes RJ, Meduri GU. The pathogenesis of ventilator-associated pneumonia: mechanisms of bacterial transcolonization and airway inoculation. *Intensive Care Med* 1995;21:365-383.
 18. Kearl RA, Hooper RG. Massive airway leaks: an analysis of the role of endotracheal tubes. *Crit Care Med* 1993;21:518-521.
- Clearing Secretions
19. Adair CG, Gorman SP, Feron BM, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. *Intensive Care Med* 1999;25: 1072-1076.
 20. Hagler DA, Traver GA. Endotracheal saline and suction catheters: sources of lower airways contamination. *Am J Crit Care* 1994;3:444-447.

21. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. *Clin Pharmacokinet* 1991;20:123-134.
- Alveolar Rupture
22. Gammon RB, Shin MS, Buchalter SE. Pulmonary barotrauma in mechanical ventilation. *Chest* 1992;102:568-572.
23. Marcy TW. Barotrauma: detection, recognition, and management. *Chest* 1993; 104:578-584.
24. Tocino IM, Miller MH, Fairfax WR. Distribution of pneumothorax in the supine and semirecumbent critically ill adult. *Am J Radiol* 1985;144:901-905.
25. Kam AC, O'Brien M, Kam PCA. Pleural drainage systems. *Anesthesia* 1993; 48:154-161.

Intrinsic PEEP

26. Pepe P, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction. *Am Rev Respir Dis* 1982;126: 166-170.
27. Blanch L, Bernabe F, Lucangelo U. Measurement of air trapping, intrinsic positive end-expiratory pressure, and dynamic hyperinflation in mechanically ventilated patients. *Respir Care* 2005;50:110-123.

28. Mughal MM, Culver DA, Minai OA, et al. Auto-positive end-expiratory pressure: mechanisms and treatment. *Cleve Clin J Med* 2005;72:801-809.

29. Shapiro JM. Management of respiratory failure in status asthmaticus. *Am J Respir Med* 2002;1:409-416.

30. Hough CL, Kallet RH, Ranieri M, et al. Intrinsic positive end-expiratory pressure in Acute Respiratory Distress Syndrome (ARDS) Network subjects. *Crit Care Med* 2005;33:527-532.

31. Rosengarten PL, Tuxen DV, Scheinkestel C, et al. Circulatory arrest induced by intermittent positive pressure ventilation in a patient with severe asthma. *Anesth Intensive Care* 1991;19:118-121.

32. Rogers PL, Schlichtig R, Miro A, et al. Auto-PEEP during CPR: an "occult" cause of electromechanical dissociation. *Chest* 1991;99:492-493.

33. Teboul J-L, Pinsky MR, Mercat A, et al. Estimating cardiac filling pressure in mechanically ventilated patients with hyperinflation. *Crit Care Med* 2000;28: 3631-3636.

34. Kress JP, O'Connor MF, Schmidt GA. Clinical examination reliably detects intrinsic positive end-expiratory pressure in critically ill, mechanically ventilated patients. *Am J Respir Crit Care Med* 1999;159:290-294.

35. Slutsky AS. Mechanical ventilation. *Chest* 1993;104:1833-1859.

36. Tobin MJ, Lodato RF. PEEP, auto-PEEP, and waterfalls. *Chest* 1989;96:449-451.

37. Caramaz MP, Borges JB, Tucci MR, et al. Paradoxical responses to positive end-expiratory pressure in patients with airway obstruction during controlled ventilation. *Crit Care Med* 2005;33:1519-1528.

Chapter 27

Discontinuing Mechanical Ventilation

References

Clinical Practice Guidelines

1. MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians, the American Association for Respiratory Care, and the American College of Critical Care Medicine. *Chest* 2001;120(suppl):375S-395S. Accessed in June, 2006 at http://www.chestjournal.org/cgi/content/full/120/6_suppl/375S.

Reviews

2. Epstein SK. Controversies in weaning from mechanical ventilation. *J Intensive Care Med* 2001;16:270-286.

3. Nevins ML, Epstein SK. Weaning from prolonged mechanical ventilation. *Clin Chest Med* 2001;22:13-33.

4. Scheinhorn DJ, Chao DC, Stearn-Hassenpflug M. Liberation from prolonged mechanical ventilation. *Crit Care Clin* 2002;18:569-595.

Readiness Criteria

5. MacIntyre NR. Respiratory mechanics in the patient who is weaning from the ventilator. *Respir Care* 2005;50:275-286.

6. Yang K, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. *N Engl J Med* 1991;324:1445-1450.

7. Kreiger BP, Isber J, Breitenbucher A, et al. Serial measurements of the rapid-shallow breathing index as a predictor of weaning outcome in elderly medical patients. *Chest* 1997;112:1029-1034.

8. Marini JJ, Smith TC, Lamb V. Estimation of inspiratory muscle strength in mechanically ventilated patients: the measurement of maximal inspiratory pressure. *J Crit Care* 1986;1:32-38.

Spontaneous Breathing Trial

9. Mehta S, Nelson DL, Klinger JR, et al. Prediction of post-extubation work of breathing. *Crit Care Med* 2000;28:1341-1346.

10. Bouley GH, Froman R, Shah H. The experience of dyspnea during weaning. *Heart Lung* 1992;21:471-476.

11. Mier-Jedrzejowicz A, Brophy C, Moxham J, et al. Assessment of diaphragm weakness. *Am Rev Respir Dis* 1988;137:877-883.

Failure of Spontaneous Breathing

12. Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. *N Engl J Med* 1995;332:345-350.

13. Ely W, Baker AM, Dunagen DP, et al. Effect of duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996;335:1864-1869.

14. Frutos-Vivar F, Esteban A. When to wean from a ventilator: an evidence-based strategy. *Cleve Clin J Med* 2003;70:389-397.

15. Pinsky MR. Cardiovascular issues in respiratory care. *Chest* 2005;128:592S-597S.

16. Nishimura Y, Maeda H, Tanaka K, et al. Respiratory muscle strength and hemodynamics in heart failure. *Chest* 1994;105:355-359.

17. Srivastava S, Chatila W, Amoaeng-Adjepong Y, et al. Myocardial ischemia and weaning failure in patients with coronary artery disease: an update. *Crit Care Med* 1999;27:2109-2112.

18. Park M, Sangean MC, Volpe M, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel airway pressure by face mask in acute cardiogenic pulmonary edema. *Crit Care Med* 2004;32: 2407-2415.

19. Talpers SS, Romberger DJ, Bunce SB, et al. Nutritionally associated increased carbon dioxide production. *Chest* 1992;102:551-555.

20. Vassilakopoulos T, Petrof BJ. Ventilator-induced diaphragmatic dysfunction. *Am Rev Respir Crit Care Med* 2004;169:336-341.

21. Fernandez R, Blanch L, Antigas A. Respiratory center activity during mechanical ventilation. *J Crit Care* 1991;6:102-111.
22. Hudson LD, Lee CM. Neuromuscular sequelae of critical illness. *N Engl J Med* 2003;348:745-747.
23. Benotti PN, Bistran B. Metabolic and nutritional aspects of weaning from mechanical ventilation. *Crit Care Med* 1989;17:181-185.
24. Malloy DW, Dhingra S, Solren F, et al. Hypomagnesemia and respiratory muscle power. *Am Rev Respir Dis* 1984;129:427-431.
- Tracheal Decannulation
25. Khamiees M, Raju P, DeGirolamo A, et al. Predictors of extubation outcome in patients who have successfully completed a spontaneous breathing trial. *Chest* 2001;120:1262-1270.
26. Chung Y-H, Chao T-Y, Chiu C-T, et al. The cuff-leak test is a simple tool to verify severe laryngeal edema in patients undergoing long-term mechanical ventilation. *Crit Care Med* 2006;34:409-414.
27. Kriner EJ, Shafazand S, Colice GL. The endotracheal tube cuff leak test as a predictor for postextubation stridor. *Respir Care* 2005;50:1632-1638.
28. Cheng K-C, Hou C-C, Huang H-C, et al. Intravenous injection of methylprednisolone reduces the incidence of post-extubation stridor in intensive care unit patients. *Crit Care Med* 2006;34:1345-1350.
29. Prinianakis G, Alexopoulou C, Mamidakis E, et al. Determinants of the cuff-leak test: a physiological study. *Crit Care* 2005;9:R24-R31.
30. Colice C, Stukel T, Dain B. Laryngeal complications of prolonged intubation. *Chest* 1989;96:877-884.
31. Shemie S. Steroids for anything that swells: dexamethasone and postextubation airway obstruction. *Crit Care Med* 1996;24:1613-1614.
32. Gaussorgues P, Boyer F, Piperno D, et al. Do corticosteroids prevent postintubation laryngeal edema? A prospective study of 276 adults. *Crit Care Med* 1988;16:649-652.
33. Kaplan JD, Schuster DP. Physiologic consequences of tracheal intubation. *Clin Chest Med* 1991;12:425-432.
34. Nutman J, Brooks LJ, Deakins K, et al. Racemic versus l-epinephrine aerosol in the treatment of postextubation laryngeal edema: results from a prospective, randomized, double-blind study. *Crit Care Med* 1994;22:1591-1594.

Chapter 28

Acid-Base Interpretations

References

Introduction

1. Gilfix BM, Bique M, Magder S. A physical chemical approach to the analysis of acid–base balance in the clinical setting. *J Crit Care* 1993;8:187–197.

Reviews

2. Narins RG, Emmett M. Simple and mixed acid–base disorders: a practical approach. *Medicine* 1980;59:161–187.

3. Morganroth ML. An analytical approach to diagnosing acid–base disorders. *J Crit Illness* 1990;5:138–150.

4. Whittier WL, Rutecki GW. Primer on clinical acid–base problem solving. *Dis Mon* 2004;50:117–162.

5. Casaletto JJ. Differential diagnosis of metabolic acidosis. *Emerg Med Clin North Am* 2005;23:771–787.

6. Kellum JA. Determinants of plasma acid–base balance. *Crit Care Clin* 2005; 21:329–346.

Selected References

7. Albert M, Dell R, Winters R. Quantitative displacement of acid–base equilibrium in metabolic acidosis. *Ann Intern Med* 1967;66:312–315.

8. Javaheri S, Kazemi H. Metabolic alkalosis and hypoventilation in humans. *Am Rev Respir Dis* 1987;136:1011–1016.

9. Emmet M, Narins RG. Clinical use of the anion gap. *Medicine* 1977;56:38–54.

10. Judge BS. Metabolic acidosis: differentiating the causes in the poisoned patient. *Med Clin North Am* 2005;89:1107–1124.

11. Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. *Arch Intern Med* 1990;150:311–313.

12. Kellum JA, Kramer DJ, Pinsky MJ. Closing the gap: a simple method of improving the accuracy of the anion gap. *Chest* 1996;110:185.

13. Figge J, Jabor A, Kazda A, Fencel V. Anion gap and hypoalbuminemia. *Crit Care Med* 1998;26:1807–1810.

14. Powner DJ, Kellum JA, Darby JM. Concepts of the strong ion difference applied to large volume resuscitation. *J Intensive Care Med* 2001;16:169–176.

15. Iberti TS, Liebowitz AB, Papadakos PJ, et al. Low sensitivity of the anion gap as a screen to detect hyperlactatemia in critically ill patients. *Crit Care Med* 1990;18:275–277.

16. Schwartz–Goldstein B, Malik AR, Sarwar A, Brandtsetter RD. Lactic acidosis associated with a normal anion gap. *Heart Lung* 1996;25:79–80.

17. Haber RJ. A practical approach to acid–base disorders. *West J Med* 1991;155: 146–151.

18. Paulson WD. Anion gap–bicarbonate relationship in diabetic ketoacidosis. *Am J Med* 1986;81:995–1000.

19. Weil MH, Rackow EC, Trevino R. Difference in acid–base state between venous and arterial blood during cardiopulmonary resuscitation. *N Engl J Med* 1986;315:153–156.

Chapter 29

Organic Acidoses

References

General Reviews

1. Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. *Crit Care Clin* 2002;18:289-308.
 2. Casaletto JJ. Differential diagnosis of metabolic acidosis. *Emerg Med Clin North Am* 2005;23:771-787.
 3. Judge BS. Metabolic acidosis: differentiating the causes in the poisoned patient. *Med Clin North Am* 2005;89:1107-1124.
- Lactic Acidosis
4. Mizock BA, Falk JL. Lactic acidosis in critical illness. *Crit Care Med* 1992;20: 80-93.
 5. Stacpoole PW. Lactic acidosis. *Endocrinol Metab Clin North Am* 1993;22:221-245.
 6. Aberti KGMM, Cuthbert C. The hydrogen ion in normal metabolism: a review. CIBA Foundation Symposium 87. Metabolic acidosis. London: Pitman Books, 1982;1-15.
 7. Lehninger AL. Bioenergetics. New York: WA Benjamin, 1965:16.
 8. Brooks GA. Lactate production under fully aerobic conditions: the lactate shuttle during rest and exercise. *Fed Proc* 1986;45:2924-2929.
 9. Weil MH, Afifi AA. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock). *Circulation* 1970;16:989-1001.
 10. Mizock BA. Metabolic derangements in sepsis and septic shock. *Crit Care Clin* 2000;16:319-336.
 11. Fink MP. Cytopathic hypoxia. *Crit Care Clin* 2001;17:219-238.
 12. Curtis SE, Cain SM. Regional and systemic oxygen delivery/uptake relations and lactate flux in hyperdynamic, endotoxin-treated dogs. *Am Rev Respir Dis* 1992;145:348-354.
 13. Campbell CH. The severe lactic acidosis of thiamine deficiency: acute, pernicious or fulminating beriberi. *Lancet* 1984;1:446-449.
 14. Yann-Erick C, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients and treatment with L-carnitine. *Crit Care Med* 2003;31:1042-1047.
 15. Wilson KC, Reardon C, Theodore AC, et al. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines. *Chest* 2005;128:1674-1681.
 16. Arrogia A, Shehab N, McCarthy K, et al. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. *Crit Care Med* 2004;32:1709-1714.
 17. Bersin RM, Arieff AI. Primary lactic alkalosis. *Am J Med* 1988;85:867-871.
 18. Kruse JA, Zaidi SAJ, Carlson RW. Significance of blood lactate levels in critically ill patients with liver disease. *Am J Med* 1987;83:77-82.
 19. Brivet F, Bernadin M, Cherin P, et al. Hyperchloremic acidosis during grand mal seizure acidosis. *Intensive Care Med* 1994;20:27-31.
 20. Mountain RD, Heffner JE, Brackett NC, et al. Acid-base disturbances in acute asthma. *Chest* 1990;98:651-655.
 21. Iberti TS, Liebowitz AB, Papadakos PJ, et al. Low sensitivity of the anion gap as a screen to detect hyperlactatemia in critically ill patients. *Crit Care Med* 1990;18:275-277.
 22. Anonymous. The colon, the rumen, and D-lactic acidosis. *Lancet* 1990;336:599-600 (editorial).
 23. Thurn JR, Pierpoint GL, Ludvigsen CW, et al. D-lactate encephalopathy. *Am J Med* 1985;79:717-720.
 24. Bustos D, Ponce S, Pernas JC, et al. Fecal lactate and the short bowel syndrome. *Dig Dis Sci* 1994;39:2315-2319.
- Alkali Therapy
25. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. *Chest* 2000;117:260-267.
 26. Sonnett J, Pagani FD, Baker LS, et al. Correction of intramyocardial hypercarbic acidosis with sodium bicarbonate. *Circ Shock* 1994;42:163-173.
 27. Mehta PM, Kloner RA. Effects of acid-base disturbance, septic shock, and calcium and phosphorous abnormalities on cardiovascular function. *Crit Care Clin* 1987;3:747-758.
 - 27a. Gores GJ, Nieminen AL, Fleischman KE, et al. Extracellular acidosis delays onset of cell death in ATP-depleted hepatocytes. *Am J Physiol* 1988; 255:C315-C322.
 - 27b. Graf H, Arieff AI. The use of sodium bicarbonate in the therapy of organic acidoses. *Intensive Care Med* 1986;12:286-288.
 28. Rhee KY, Toro LO, McDonald GG, et al. Carbicarb, sodium bicarbonate, and sodium chloride in hypoxic lactic acidosis. *Chest* 1993;104:913-918.
 29. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 4th ed. New York: McGraw-Hill, 1994;590.
- Diabetic Ketoacidosis

30. Charfen MA, Fernandez-Frackelton M. Diabetic ketoacidosis. *Emerg Med Clin North Am* 2005;23:609-628.
 31. Brandt KR, Miles JM. Relationship between severity of hyperglycemia and metabolic acidosis in diabetic ketoacidosis. *Mayo Clin Proc* 1988;63:1071-1074.
 32. Gamblin GT, Ashburn RW, Kemp DG, et al. Diabetic ketoacidosis presenting with a normal anion gap. *Am J Med* 1986;80:758-760.
 33. Kitabachi AE, Umpierrez GE, Murphy MB, et al. American Diabetes Association. hyperglycemic crisis in diabetes. *Diabetes Care* 2004;27(Suppl):S94-S102.
- Alcoholic Ketoacidosis**
34. Wrenn KD, Slovis CM, Minion GE, et al. The syndrome of alcoholic ketoacidosis. *Am J Med* 1991;91:119-128.
- Toxic Alcohols**
35. Watson WA, Litovitz TL, Klein-Schwartz W, et al. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. *Am J Emerg Med* 2004;22:335-404.
 36. Caravati EM, Erdman AR, Christianson G, et al. Ethylene glycol exposure: an evidence-based consensus guideline for out-of-hospital management. *Clin Toxicol* 2005;43:327-345.
 37. Weiner SW. Toxic alcohols. In Goldfrank LR, Flomenbaum NE, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 7th ed. New York: McGraw-Hill, 2002: 1447-1459.
 38. Gabow PA, Clay K, Sullivan JB, et al. Organic acids in ethylene glycol intoxication. *Ann Intern Med* 1986;105:16-20.
 39. Borkan SC. Extracorporeal therapies for acute intoxications. *Crit Care Clin* 2002;18:393-420.
 40. Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. *N Engl J Med* 1999;340:832-838.
 41. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. *J Toxicol Clin Toxicol* 2002;40:415-446.

Chapter 30

Metabolic Alkalosis

References

Reviews

1. Khanna A, Kurtzman NA. Metabolic alkalosis. *Respir Care* 2001;46:354-365.
2. Galla JH. Metabolic alkalosis. *J Am Soc Nephrol* 2000;11:360-375. (Available at <http://www.jasn.asnjournals.org/cgi/reprint/11/2/369>, Accessed June, 2006)
3. Androque HJ, Madias N. Management of life-threatening acid-base disorders. Part 2. *N Engl J Med* 1998;338:107-111

Selected References

4. Driscoll DF, Bistrian BR, Jenkins RL. Development of metabolic alkalosis after massive transfusion during orthotopic liver transplantation. *Crit Care Med* 1987;15:905-908.
5. Rose BD, Post TW. Metabolic alkalosis. In: *Clinical physiology of acid-base and electrolyte disorders*. 5th ed. New York: McGraw-Hill, 2001, pp 551-577.
6. Javaheri S, Kazemi H. Metabolic alkalosis and hypoventilation in humans. *Am Rev Respir Dis* 1987;136:1011-1016.
7. Rastegar HR, Woods M, Harken AH. Respiratory alkalosis increases tissue oxygen demand. *J Surg Res* 1979;26:687-692.
8. Whang R, Flink EB, Dyckner T, et al. Mg depletion as a cause of refractory potassium depletion. *Arch Intern Med* 1985;145:1686-1689.
9. Brimiouille S, Vincent JL, Dufaye P, et al. Hydrochloric acid infusion for treatment of metabolic alkalosis: effects on acid-base balance and oxygenation. *Crit Care Med* 1985;13:738-742.
10. Jankauskas SJ, Gursel E, Antonenko DR. Chest wall necrosis secondary to hydrochloric acid use in the treatment of metabolic alkalosis. *Crit Care Med* 1989;17:963-964.

11. Kopel R, Durbin CG. Pulmonary artery catheter deterioration during hydrochloric infusion for the treatment of metabolic alkalosis. *Crit Care Med* 1989; 17:688-689.

12. Marik PE, Kussman BD, Lipman J, Kraus P. Acetazolamide in the treatment of metabolic alkalosis in critically ill patients. *Heart Lung* 1991;20:455-458.

Chapter 31

Oliguria and Acute Renal Failure

References

Introduction

1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 2005;294:813-818.

Reviews

2. Bellomo R. Defining, quantifying, and classifying acute renal failure. *Crit Care Clin* 2005;21:223-237.

3. Abernathy VE, Lieberthal W. Acute renal failure in the critically ill patient. *Crit Care Clin* 2002;18:203-222.

4. Singri N, Ahya SN, Levin ML. Acute renal failure. *JAMA* 2003;289:747-751.

5. Klahr S, Miller SB. Acute oliguria. *N Engl J Med* 1998;338:671-675.

Evaluation of Oliguria

6. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32:858-873.

7. Steiner RW. Interpreting the fractional excretion of sodium. *Am J Med* 1984; 77:699-702.

8. Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.

Initial Management

9. Vincent J-L, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. *Crit Care Med* 2004;32(suppl):S451-S454.

10. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001;29:1526-1531.

11. Holmes CL, Walley KR. Bad medicine: low-dose dopamine in the ICU. *Chest* 2003;123:1266-1275.

12. Brater DC, Anderson SA, Brown-Cartwright D. Response to furosemide in chronic renal insufficiency: rationale for limited doses. *Clin Pharmacol Ther* 1986;40:134-139.

Specific Renal Disorders

13. Schrier RW, Wang W. Acute renal failure and sepsis. *N Engl J Med* 2004;351: 159-169.

14. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. *Crit Care Clin* 2000;16:337-352.

15. Pinsky MR, Vincent J-L, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. *Chest* 1993;103:565-575.

16. McCullough PA, Soman S. Contrast-induced nephropathy. *Crit Care Clin* 2005;21:261-280.

17. Liu R, Nair D, Ix J, et al. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. *J Gen Intern Med* 2005;20:193-200.

18. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med* 2006;354:2772-2782.

19. Taber SS, Mueller BA. Drug-associated renal dysfunction. *Crit Care Clin* 2006;22:357-374.

20. Ten RM, Torres VE, Millner DS, et al. Acute interstitial nephritis. *Mayo Clin Proc* 1988;3:921-930.

21. Beetham R. Biochemical investigation of suspected rhabdomyolysis. *Ann Clin Biochem* 2000;2000:37:581-587.

22. Sharp LS, Rozycki GS, Feliciano DV. Rhabdomyolysis and secondary renal failure in critically ill surgical patients. *Am J Surg* 2004;188:801-806.

23. Visweswaran P, Guntupalli J. Rhabdomyolysis. *Crit Care Clin* 1999;15:415-428.

Renal Replacement Therapy

24. O'Reilly P, Tolwani A. Renal replacement therapy III. IHD, CRRT, SLED. *Crit Care Clin* 2005;21:367-378.

25. Hernandez D, Diaz F, Rufino M, et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. *J Am Soc Nephrol* 1998;9: 1507-1511.

Chapter 32

Hypertonic and Hypotonic Conditions

References

Reviews

1. Verbalis JG. Disorders of body water homeostasis. *Best Pract Res Clin Endocrinol Metab* 2003;17:471-503.

2. Rose BD, Post TW. The total body water and the plasma sodium concentration. In: *Clinical physiology of acid-base and electrolyte disorders*. 5th ed. New York: McGraw-Hill, 2001: 241-257.

Basic Concepts

3. Gennari FJ. Current concepts: serum osmolality: uses and limitations. *N Engl J Med* 1984;310:102-105.

4. Erstad BL. Osmolality and osmolarity: narrowing the terminology gap. *Pharmacotherapy* 2003;23:1085-1086.

5. Turchin A, Seifter JL, Seely EW. Clinical problem-solving: mind the gap. *N Engl J Med* 2003;349:1465-1469.

6. Purssell RA, Lynd LD, Koga Y. The use of the osmole gap as a screening test for the presence of exogenous substances. *Toxicol Rev* 2004;23:189-202.

7. Sklar AH, Linas SL. The osmolal gap in renal failure. *Ann Intern Med* 1983;98:481-482.

Hypernatremia

8. Adroque HJ, Madias NE. Hypernatremia. *N Engl J Med* 2000;342:1493-1499.

9. McGee S, Abernethy WB 3rd, Simel DL. The rational clinical examination: Is this patient hypovolemic? *JAMA* 1999;281:1022-1029.

10. Arieff AI, Ayus JC. Strategies for diagnosing and managing hypernatremic encephalopathy. *J Crit Illness* 1996;11:720-727.

11. Rose BD, Post TW. Hyperosmolal states: hyperglycemia. In: *Clinical physiology of acid-base and electrolyte disorders*. 5th ed. New York: McGraw-Hill, 2001: 794-821.

12. Marino PL, Krasner J, O'Moore P. Fluid and electrolyte expert. Philadelphia: WB Saunders, 1987.
13. Makaryus AN, McFarlane SI. Diabetes insipidus: diagnosis and treatment of a complex disease. *Cleve Clin J Med* 2006;73:65–71.
14. Blevins LS Jr, Wand GS. Diabetes insipidus. *Crit Care Med* 1992;20:69–79.
15. Ghirardello S, Malattia C, Scagnelli P, et al. Current perspective on the pathogenesis of central diabetes insipidus. *J Pediatr Endocrinol Metab* 2005;18:631–645.
16. Geheb MA. Clinical approach to the hyperosmolar patient. *Crit Care Clin* 1987;3:797–815.
17. Garofeanu CG, Weir M, Rosas–Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. *Am J Kidney Dis* 2005;45:626–637.
18. Moran SM, Jamison RL. The variable hyponatremic response to hyperglycemia. *West J Med* 1985;142:49–53.
19. Ofra Y, Lavi D, Opher D, et al. Fatal voluntary salt intake resulting in the highest ever documented sodium plasma level in adults (255 mmol L⁻¹): a disorder linked to female gender and psychiatric disorders. *J Intern Med* 2004;256:525–528.

Hyponatremia

20. Adroque HJ, Madias NE. Hyponatremia. *N Engl J Med* 2000;342:1581–1589.
21. Dinger MN, Zazulia AR. Hyponatremia in neurologic patients: consequences and approaches to treatment. *Neurologist* 2006;12:117–126.
22. Tang WW, Kaptein EM, Feinstein EI, et al. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. *Am J Med* 1993;94:169–174.
23. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in the elderly: factors influencing prognosis. *J Gen Intern Med* 1994;9:89–91.
24. Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. *Ann Intern Med* 1992;117:891–897.
25. Weisberg LS. Pseudohyponatremia: a reappraisal. *Am J Med* 1989; 86:315–318.
26. Maesaka JK, Gupta S, Fishbane S. Cerebral salt-wasting syndrome: does it exist? *Nephron* 1999;82:100–109.
27. Ayus JC, Arieff AI. Pathogenesis and prevention of hyponatremic encephalopathy. *Endocrinol Metab Clin North Am* 1993;22:425–446.
28. Arieff AI, Ayus JC. Pathogenesis of hyponatremic encephalopathy: current concepts. *Chest* 1993;103:607–610.
29. Ayus JC, Arieff AI. Pulmonary complications of hyponatremic encephalopathy: noncardiogenic pulmonary edema and hypercapnic respiratory failure. *Chest* 1995;107:517–521.
30. Brunner JE, Redmond JM, Haggard AM, et al. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. *Ann Neurol* 1990;27:61–66.

Chapter 33

Potassium

References

Potassium Distribution

1. Rose BD, Post TW. Potassium homeostasis. In: *Clinical physiology of acid–base and electrolyte disorders*. 5th ed. New York: McGraw–Hill, 2001:372–402.
2. Halperin ML, Kamel KS. Potassium. *Lancet* 1998;352:135–140.

3. Schaefer TJ, Wolford RW. Disorders of potassium. *Emerg Med Clin North Am* 2005;23:723-747, viii-ix.
 4. Brown RS. Extrarenal potassium homeostasis. *Kidney Int* 1986;30:116-127.
 5. Sterns RH, Cox M, Feig PU, et al. Internal potassium balance and the control of the plasma potassium concentration. *Medicine* 1981;60:339-354.
- Hypokalemia
6. Glover P. Hypokalaemia. *Crit Care Resusc* 1999;1:239-251.
 7. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. *Kidney Int* 1990;38:869-872.
 8. Lipworth BJ, McDevitt DG, Struthers AD. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. *Am J Med* 1989;86:653-657.
 9. Adrogue HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. *Am J Med* 1981;71:456-467.
 10. Bernard SA, Buist M. Induced hypothermia in critical care medicine: a review. *Crit Care Med* 2003;31:2041-2051.
 11. Schaller MD, Fischer AP, Perret CH. Hyperkalemia: a prognostic factor during acute severe hypothermia. *JAMA* 1990;264:1842-1845.
 12. Salem M, Munoz R, Chernow B. Hypomagnesemia in critical illness: a common and clinically important problem. *Crit Care Clin* 1991;7:225-252.
 13. Flakeb G, Villarread D, Chapman D. Is hypokalemia a cause of ventricular arrhythmias? *J Crit Illness* 1986;1:66-74.
 14. Stanaszek WF, Romankiewicz JA. Current approaches to management of potassium deficiency. *Drug Intell Clin Pharm* 1985;19:176-184.
 15. Trissel LA. Handbook on injectable drugs. 13th ed. Bethesda, MD: American Society of Health System Pharmacists, 2005:1230.
 16. Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. *Arch Intern Med* 1990;150:613-617.
 17. Kim GH, Han JS. Therapeutic approach to hypokalemia. *Nephron* 2002;92 (suppl 1):28-32.
 18. Whang R, Flink EB, Dyckner T, et al. Magnesium depletion as a cause of refractory potassium repletion. *Arch Intern Med* 1985;145:1686-1689.
- Hyperkalemia
19. Williams ME. Endocrine crises: hyperkalemia. *Crit Care Clin* 1991;7:155-174.
 20. Evans KJ, Greenberg A. Hyperkalemia: a review. *J Intensive Care Med* 2005; 20:272-290.
 21. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. *Arch Intern Med* 1987;147:867-869.
 22. Don BR, Sebastian A, Cheitlin M, et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. *N Engl J Med* 1990;322:1290-1292.
 23. Medbo JI, Sejersted OM. Plasma potassium changes with high intensity exercise. *J Physiol* 1990;421:105-122.
 24. Williams ME, Rosa RM. Hyperkalemia: disorders of internal and external potassium balance. *J Intensive Care Med* 1988;3:52-64.
 25. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. *Am J Med* 2000;109:307-314.
 26. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004;351:585-592.

27. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. *Am J Med* 1995;98:575-586.
28. Greenberg S, Reiser IW, Chou SY, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. *Ann Intern Med* 1993;119:291-295.
29. Peltz S, Hashmi S. Pentamidine-induced severe hyperkalemia. *Am J Med* 1989;87:698-699.
30. Leveen HH, Pasternack HS, Lustrin I, et al. Hemorrhage and transfusion as the major cause of cardiac arrest. *JAMA* 1960;173:770-777.
31. Michael JM, Dorner I, Bruns D, et al. Potassium load in CPD-preserved whole blood and two types of packed red blood cells. *Transfusion* 1975;15:144-149.
32. Dreyfuss D, Jondeau G, Couturier R, et al. Tall T waves during metabolic acidosis without hyperkalemia: a prospective study. *Crit Care Med* 1989;17: 404-408.
33. Bosnjak ZJ, Lynch C, III. Cardiac electrophysiology. In: Yaksh T, Lynch C, III, Zapol WM, et al, eds. *Anesthesia: biologic foundations*. New York: Lippincott-Raven, 1998:1001-1040.
34. Blumberg A, Weidmann P, Shaw S, et al. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. *Am J Med* 1988;85:507-512.

Chapter 34

Magnesium

References

General Reviews

1. Noronha JL, Matuschak GM. Magnesium in critical illness: metabolism, assessment, and treatment. *Intensive Care Med* 2002;28:667-679.
2. Tong GM, Rude RK. Magnesium deficiency in critical illness. *J Intensive Care Med* 2005;20:3-17.
3. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. *Lancet* 1998;352: 391-396.
4. Rude RK, Shils ME. Magnesium. In: Shils ME, Shike M, Ross AC, et al. eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:223-247.
5. White RE, Hartzell HC. Magnesium ions in cardiac function: regulator of ion channels and second messengers. *Biochem Pharmacol* 1989;38:859-867.
6. McLean RM. Magnesium and its therapeutic uses: a review. *Am J Med* 1994; 96:63-76.
7. Marino PL. Calcium and magnesium in critical illness: a practical approach. In: Sivak ED, Higgins TL, Seiver A, eds. *The high risk patient: management of the critically ill*. Baltimore: Williams & Wilkins, 1995:1183-1195.

Magnesium Balance

8. Elin RJ. Assessment of magnesium status. *Clin Chem* 1987;33:1965-1970.
9. Reinhart RA. Magnesium metabolism: a review with special reference to the relationship between intracellular content and serum levels. *Arch Intern Med* 1988;148:2415-2420.
10. Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. *J Am Coll Nutr* 1986;5:399-414.
11. Altura BT, Altura BM. A method for distinguishing ionized, complexed and protein-bound Mg in normal and diseased subjects. *Scand J Clin Lab Invest* 1994;217:83-87.
12. Kroll MH, Elin RJ. Relationships between magnesium and protein concentrations in serum. *Clin Chem* 1985;31:244-246.
13. Alvarez-Leefmans FJ, Giraldez F, Gamino SM. Intracellular free magnesium in excitable cells: its measurement and its biologic significance. *Can J Physiol Pharmacol* 1987;65:915-925.
14. Munoz R, Khilnani P, Salem M. Ionized hypomagnesemia: a frequent problem in critically ill neonates. *Crit Care Med* 1991;19:S48.

Magnesium Depletion

15. Whang R. Magnesium deficiency: pathogenesis, prevalence, and clinical implications. *Am J Med* 1987;82:24-29.
16. Dyckner T, Wester PO. Potassium/magnesium depletion in patients with cardiovascular disease. *Am J Med* 1987;82:11-17.
17. Hollifield JW. Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity. *Am J Cardiol* 1989;63:22G-25G.
18. Ryan MP. Diuretics and potassium/magnesium depletion: directions for treatment. *Am J Med* 1987;82:38-47.
19. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. *Drug Safety* 2005;28:763-788.
20. Zaloga GP, Chernow B, Pock A, et al. Hypomagnesemia is a common complication of aminoglycoside therapy. *Surg Gynecol Obstet* 1984;158:561-565.
21. Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. *Arch Intern Med* 1985;145:655-656.
22. Balesteri FJ. Magnesium metabolism in the critically ill. *Crit Care Clin* 1985;5: 217-226.
23. Martin HE. Clinical magnesium deficiency. *Ann N Y Acad Sci* 1969;162:891-900.
24. Dyckner T, Ek B, Nyhlin H, et al. Aggravation of thiamine deficiency by magnesium depletion: a case report. *Acta Med Scand* 1985;218:129-131.
25. Kassirer J, Hricik D, Cohen J. *Repairing body fluids: principles and practice*. 1st ed. Philadelphia: WB Saunders, 1989:118-129.
26. Sjogren A, Floren CH, Nilsson A. Magnesium deficiency in IDDM related to level of glycosylated hemoglobin. *Diabetes* 1986;35:459-463.
27. Lau K. Magnesium metabolism: normal and abnormal. In: Arieff AI, DeFronzo RA, eds. *Fluids, electrolytes, and acid base disorders*. New York: Churchill Livingstone, 1985:575-623.
28. Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. *Arch Intern Med* 1987; 147:753-755.

Clinical Manifestations

29. Whang R, Oei TO, Aikawa JK, et al. Predictors of clinical hypomagnesemia: hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia. *Arch Intern Med* 1984;144:1794-1796.
30. Whang R, Flink EB, Dyckner T, et al. Magnesium depletion as a cause of refractory potassium repletion. *Arch Intern Med* 1985;145:1686-1689.
31. Anast CS, Winnacker JL, Forte LR, et al. Impaired release of parathyroid hormone in magnesium deficiency. *J Clin Endocrinol Metab* 1976;42:707-717.
32. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. *Clin Endocrinol* 1976;5:209-224.
33. Graber ML, Schulman G. Hypomagnesemic hypocalcemia independent of parathyroid hormone. *Ann Intern Med* 1986;104:804-805.
34. Dominguez JH, Gray RW, Lemann J Jr. Dietary phosphate deprivation in women and men: effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D. *J Clin Endocrinol Metab* 1976;43: 1056-1068.
35. Cohen L, Kitzes R. Magnesium sulfate and digitalis-toxic arrhythmias. *JAMA* 1983;249:2808-2810.
36. French JH, Thomas RG, Siskind AP, et al. Magnesium therapy in massive digoxin intoxication. *Ann Emerg Med* 1984;13:562-566.
37. Tzivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. *Am J Cardiol* 1990;65:1397-1399.

38. Langley WF, Mann D. Central nervous system magnesium deficiency. *Arch Intern Med* 1991;151:593-596.

Diagnosis

39. Fleming CR, George L, Stoner GL, et al. The importance of urinary magnesium values in patients with gut failure. *Mayo Clin Proc* 1996;71:21-24.

40. Clague JE, Edwards RH, Jackson MJ. Intravenous magnesium loading in chronic fatigue syndrome. *Lancet* 1992;340:124-125.

41. Hebert P, Mehta N, Wang J, et al. Functional magnesium deficiency in critically ill patients identified using a magnesium-loading test. *Crit Care Med* 1997;25:749-755.

Magnesium Replacement Therapy

42. DiPalma JR. Magnesium replacement therapy. *Am Fam Physician* 1990;42: 173-176.

43. Trissel LA. Handbook on injectable drugs. 13th ed. Bethesda, MD: American Social Health System Pharmacists, 2005.

44. Oster JR, Epstein M. Management of magnesium depletion. *Am J Nephrol* 1988;8:349-354.

Magnesium Accumulation

45. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia: requested vs routine. *JAMA* 1990;263:3063-3064.

46. Elin RJ. Magnesium metabolism in health and disease. *Dis Mon* 1988;34:161-218.

47. Van Hook JW. Hypermagnesemia. *Crit Care Clin* 1991;7:215-223.

48. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. *Am Heart J* 1984;108:188-193.

49. Mordes JP, Wacker WE. Excess magnesium. *Pharmacol Rev* 1977;29:273-300

Chapter 35

Calcium and Phosphorus

References

Calcium Reviews

1. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. *Lancet* 1998;352:306-311.

2. Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism, part I: physiology. *Crit Care Resusc* 2002;4:301-306.

3. Weaver CM, Heaney RP. Calcium. In: Shils ME, Shike M, Ross AC, et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:194-210.

Plasma Calcium

4. Slomp J, van der Voort PH, Gerritsen RT, et al. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. *Crit Care Med* 2003;31:1389-1393.

5. Koch SM, Warters RD, Mehlhorn U. The simultaneous measurement of ionized and total calcium and ionized and total magnesium in intensive care unit patients. *J Crit Care* 2002;17:203-205.

6. Byrnes MC, Huynh K, Helmer SD, et al. A comparison of corrected serum calcium levels to ionized calcium levels among critically ill surgical patients. *Am J Surg* 2005;189:310-314.

7. Forman DT, Lorenzo L. Ionized calcium: its significance and clinical usefulness. *Ann Clin Lab Sci* 1991;21:297-304.

Hypocalcemia

8. Zaloga GP. Hypocalcemia in critically ill patients. *Crit Care Med* 1992;20:251-262.

9. Burchard KW, Simms HH, Robinson A, et al. Hypocalcemia during sepsis: relationship to resuscitation and hemodynamics. *Arch Surg* 1992;127:265-272.

10. Steinberg W, Tenner S. Acute pancreatitis. *N Engl J Med* 1994;330:1198-1210.

11. Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism, part II: disorders. *Crit Care Resusc* 2002;4:307-315.

12. Zaloga G. Divalent cations: calcium, magnesium, and phosphorus. In: Chernow B, ed. *The pharmacologic approach to the critically ill patient*. 3rd ed. Baltimore: Williams & Williams, 1994:777-804.

13. Shapiro MJ, Mistry B. Calcium regulation and nonprotective properties of calcium in surgical ischemia. *New Horiz* 1996;4:134-138.

14. Trump BF, Berezesky IK. Calcium-mediated cell injury and cell death. *FASEB J* 1995;9:219-228.

15. Shek CC, Natkunam A, Tsang V, et al. Incidence, causes and mechanism of hypercalcaemia in a hospital population in Hong Kong. *Q J Med* 1990;77: 1277-1285.

16. Ziegler R. Hypercalcemic crisis. *J Am Soc Nephrol* 2001;12(suppl 17):S3-S9.

17. Stewart AF. Clinical practice: hypercalcemia associated with cancer. *N Engl J Med* 2005;352:373-379.

18. Knochel JP. Phosphorous. In: Shils ME, Shike M, Ross AC, et al., eds. *Modern nutrition in health and disease*. 10th ed Philadelphia: Williams & Williams, 2006:211-222.

Hypophosphatemia

19. Bugg NC, Jones JA. Hypophosphataemia: pathophysiology, effects and management on the intensive care unit. *Anaesthesia* 1998;53:895-902.

20. French C, Bellomo R. A rapid intravenous phosphate replacement protocol for critically ill patients. *Crit Care Resusc* 2004;6:175-179.

21. Fiaccadori E, Coffrini E, Fracchia C, et al. Hypophosphatemia and phosphorus depletion in respiratory and peripheral muscles of patients with respiratory failure due to COPD. *Chest* 1994;105:1392-1398.

22. Marinella MA. Refeeding syndrome and hypophosphatemia. *J Intensive Care Med* 2005;20:155-159.

23. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. *Clin Sci* 2000;98:619-625.

24. Bodenhamer J, Bergstrom R, Brown D, et al. Frequently nebulized beta-agonists for asthma: effects on serum electrolytes. *Ann Emerg Med* 1992;21:1337-1342.

25. Halevy J, Bulvik S. Severe hypophosphatemia in hospitalized patients. *Arch Intern Med* 1988;148:153-155.

26. Brown GR, Greenwood JK. Drug- and nutrition-induced hypophosphatemia: mechanisms and relevance in the critically ill. *Ann Pharmacother* 1994; 28:626-632.

27. King AL, Sica DA, Miller G, et al. Severe hypophosphatemia in a general hospital population. *South Med J* 1987;80:831-835.

28. Davis SV, Olichwier KK, Chakko SC. Reversible depression of myocardial performance in hypophosphatemia. *Am J Med Sci* 1988;295:183-187.
29. Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. *Am J Med* 1992;92:458-464.
30. Agusti AG, Torres A, Estopa R, et al. Hypophosphatemia as a cause of failed weaning: the importance of metabolic factors. *Crit Care Med* 1984;12:142-143.
31. Gravelyn TR, Brophy N, Siegert C, et al. Hypophosphatemia-associated respiratory muscle weakness in a general inpatient population. *Am J Med* 1988;84:870-876.
32. Clark CL, Sacks GS, Dickerson RN, et al. Treatment of hypophosphatemia in patients receiving specialized nutrition support using a graduated dosing scheme: results from a prospective clinical trial. *Crit Care Med* 1995;23:1504-1511.
33. Miller SJ, Simpson J. Medication-nutrient interactions: hypophosphatemia associated with sucralfate in the intensive care unit. *Nutr Clin Pract* 1991; 6:199-201.
34. Kraft MD, Btaiche IF, Sacks GS, et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. *Am J Health Syst Pharm* 2005;62: 1663-1682.
35. Lorenzo Sellares V, Torres Ramirez A. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly. *Drugs Aging* 2004;21:153-165.

Chapter 36

Anemia and Red Blood Cell Transfusions in the ICU

References

Introduction

1. Vincent JL, Baron J-F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. *JAMA* 2002;288:1499-1507.
2. Corwin HL, Gettinger A, Pearl R, et al. The CRIT study: anemia and blood transfusion in the critically ill: current clinical practice in the United States. *Crit Care Med* 2004;32:39-52.

Reviews

3. Ward NS, Levy MM. Blood transfusion practice today. *Crit Care Clin* 2004; 20:179-186.
4. Hebert PC, Van der Linden P, Biro G, et al. Physiologic aspects of anemia. *Crit Care Clin* 2004;20:187-212.
5. Hebert PC, McDonald BJ, Tinmouth A. Clinical consequences of anemia and red cell transfusion in the critically ill. *Crit Care Clin* 2004;20:225-235.
6. Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. *Crit Care Clin* 2004;20:237-253.

Anemia in the ICU

7. Jacob G, Raj SR, Ketch T, et al. Postural pseudoanemia: posture-dependent change in hematocrit. *Mayo Clin Proc* 2005;80:611-614.
8. Jones JG, Holland BM, Wardrop CAJ. Total circulating red cells versus hematocrit as a primary descriptor of oxygen transport by the blood. *Br J Haematol* 1990; 76:228-232.
9. Cordts PR, LaMorte WW, Fisher JB, et al. Poor predictive value of hematocrit and hemodynamic parameters for erythrocyte deficits after extensive elective vascular operations. *Surg Gynecol Obstet* 1992;175:243-248.
10. Walker RH (ed). American Association of Blood Banks technical manual. 10th ed. Arlington, VA: American Association of Blood Banks, 1990:37-58, 635-637, 649-651.
11. Finch CA. Red cell manual. 6th ed. Philadelphia: FA Davis, 1994:30-38.
12. Shander A. Anemia in the critically ill. *Crit Care Clin* 2004;20:159-178.

13. Stubbs JR. Alternatives to blood product transfusion in the critically ill: erythropoietin. *Crit Care Med* 2006;34(suppl):S160-S169.

14. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. *N Engl J Med* 1986;314:1233-1235.
15. Corwin HL, Parsonnet KC, Gettinger A, et al. RBC transfusion in the ICU: is there a reason? *Chest* 1995;108:767-771.
16. Silver MJ, Li Y-H, Gragg LA, et al. Reduction of blood loss from diagnostic sampling in critically ill patients using a blood-conserving arterial line system. *Chest* 1993;104:1711-1715.
17. Wilkerson DK, Rosen AL, Gould SA, et al. Oxygen extraction ratio: a valid indicator of myocardial metabolism in anemia. *J Surg Res* 1987;42:629-634.
18. Levine E, Rosen A, Sehgal L, et al. Physiologic effects of acute anemia: implications for a reduced transfusion trigger. *Transfusion* 1990;30:11-14.

19. Weiskopf RB, Viele M, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe, isovolemic anemia. *JAMA* 1998;279:217-221.

20. Hansen ES, Gellett S, Kirkegard L, et al. Tissue oxygen tension in random pattern skin flaps during normovolemic hemodilution. *J Surg Res* 1989; 47:24-29.

Erythrocyte Transfusions

21. Adam RC, Lundy JS. Anesthesia in cases of poor risk: some suggestions for decreasing the risk. *Surg Gynecol Obstet* 1942;74:1011-1101.
22. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med* 1999; 340:409-417.
23. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? *Crit Care Med* 2001;29:227-234.
24. Consensus Conference on Perioperative Red Blood Cell Transfusion. *JAMA* 1988;260:2700-2702.
25. American College of Physicians. Practice strategies for elective red blood cell transfusion: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 1992;116:403-406.
26. Levy PS, Chavez RP, Crystal GJ, et al. Oxygen extraction ratio: a valid indicator of transfusion need in limited coronary vascular reserve? *J Trauma* 1992;32:769-774.
27. Shah DM, Gottlieb M, Rahm R, et al. Failure of red cell transfusions to increase oxygen transport or mixed venous PO₂ in injured patients. *J Trauma* 1982; 22:741-746.
28. Silverman H, Tuma P. Gastric tonometry in patients with sepsis: effects of dobutamine and packed red cell transfusions. *Chest* 1992;102:184-188.
29. Marik PE, Sibbald W. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. *JAMA* 1993;269:3024-3029.

30. Robbins JM, Keating K, Orlando R, et al. Effects of blood transfusion on oxygen delivery and consumption in critically ill surgical patients. *Contemp Surg* 1993;43:281–285.
31. Davies SC. Transfusion of red cells. In: Contreras M, ed. *ABCs of transfusion*. London: British Medical Journal, 1990:9–13.
32. Dula DJ, Muller A, Donovan SW. Flow rate variance of commonly used IV infusion techniques. *J Trauma* 1981;21:480–482.
33. Blood Transfusion Practice. In: American Association of Blood Banks technical manual. 10th ed. Arlington, VA: American Association of Blood Banks, 1990:341–375.
34. Kruskall MS, Bergen JJ, Klein HG, et al. Transfusion therapy in emergency medicine. *Ann Emerg Med* 1988;17:327–335.
35. Iserson KV, Huestis DW. Blood warming: current applications and techniques. *Transfusion* 1991;31:558–571.
36. Uhl L, Pacini D, Kruskall MS. A comparative study of blood warmer performance. *Anesthesiology* 1992;77:1022–1028.
37. Kuriyan M, Carson JL. Blood transfusion risks in the intensive care unit. *Crit Care Clin* 2004;20:237–253.
38. Goodnough LT. Risks of blood transfusion. *Crit Care Med* 2003;31:S678–S686.
39. Greenberger PA. Plasma anaphylaxis and immediate-type reactions. In: Rossi EC, Simon TL, Moss GS, eds. *Principles of transfusion medicine*. Philadelphia: Williams & Wilkins, 1991:635–639.
40. Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. *Crit Care Med* 2006;34(suppl):S114–S117.
41. Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. *Crit Care Med* 2006;34(suppl):S118–S123.
42. Vamvakas EC. Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRM). *Crit Care Med* 2006;34(suppl):S151–S159.

Blood Conservation in the ICU

43. Ward HB, Smith RR, Landis KP, et al. Prospective, randomized trial of autotransfusion after routine cardiac operations. *Ann Thorac Surg* 1993;56:137–141.
44. Roberts SR, Early G, Brown B, et al. Autotransfusion of unwashed mediastinal shed blood fails to decrease banked blood requirements in patients undergoing aortocoronary bypass surgery. *Am J Surg* 1991;162:477–480.
45. Stubbs JR. Alternatives to blood product transfusion in the critically ill: erythropoietin. *Crit Care Med* 2006;34(suppl):S160–S169.

1. DeLoughery TG. Critical care clotting catastrophies. *Crit Care Clin* 2005;21:531-562.
2. Delinas J-P, Stoddart LV, Snyder EL. Thrombocytopenia and critical care medicine. *J Intensive Care Med* 2001;16:1-21.
3. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol* 2001;19:1519-1538.

Platelets and Hemostasis

4. Tomer A, Harker LA. Megakaryocytopoiesis and platelet kinetics. In: Rossi EC, Simon TL, Moss GS, eds. *Principles of transfusion therapy*. Baltimore: Williams & Wilkins, 1991:167-179.
5. American Association of Blood Banks. *Technical Manual*, 10th ed. Arlington, VA: American Association of Blood Banks, 1990:649.
6. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. *Clin Haematol* 1978;7:523-527.
7. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. *Mayo Clin Proc* 1984;59:123-125.
8. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. *Semin Thromb Hemost* 1990;16:1-20.
- Thrombocytopenia
9. Stephan F, Hollande J, Richard O, et al. Thrombocytopenia in a surgical ICU. *Chest* 1999;115:1363-1379.
10. Strauss R, Wehler M, Mehler K, et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. *Crit Care Med* 2002;30:1765-1771.

11. Warkentin TE, Cook DJ. Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU. *Crit Care Clin* 2005;21:513-529.

12. Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. *J Vasc Surg* 1988;7:667-672.

13. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. *Chest* 2005;127(suppl):35S-45S.

14. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. *Circulation* 1999;100:587-593.

15. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. *Chest* 2005;127(suppl):1S-8S.

16. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. *Chest* 2006;129:1167-1175.

17. Francois B, Trimoreau F, Vignon P, et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating hormone. *Am J Med* 1997;103:114-120.

18. Doweiko JP, Groopman JE. Hematologic consequences of HIV infection. In: Broder S, Merigan TC, Bolognesi D, eds. *Textbook of AIDS medicine*. Baltimore: Williams & Wilkins, 1994:617-628.
21. Senno SL, Pechet L, Bick RL. Disseminated intravascular coagulation (DIC): pathophysiology, laboratory diagnosis, and management. *J Intensive Care Med* 2000;15:144-158.

19. Angstwurm MWA, Dempfle C-E, Spannagl M. New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with Acute Physiology And Chronic Health Evaluation II And Logistic Organ Dysfunction Scores. *Crit Care Med* 2006;34:314-320.

20. Clark J, Rubin RN. A practical approach to managing disseminated intravascular coagulation. *J Crit Illness* 1994;9:265-280.
22. Fourrier F, Chopin C, Huart J-J, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. *Chest* 1993;104:882-888.
23. Rock GA, Shumack KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenia purpura. *N Engl J Med* 1991;325:393-397.
24. Hayward CP, Sutton DMC, Carter WH Jr, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. *Arch Intern Med* 1994;154:982-987.
25. Reiner A, Kickler TS, Bell W. How to administer massive transfusions effectively. *J Crit Illness* 1987;2:15-24.
26. Heffner JE. What caused post-op thrombocytopenia in this 82 year-old man? *J Crit Illness* 1996;11:666-671.
27. Magann EF, Martin JN. Twelve steps to optimal management of HELLP syndrome. *Clin Obstet Gynecol* 1999;42:532-550.

Abnormal Platelet Function

28. Salman S. Uremic bleeding: pathophysiology, diagnosis, and management. *Hosp Physician* 2001;37:45-76.
 29. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. *Blood* 1997;90:2515-2521.
 30. Vigano G, Gaspari F, Locatelli M, et al. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. *Kidney Int* 1988;34:853-858.
 31. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. *N Engl J Med* 1991;324:27-39.
- #### Platelet Transfusions
32. Lundberg GD. Practice parameter for the use of fresh frozen plasma, cryoprecipitate, and platelets. *JAMA* 1994;271:777-781.
 33. Doerfler ME, Kaufman B, Goldenberg AS. Central venous catheter placement in patients with disorders of hemostasis. *Chest* 1996;110:185-188.
 34. DeLoughery TG, Liebler JM, Simonds V, et al. Invasive line placement in critically ill patients: do hemostatic defects matter? *Transfusion* 1996;36:827-831.

Chapter 38

Hyperthermia and Hypothermia Syndromes

References

Mechanisms of Heat Exchange

1. Keel CA, Neil E, Joels N. Regulation of body temperature in man. In: Samson Wright's applied physiology, 13th ed. New York: Oxford University Press, 1982:346.
2. Guyton AC, Hall JE. Body temperature, temperature regulation, and fever. In: Medical physiology, 10th ed. Philadelphia: WB Saunders, 2000:822-833.

Heat-Related Illness

3. Khosla R, Guntupalli KK. Heat-related illnesses. *Crit Care Clin* 1999;15:251-263.
4. Lugo-Amador NM, Rothenhaus T, Moyer P. Heat-related illness. *Emerg Med Clin North Am* 2004;22:315-327.
5. Glazer JL. Management of heat stroke and heat exhaustion. *Am Fam Physician* 2005;71:2133-2142.

6. Hadad E, Rav-Acha M, Heled Y, et al. Heat stroke: a review of cooling methods. *Sports Med* 2004;34:501-511.

7. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. *Arch Intern Med* 1988;148:1553-1557.

8. Visweswaran P, Guntupalli J. Rhabdomyolysis. *Crit Care Clin* 1999;15:415-429.

Malignant Hyperthermia

9. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. *Med Clin North Am* 2005;89:1277-1296.

10. Litman RS, Rosenberg H. Malignant hyperthermia. *JAMA* 2005;293:2918-2924.

11. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2001:1328-1331.

Neuroleptic Malignant Syndrome

12. Bhanushali NJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. *Neurol Clin North Am* 2004;22:389-411.

13. Khaldarov V. Benzodiazepines for treatment of neuroleptic malignant syndrome. *Hosp Physician* 2000;36:51-55.

14. Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? *Br J Psychiatry* 1991;158:850-853.

15. Lev R, Clark RF. Neuroleptic malignant syndrome presenting without fever: case report and review of the literature. *J Emerg Med* 1996;12:49-55.

16. Guze BH, Baxter LR. Neuroleptic malignant syndrome. *N Engl J Med* 1985; 313:163-166.

Serotonin Syndrome

17. Boyer EH, Shannon M. The serotonin syndrome. *N Engl J Med* 2005;352:1112-1120.

18. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. *Clin Neuropharmacol* 1996;19:157-164.

19. Hick JL, Smith SW, Lynch MT. Metabolic acidosis in restraint-associated cardiac arrest. *Acad Emerg Med* 1999;6:239-245.

20. Graudins A, Stearman A, Chan B. Treatment of serotonin syndrome with cyproheptadine. *J Emerg Med* 1998;16:615-619.

Hypothermia Syndromes

21. Hanania NA, Zimmerman NA. Accidental hypothermia. *Crit Care Clin* 1999; 15:235-249.

22. Aslam AF, Aslam AK, Vasavada BC, et al. Hypothermia: evaluation: electrocardiographic manifestations, and management. *Am J Med* 2006;119:297-301.

23. Cornell HM. Hot topics in cold medicine: controversies in accidental hypothermia. *Clin Pediatr Emerg Med* 2001;2:179-191.

24. Vassal T, Bernoit-Gonin B, Carrat F, et al. Severe accidental hypothermia treated in an ICU. *Chest* 2001;120:1998-2003.

25. Ireland AJ, Pathi VL, Crawford R, et al. Back from the dead: extracorporeal rewarming of severe accidental hypothermia victims in accidental emergency. *J Accid Emerg Med* 1997;14:255-303.

26. Handrigen MT, Wright RO, Becker BM, et al. Factors and methodology in achieving ideal delivery temperatures for intravenous and lavage fluid in hypothermia. *Am J Emerg Med* 1997;15:350-359.

Chapter 39

Fever in the ICU

References

Reviews

1. O'Grady NP, Barie PS, Bartlett J, et al. Practice parameters for evaluating new fever in critically ill adult patients. *Crit Care Med* 1998;26:392-408. (Also available at <http://www.sccm.org/publications/index.asp>)
2. Marik PE. Fever in the ICU. *Chest* 2000;117:855-869.

Body Temperature

3. Stimson HF. Celsius versus centigrade: the nomenclature of the temperature scale of science. *Science* 1962;136:254-255.
 4. Wunderlich CA, Sequine E. Medical thermometry and human temperature. New York: William Wood, 1871.
 5. Mellors JW, Horwitz RI, Harvey MR, et al. A simple index to identify occult bacterial infection in adults with acute unexplained fever. *Arch Intern Med* 1987;147:666-671.
 6. Tandberg D, Sklar D. Effect of tachypnea on the estimation of body temperature by an oral thermometer. *N Engl J Med* 1983;308:945-946.
 7. Marion GS, McGann KP, Camp DL. Core body temperature in the elderly and factors which influence its measurement. *Gerontology* 1991;37:225-232.
 8. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6°F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. *JAMA* 1992;268:1578-1580.
 9. Amoateng-Adjepong Y, Del Mundo J, Manthous CA. Accuracy of an infrared tympanic thermometer. *Chest* 1999;115:1002-1005.
 10. Giuliano KK, Scott SS, Elliot S, et al. Temperature measurement in critically ill orally intubated adults: a comparison of pulmonary artery core, tympanic, and oral methods. *Crit Care Med* 1999;27:2188-2193.
 11. Erickson RS. The continuing question of how best to measure body temperature. *Crit Care Med* 1999;27:2307-2310.
 12. Saper CB, Breder CB. The neurologic basis of fever. *N Engl J Med* 1994;330: 1880-1886.
 13. Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. *Intensive Care Med* 1999;25:668-673.
 14. Commichau C, Scarneas N, Mayer SA. Risk factors for fever in the intensive care unit. *Neurology* 2003; 60:837-841.
- #### **Noninfectious Causes of Fever**
15. Fry DE. Postoperative fever. In: Mackowiak PA, ed. *Fever: basic mechanisms and management*. New York: Raven Press, 1991:243-254.
 16. Freischlag J, Busuttill RW. The value of postoperative fever evaluation. *Surgery* 1983;94:358-363.
 17. Engoren M. Lack of association between atelectasis and fever. *Chest* 1995; 107:81-84.

18. Shelds RT. Pathogenesis of postoperative pulmonary atelectasis: an experimental study. *Arch Surg* 1949;48:489-503.
19. Meyers JK, Lembeck L, O'Kane H, et al. Changes in functional residual capacity of the lung after operation. *Arch Surg* 1975;110:576-583.
20. Warlittier DC. Pulmonary atelectasis. *Anesthesiology* 2005;102:838-854.
21. Pollack VE. Adverse effects and pyrogenic reactions during hemodialysis. *JAMA* 1988;260:2106-2107.
22. Um SW. Prospective analysis of clinical characteristics and risk factors for postbronchoscopy fever. *Chest* 2004;125:945-952.
23. Spach DH, Silverstein FE, Stamm WE. Transmission of infection by gastrointestinal endoscopy and bronchoscopy. *Ann Intern Med* 1993;118:117-128.
24. Murray HW, Ellis GC, Blumenthal DS, et al. Fever and pulmonary thrombo-embolism. *Am J Med* 1979;67:232-235.
25. Walden DT, Urrutia F, Soloway RD. Acute acalculous cholecystitis. *J Intensive Care Med* 1994;9:235-243.
26. Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. *Ann Intern Med* 1987;106:728-733.
27. Cunha B. Drug fever: the importance of recognition. *Postgrad Med* 1986;80: 123-129.
28. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). *JAMA* 1995;273:117-123.
29. Gonzalez EB, Suarez L, Magee S. Nosocomial (water bed) fever [Letter]. *Arch Intern Med* 1990;150:687.

Nosocomial Infections

30. Richards MJ, Edwards JR, Culver DH, et al. The National Nosocomial Infections Surveillance System: nosocomial infections in combined medical-surgical intensive care units in the United States. *Infect Control Hosp Epidemiol* 2000;21:510-515.
31. Richards MJ, Edwards JR, Culver DH, et al. The National Nosocomial Infection Surveillance System: nosocomial infections in medical intensive care units in the United States. *Crit Care Med* 1999;27:887-892.
32. American Thoracic Society and the Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
33. Ehrenkrantz NJ, Meakins JL. Surgical infections. In: Bennet JV, Brachman PS, eds. *Hospital infections*, 3rd ed. Boston: Little, Brown, 1992:685-710.
34. Loopp FD, Lytle BW, Cosgrove DM, et al. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. *Ann Thorac Surg* 1990;49:179-187.
35. Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. *Crit Care Med* 1993;21: 1132-1138.
36. Rouby J-J, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. *Am Rev Respir Dis* 1994; 150:776-783.

37. Williams JW, Jr., Roberts L, Jr., Distell B, et al. Diagnosing sinusitis by x ray: is a single Waters view adequate? *J Gen Intern Med* 1992;7:481-485.
38. Roberts DN, Hampal S, East CA, et al. The diagnosis of inflammatory sinonasal disease. *J Laryngol Otol* 1995;109:27-30.
39. Kelley CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. *N Engl J Med* 1994;330:257-262.
40. Stilwell M, Caplan ES. The septic multiple-trauma patient. *Crit Care Clin* 1988;4:345-373.
- Early Management Decisions
41. Aronson MD, Bor DH. Blood cultures. *Ann Intern Med* 1987;106:246-253.
42. Hughes WH, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34.
43. van Oss CJ, Absolom DR, Moore LL, et al. Effect of temperature on the chemotaxis, phagocytic engulfment, digestion, and O₂ consumption of human polymorphonuclear leukocytes. *J Reticuloendothel Soc* 1980;27:561-565.
44. Azocar J, Yunis EJ, Essex M. Sensitivity of human natural killer cells to hyperthermia. *Lancet* 1982;1:16-17.
45. Small PM, Tauber MG, Hackbarth CJ, et al. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. *Infect Immun* 1986;52:484-487.
46. Clemmer TP, Fisher CJ, Bone RC, et al. Hypothermia in the sepsis syndrome and clinical outcome. *Crit Care Med* 1990;18:801-806.
47. Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. *Crit Care Med* 1999;27:699-707.
48. Kim Y, Busto R, Dietrich WD, et al. Delayed postischemic hyperthermia in awake rats worsens the histopathological outcome of transient focal cerebral ischemia. *Stroke* 1996;27:2274-2281.
49. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. *Stroke* 2000;31:410-414.
50. Plaisance KI, Mackowiak PA. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. *Arch Intern Med* 2000;160: 449-456.
51. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. *N Engl J Med* 1997;336:912-918.

Chapter 40

Infection, Inflammation, and Multiorgan Injury

References

Reviews

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32:858-873.
 2. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. *Crit Care Med* 2004;32:1928-1948.
 3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101: 1644-1655.
- Inflammatory Injury

4. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. *Intensive Care Med* 1995;21:277-285.
5. Pinsky MR, Matuschak GM. Multiple systems organ failure: failure of host defense mechanisms. *Crit Care Clin* 1989;5:199-220.
6. Pinsky MR, Vincent J-L, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. *Chest* 1993;103:565-575.
7. Pittet D, Rangel-Frausto S, Li N, et al. Systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock: incidence, morbidities and outcomes in surgical ICU patients. *Intensive Care Med* 1995;21:302-309.
8. Rangel-Frausto MS, Pittet D, Costigan M, et al. Natural history of the systemic inflammatory response syndrome (SIRS). *JAMA* 1995;273:117-123.
9. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303-1310.
10. Vincent J-L, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. *Crit Care Med* 1998;26:1793-1800.

Management of Severe Sepsis and Septic Shock

11. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. *Crit Care Med* 2003;31:462-467.
12. Friedman C, Silva E, Vincent J-L. Has the mortality of septic shock changed with time? *Crit Care Med* 1998;26:2078-2086.
13. Fink MP. Cytopathic hypoxia: mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. *Crit Care Clin* 2001;17:219-237.
14. Sair M, Etherington PJ, Winlove CP, et al. Tissue oxygenation and perfusion in patients with systemic sepsis. *Crit Care Med* 2001;29:1343-1349.
15. Vlessis AA, Goldman RK, Trunkey DD. New concepts in the pathophysiology of oxygen metabolism during sepsis. *Br J Surg* 1995;82:870-876.
16. Marik PE. The treatment of hypoalbuminemia in the critically ill patient. *Heart Lung* 1993;22:166-170.
17. Beale RJ, Hollenberg SM, Vincent J-L, et al. Vasopressor and inotropic support in septic shock: an evidence-based review. *Crit Care Med* 2004; 32(suppl):S455-S465.
18. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. *JAMA* 1994;272:1354-1357.
19. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. *Intensive Care Med* 2001;27:1416-1421.

20. Aronson MD, Bor DH. Blood cultures. *Ann Intern Med* 1987;106:246–253.
21. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;288:862–871.
22. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999;27:723–732.
23. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998;26:645–650.

Anaphylaxis

24. Ellis AK, Day JH. Diagnosis and management of anaphylaxis. *Can Med Assoc J* 2003;169:307–311.
25. Crnkovich DJ, Carlson RW. Anaphylaxis: an organized approach to management and prevention. *J Crit Illness* 1993;8:332–246.
26. Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. *J Allergy Clin Immunol* 2001;108:871–873.

Chapter 41

Pneumonia in the ICU

References

Clinical Practice Guidelines

1. American Thoracic Society and Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388–416.

General Features

2. Bregeon F, Cias V, Carret V, et al. Is ventilator-associated pneumonia an independent risk factor for death? *Anesthesiology* 2001;94:554–560.
3. Estes RJ, Meduri GU. The pathogenesis of ventilator-associated pneumonia, I: mechanisms of bacterial transcolonization and airway inoculation. *Intensive Care Med* 1995;21:365–383.
4. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. *Chest* 2000;117:191S–194S.
5. Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients: use of a protected specimen brush and quantitative culture techniques in 147 patients. *Am Rev Respir Dis* 1988;138:110–116.
6. Timsit JF, Misset B, Goldstein FW, et al. Reappraisal of distal diagnostic testing in the diagnosis of ICU-acquired pneumonia. *Chest* 1995;108:1632–1639.
7. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988;16:128–140.
8. Nsieur S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology, and outcome. *Eur Respir J* 2002;20:1483–1489.
9. Pistolesi M, Miniati M, Milne ENC, et al. Measurement of extravascular lung water. *Intensive Care World* 1991;8:16–21.

10. Caldwell A, Glauser FL, Smith WP, et al. The effects of dehydration on the radiologic and pathologic appearance of experimental canine segmental pneumonia. *Am Rev Respir Dis* 1975;112:651-659.
11. Louthan FB, Meduri GU. Differential diagnosis of fever and pulmonary densities in mechanically ventilated patients. *Semin Resp Infect* 1996;11:77-95.
12. Singh N, Falestiny MN, Rogers P, et al. Pulmonary infiltrates in the surgical ICU. *Chest* 1998;114:1129-1136.
13. Bauer TT, Torres A. Acute respiratory distress syndrome and nosocomial pneumonia. *Thorax* 1999;54:1036-1040.

Diagnostic Evaluation

14. Luna CM, Videla A, Mattera J, et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. *Chest* 1999;116:1075-1084.
15. Cook D, Mandell L. Endotracheal aspiration in the diagnosis of ventilator-associated pneumonia. *Chest* 2000;117:195S-197S.
16. Washington JA. Techniques for noninvasive diagnosis of respiratory tract infections. *J Crit Illness* 1996;11:55-62.
17. Rankin JA, Marcy T, Rochester CL, et al. Human airway macrophages. *Am Rev Respir Dis* 1992;145:928-933.
18. Wong LK, Barry AL, Horgan S. Comparison of six different criteria for judging the acceptability of sputum specimens. *J Clin Microbiol* 1982;16:627-631.
19. Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. *Chest* 1992;102:557S-564S.
20. Torres A, El-Ebiary M. Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia. *Chest* 2000;117:198S-202S.
21. Veber B, Souweine B, Gachot B, et al. Comparison of direct examination of three types of bronchoscopy specimens used to diagnose nosocomial pneumonia. *Crit Care Med* 2000;28:962-968.
22. Chastre J, Fagon JY, Domart Y, et al. Diagnosis of nosocomial pneumonia in intensive care unit patients. *Eur J Clin Microbiol Infect Dis* 1989;8:35-39.
23. Kollef MH, Bock KR, Richards RD, et al. The safety and diagnostic accuracy of minibronchoalveolar lavage in patients with suspected ventilator-associated pneumonia. *Ann Intern Med* 1995;122:743-748.
24. Perkins GD, Chatterjee S, Giles S, et al. Safety and tolerability of nonbronchoscopic lavage in ARDS. *Chest* 2005;127:1358-1363.
25. Campbell CD Jr. Blinded invasive diagnostic procedures in ventilator-associated pneumonia. *Chest* 2000;117:207S-211S.
26. Fujitani S, Yu V. Diagnosis of ventilator-associated pneumonia: focus on nonbronchoscopic techniques (nonbronchoscopic lavage, including mini-BAL, blinded protected specimen brush, and blinded bronchial sampling) and endotracheal aspirates. *J Intensive Care Med* 2006;21:17-21.
27. Shorr AF, Sherner JH, Jackson WL, et al. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. *Crit Care Med* 2005; 33:46-53.
28. Light RW, Meyer RD, Sahn SA, et al. Parapneumonic effusions and empyema. *Clin Chest Med* 1985;6:55-62.

Early Antimicrobial Therapy

29. Bergmanns DCJJ, Bonten MJM, Gaillard CA, et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. *J Antimicrob Chemother* 1997;111:676-685.
30. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. *Chest* 2002;122:262-268.
31. Rello J, Quintana E, Ausina A, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. *Chest* 1991;100:439-444.
32. Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. *Am J Respir Crit Care Med* 1996;154:91-97.
33. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. *Am J Respir Crit Care Med* 2000;162:505-511.
34. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. *Am J Respir Crit Care Med* 2001;163:1730-1754.
35. Marik P, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. *Chest* 1999;115:178-183.
36. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective study of 200 patients. *Am J Med* 1989;87:540-546.
37. Cometta A, Baumgartner JD, Lew D, et al. Prospective, randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. *Antimicrob Agents Chemother* 1994;38:1309-1313.
38. Chastre J, Wolff M, Fagon J-Y, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. *JAMA* 2003;290:2588-2598.
39. Bergmans C, Bonten M, Gaillard C, et al. Prevention of ventilator-associated pneumonia by oral decontamination. *Am J Respir Crit Care Med* 2001;164:382-388.

Chapter 42

Sepsis from the Abdomen and Pelvis

References

Acalculous Cholecystitis

1. Walden D, Urrutia F, Soloway RD. Acute acalculous cholecystitis. *J Intensive Care Med* 1994;9:235-243.
2. Imhof M, Raunest J, Ohmann Ch, Rohrer H-D. Acute acalculous cholecystitis complicating trauma: A prospective sonographic study. *World J Surg* 1992; 1160-1166.
3. Te HS. Cholestasis in HIV-infected patients. *Clin Liver Dis* 2004;8:213-228.

Colonization of the GI Tract

4. Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract: the "un-drained abscess" of multiple organ failure. *Ann Surg* 1993;218:111-119.
5. Bartlett JG. Antibiotic-associated diarrhea. *N Engl J Med* 2002;346:334-339.
6. Mylonakis E, Ryan ET, Calderwood SB. *Clostridium difficile*-associated diarrhea. *Arch Intern Med* 2001;161:525-533.
7. Fekety R, Kim F H, Brown D, et al. Epidemiology of antibiotic associated colitis. *Am J Med* 1981;70:906-908.
8. Samore MH, Venkataraman L, DeGirolami, et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial *Clostridium difficile* diarrhea. *Am J Med* 1996;100:32-40.
9. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* 1990;88:137-140.
10. Lipsett PA, Samantaray DK, Tam ML, et al. Pseudomembranous colitis: a surgical disease? *Surgery* 1994;116:491-496.

11. Yassin SF, Young-Fadok TM, Zein NN, Pardi DS. Clostridium difficile-associated diarrhea and colitis. Mayo Clin Proc 2001;76:725-730.
12. Fishman EK, Kavuru M, Jones B, et al. Pseudomembranous colitis: CT evaluation of 26 cases. Radiology 1991;180:57-60.
13. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea: Infectious Disease Society of America. Clin Infect Dis 2001;32:331-350.
14. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: Old therapies and new strategies. Lancet Infect Dis 2005;5:549-557.
15. Surawicz C. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 1989;96:981-988.
16. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic-associated diarrhea: Meta-analysis. Br Med J 2002;324:1361-1366.

Abdominal Abscesses

17. Mirvis SE, Shanmuganthan K. Trauma radiology, Part I: Computerized tomographic imaging of abdominal trauma. J Intensive Care Med 1994;9:151-163.
18. Fry DE. Noninvasive imaging tests in the diagnosis and treatment of intra-abdominal abscesses in the postoperative patient. Surg Clin North Am 1994; 74:693-709.
19. Oglevie SB, Casola G, van Sonnenberg E, et al. Percutaneous abscess drainage: Current applications for critically ill patients. J Intensive Care Med 1994; 9:191-206.
20. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-549.

Urinary Tract Infections

21. Richards MJ, Edwards JR, Culver D, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27:887-892.
22. Amin M. Antibacterial prophylaxis in urology: A review. Am J Med 1992;92 (suppl 4A):114-117.
23. Howard RJ. Host defense against infection: Part 1. Curr Probl Surg 1980;27: 267-316.
24. Daifuku R, Stamm WE. Bacterial adherence to bladder uroepithelial cells in catheter-associated urinary tract infection. N Engl J Med 1986;314:1208-1213.
25. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-442.
26. Calandra T, Cohen J, for the International Sepsis Forum Definition of Infection in the ICU Consensus Conference. Crit Care Med 2005;33:1538-1548.
27. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
28. McCue JD. How to manage urinary tract infections in the elderly. J Crit Illness 1996;11(suppl):S30-S40.
29. Bone RC, Larson CB. Gram-negative urinary tract infections and the development of SIRS. J Crit Illn 1996;11(suppl):S20-S29.
30. Stamm WE, Hooten TM. Management of urinary tract infection in adults. N Engl J Med 1993;329:1328-1334.
31. Jenkins SG. Changing spectrum of uropathogens: implications for treating complicated UTIs. J Crit Illn 1996;11(suppl):S7-S13.

Candiduria

32. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. *Intensive Care Med* 1994;20:522-528.
33. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161-189.
34. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: A randomized double-blind study of treatment with fluconazole or placebo. *Clin Infect Dis* 2000;30:19-24.

Chapter 43

The Immuno-Compromised Patient

References

The HIV-Infected Patient

1. Narashimhan M, Posner AJ, DePalo VA, et al. Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. *Chest* 2004; 125:1800-1804.
2. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. *Chest* 2001;120:1888-1893.
3. Bartlett JG. Pneumonia in the patient with HIV infection. *Infect Dis Clin North Am* 1998;12:807-820.
4. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection. *Chest* 2000;117:1017-1022.
5. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. *N Engl J Med* 1995;333: 845-851.
6. Thomas CF, Limper AH. Pneumocystis pneumonia. *N Engl J Med* 2004;350: 2487-2498.
7. Opravil M, Marinchek B, Fuchs WA, et al. Shortcomings of chest radiography in detecting *Pneumocystis carinii* pneumonia. *J Acquir Immune Defic Syndrome* 1994;7:39-45.
8. Uphold CR, Deloria-Knoll M, Parada FJ, et al. U.S. hospital care for patients with HIV infection and pneumonia. *Chest* 2004;125:548-556.
9. Datta D, Abbas S, Henken EM, et al. *Pneumocystis carinii* pneumonia: the time course of clinical and radiographic improvement. *Chest* 2003;124:1820-2823.
10. Brooks KR, Ong R, Spector RS, et al. Acute respiratory failure due to *Pneumocystis carinii* pneumonia. *Crit Care Clin* 1993;9:31-48.
11. Johnson MP, Goodwin D, Shands JW. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. *Pharmacotherapy* 1990;10:423-426.
12. van der Ven AJAM, Koopmans PP, Vree TB, et al. Adverse reactions to co-trimoxazole in HIV infection. *Lancet* 1991;338:431-433.
13. Greenberg S, Reiser IW, Chou S-Y, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. *Ann Intern Med* 1993;119:291-295.
14. Jost R, Stey C, Salomon F. Fatal drug-induced pancreatitis in HIV. *Lancet* 1993;341:1412.
15. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for *Pneumocystis carinii* pneumonia in patients with AIDS. *Ann Intern Med* 1994;121:174-180.
16. Eisenhauer MD, Eliasson AH, Taylor AJ, et al. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. *Chest* 1994;105:389-394.
17. Foisey MM, Slayter KL, Morse GD. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. *Ann Pharmacother* 1994;28:1025-1028.

18. National Institutes of Health: University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. *N Engl J Med* 1990; 323:1500–1504.
19. Schiff MJ, Farber BF, Kaplan MH. Steroids for Pneumocystis carinii pneumonia and respiratory failure in the acquired immunodeficiency syndrome. *Arch Intern Med* 1990;150:1819–1821.
20. Pastores SM, Garay SM, Naidich DP, et al. Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. *Am J Med Sci* 1996;312: 229–234.
21. Levy RM, Berger JR. Neurologic critical care in patients with human immunodeficiency virus + infection. *Clin Crit Care* 1993;9:49–72.
22. Ennis DM, Saag MS. Cryptococcal meningitis in AIDS. *Hosp Pract* 1993;28:99–112.
23. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal diseases: Infectious Disease Society of America. *Clin Infect Dis* 2000;30:710–718.
24. Lucet J-C, Bailey M-P, Bedos J-P, et al. Septic shock due to toxoplasmosis in patients infected with the human immunodeficiency virus. *Chest* 1993;104: 1054–1058.
25. Knobel H, Graus F, Miro JM, et al. Toxoplasmic encephalitis with normal CT scan and pathologic MRI. *Am J Med* 1995;99:220–221.
26. Drew WL. Toxoplasmic encephalitis in HIV patients: how to prevent, how to treat. *J Crit Illness* 1994;9:223–224.
27. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1993;329:995–1000.
28. Morris A, Masur H, Huang L. Current issues in critical care of the human immunodeficiency virus-infected patient. *Crit Care Med* 2006;34:42–49.
29. Miller RD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with the use of stavudine: report of four cases. *Ann Intern Med* 2000;133:192–196.
- The Neutropenic Patient
30. Pizzo PA. Fever in immunocompromised patients. *N Engl J Med* 1999;341:893–900.
31. Piekert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. *Mayo Clin Proc* 2005;80:1414–1420.
32. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34:730–751.
33. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. *MMWR* 1997;46(RR-8).

Chapter 44

Antimicrobial Therapy

References

Aminoglycosides

1. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. *Infect Dis Clin N Am* 2003;17:503–528.
2. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units. *JAMA* 2003;289:885–888.
3. Wilson SE. Aminoglycosides: Assessing the potential for nephrotoxicity. *Surg Gynecol Obstet* 1986;171(suppl):24–30.

4. Lippmann M, Yang E, Au E, Lee C. Neuromuscular blocking effects of tobramycin, gentamicin, and cefazolin. *Anesth Analg* 1982;61:767-770.
5. Drachman DB. Myasthenia gravis. *N Engl J Med* 1994;330:179-180.
- Antifungal Agents
6. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. *Infect Dis Clin N Am* 2003;17:159-191.
7. Bult J, Franklin CM. Using amphotericin B in the critically ill: A new look at an old drug. *J Crit Illn* 1996;11:577-585.
8. Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. *J Am Coll Surg* 1994;179:361-381.
9. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 1999; 340:764-771.
10. Wingard JR, Kublis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis* 1999;29:1402-1407.
11. Hoesly CJ, Dismukes WE. New antifungal agents: Emphasis on lipid formulations of amphotericin B: National Foundation for Infectious Disease, clinical updates: Available at <http://www.nfid.org/publications/clinicalupdates/fungal/ampho.html> (Accessed on 5/2006).
12. Red Book, 2005. Montvale, NJ: Thompson PDR, 2005.
13. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N Engl J Med* 1994;331:1325-1330.
14. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. *Crit Care Med* 2006;34:857-863.
15. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161-189.
16. Perfect JR. Management of invasive mycoses in hematology patients: Current approaches. *J Crit Illn* 2004;19:3-12.
17. Walsh TJ, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med* 2002;346:225-234.
18. Gearhart MO. Worsening of liver function with fluconazole and a review of azole antifungal hepatotoxicity. *Ann Pharmacother* 1994;28:1177-1181.
19. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002;347:2020-2029.
- Cephalosporins
20. Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. *Infect Dis Clin North Am* 2000;14:1-10.
21. Gustaffero CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. *Mayo Clin Proc* 1991;66:1064-1073.
22. Bennett WM, Aronoff GR, Golper TA, et al., eds. Drug prescribing in renal failure. 3rd ed. Philadelphia: American College of Physicians, 1994.
- Fluoroquinolones
23. O'Donnell JA, Gelone SP. Fluoroquinolones. *Infect Dis Clin North Am* 2000;14:489-513.
24. Walker RC, Wright AJ. The fluoroquinolones. *Mayo Clin Proc* 1991;66:1249-1259.
25. Robson RA. The effects of quinolones on xanthine pharmacokinetics. *Am J Med* 1992;92(suppl 4A):22S-26S.

26. Maddix DS. Do we need an intravenous fluoroquinolone? *West J Med* 1992; 157:55-59.
27. Finch C, Self T. Quinolones: recognizing the potential for neurotoxicity. *J Crit Illn* 2000;15:656-657.
28. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. *Pharmacotherapy* 2001;21:1468-1472.

Imipenem

29. Hellinger WC, Brewer NS. Imipenem. *Mayo Clin Proc* 1991;66:1074-1081.
30. Freifield A, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. *J Clin Oncol* 1995;13:165-176.
31. Cunha B. Meropenem for clinicians. *Antibiot Clin* 2000;4:59-66.

Penicillins

32. Wright AJ. The penicillins. *Mayo Clin Proc* 1999;74:290-307.
33. McEvoy GK, ed. AHFS drug information, 2001. Bethesda, MD: American Society of Hospital Pharmacists, 2001:419-422.

Vancomycin

34. Lundstrom TS, Sobel R. Antibiotics for gram-positive bacterial infections: Vancomycin, quinapristin-dalfopristin, linezolid, and daptomycin. *Infect Dis Clin North Am* 2004;18:651-668.

35. Ena J, Dick RW, Jones RN. The epidemiology of intravenous vancomycin usage in a university hospital. *JAMA* 1993;269:598-605.

36. Saunders NJ. Why monitor peak vancomycin concentrations? *Lancet* 194; 344:1748-1750.

Linezolid

37. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant gram-positive infections: experience from a compassionate use program. *Clin Infect Dis* 2003;36:159-164.

38. Wunderink RG, Rello J, Norden C, et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant *Staphylococcus aureus* pneumonia. *Chest* 2003;124:1789-1795.

39. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. *Neurology* 2006;66:595-598.

Chapter 45

Metabolic Substrate Requirements

References

Reviews

1. Mandt J, Teasley-Strausberg K, Shrouts E. Nutritional requirements. In: Teasley-Strausberg K, ed. *Nutritional support handbook*. Cincinnati, OH: Harvey-Whitney Books, 1992:19-36.
2. McClave S, Snider H. Use of indirect calorimetry in clinical nutrition. *Nutr Clin Pract* 1992;7:207-221.

3. Headley JM. Indirect calorimetry: a trend toward continuous metabolic assessment. *AACN Clin Issues* 2003;14:155-167.

4. Biolo G, Grimble G, Preiser JC, et al. Position paper of the ESICM Working Group on Nutrition and Metabolism: metabolic basis of nutrition in intensive care unit patients: ten critical questions. *Intensive Care Med* 2002;28:1512-1520.

5. Bistrian BR, McCowen KC. Nutritional and metabolic support in the adult intensive care unit: key controversies. *Crit Care Med* 2006;34:1525-1531.

6. Sabol VK. Nutrition assessment of the critically ill adult. *AACN Clin Issues* 2004;15:595-606.

Daily Energy Expenditure

7. Harris JA, Benedict FG. A biometric study of human basal metabolism. *Proc Natl Acad Sci U S A* 1918;4:370-373.

8. Paauw JD, McCamish MA, Dean RE, et al. Assessment of caloric needs in stressed patients. *J Am Coll Nutr* 1984;3:51-59.

9. Mann S, Westenskow DR, Houtchens BA. Measured and predicted caloric expenditure in the acutely ill. *Crit Care Med* 1985;13:173-177.

10. Weissman C, Kemper M, Askanazi J, et al. Resting metabolic rate of the critically ill patient: measured versus predicted. *Anesthesiology* 1986;64:673-679.

11. Makk LJ, McClave SA, Creech PW, et al. Clinical application of the metabolic cart to the delivery of total parenteral nutrition. *Crit Care Med* 1990;18:1320-1327.

12. Kan MN, Chang HH, Sheu WF, et al. Estimation of energy requirements for mechanically ventilated, critically ill patients using nutritional status. *Crit Care* 2003;7:R108-R115.

13. Bursztein S, Saphar P, Singer P, et al. A mathematical analysis of indirect calorimetry measurements in acutely ill patients. *Am J Clin Nutr* 1989;50:227-230.

14. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. *J Physiol* 1949;109:1-9.

15. Westenskow DR, Schipke CA, Raymond JL, et al. Calculation of metabolic expenditure and substrate utilization from gas exchange measurements. *J Parenter Enteral Nutr* 1988;12:20-24.

16. Cunningham JJ. Calculation of energy expenditure from indirect calorimetry: assessment of the Weir equation. *Nutrition* 1990;6:222-223.

17. Koea JB, Wolfe RR, Shaw JH. Total energy expenditure during total parenteral nutrition: ambulatory patients at home versus patients with sepsis in surgical intensive care. *Surgery* 1995;118:54-62.

Nonprotein Calories

18. Rodriguez JL, Askanazi J, Weissman C, et al. Ventilatory and metabolic effects of glucose infusions. *Chest* 1985;88:512-518.

19. Talpers SS, Romberger DJ, Bunce SB, et al. Nutritionally associated increased carbon dioxide production: excess total calories vs high proportion of carbohydrate calories. *Chest* 1992;102:551-555.

20. Jones PJH, Kubow S. Lipids, sterols, and their metabolites. In: Shils ME et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:92-121.

21. Matthews DE. Proteins and amino acids. In: Shils ME et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:23-61.

22. Blackburn GL, Bistrian BR, Maini BS, et al. Nutritional and metabolic assessment of the hospitalized patient. *J Parenter Enteral Nutr* 1977;1:11-22.

23. Velasco N, Long CL, Otto DA, et al. Comparison of three methods for the estimation of total nitrogen losses in hospitalized patients. *J Parenter Enteral Nutr* 1990;14:517-522.

24. Konstantinides FN, Konstantinides NN, Li JC, et al. Urinary urea nitrogen: too insensitive for calculating nitrogen balance studies in surgical clinical nutrition. *J Parenter Enteral Nutr* 1991;15:189-193.

25. Burge J, Choban P, McKnight T. Urinary ammonia excretion as an estimate of total urinary nitrogen in patients receiving parenteral nutritional support. *J Parenter Enteral Nutr* 1993;17:529-531.

Vitamin Requirements

26. Dempsey DT, Mullen JL, Rombeau JL, et al. Treatment effects of parenteral vitamins in total parenteral nutrition patients. *J Parenter Enteral Nutr* 1987;11:229-237.

27. Beard ME, Hatipov CS, Hamer JW. Acute onset of folate deficiency in patients under intensive care. *Crit Care Med* 1980;8:500-503.

28. Butterworth RF. Thiamin. In: Shils ME et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:426-433.

29. McConachie I, Haskew A. Thiamine status after major trauma. *Intensive Care Med* 1988;14:628-631.

30. Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. *Am J Med* 1991;91:151-155.

31. Dyckner T, Ek B, Nyhlin H, et al. Aggravation of thiamine deficiency by magnesium depletion: a case report. *Acta Med Scand* 1985;218:129-131.

32. Tan GH, Farnell GF, Hensrud DD, et al. Acute Wernicke's encephalopathy attributable to pure dietary thiamine deficiency. *Mayo Clin Proc* 1994;69:849-850.

33. Oriot D, Wood C, Gottesman R, et al. Severe lactic acidosis related to acute thiamine deficiency. *J Parenter Enteral Nutr* 1991;15:105-109.

34. Koike H, Misu K, Hattori N, et al. Postgastrectomy polyneuropathy with thiamine deficiency. *J Neurol Neurosurg Psychiatry* 2001;71:357-362.

35. Boni L, Kieckens L, Hendrikx A. An evaluation of a modified erythrocyte transketolase assay for assessing thiamine nutritional adequacy. *J Nutr Sci Vitaminol (Tokyo)* 1980;26:507-514.

Essential Trace Elements

36. Fleming CR. Trace element metabolism in adult patients requiring total parenteral nutrition. *Am J Clin Nutr* 1989;49:573-579.

37. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. *Methods Enzymol* 1990;186:1-85.

38. Herbert V, Shaw S, Jayatilake E, et al. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin. *Stem Cells* 1994;12:289-303.

39. Shanbhogue LK, Paterson N. Effect of sepsis and surgery on trace minerals. *J Parenter Enteral Nutr* 1990;14:287-289.

40. Guyatt GH, Patterson C, Ali M, et al. Diagnosis of iron-deficiency anemia in the elderly. *Am J Med* 1990;88:205-209.

41. Hawker FH, Stewart PM, Snitch PJ. Effects of acute illness on selenium homeostasis. *Crit Care Med* 1990;18:442-446.

42. Yusuf SW, Rehman Q, Casscells W. Cardiomyopathy in association with selenium deficiency: a case report. *J Parenter Enteral Nutr* 2002;26:63-66.

43. Sando K, Hoki M, Nezu R, et al. Platelet glutathione peroxidase activity in long-term total parenteral nutrition with and without selenium supplementation. *J Parenter Enteral Nutr* 1992;16:54-58.

44. Ishida T, Himeno K, Torigoe Y, et al. Selenium deficiency in a patient with Crohn's disease receiving long-term total parenteral nutrition. *Intern Med* 2003;42:154-157.

45. Geoghegan M, McAuley D, Eaton S, et al. Selenium in critical illness. *Curr Opin Crit Care* 2006;12:136–141.
46. Rayman MP. The importance of selenium to human health. *Lancet* 2000;356:233–241.
47. Food and Nutrition Board IOM. DRI: dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids. Washington, DC: National Academy Press, 2000.
- A Final Word
48. Marino PL, Finnegan MJ. Nutrition support is not beneficial and can be harmful in critically ill patients. *Crit Care Clin* 1996;12:667–676.
49. Gunther B, Jauch KW, Hartl W, et al. Low-dose glucose infusion in patients who have undergone surgery: possible cause of a muscular energy deficit. *Arch Surg* 1987;122:765–771.
50. Degoute CS, Ray MJ, Manchon M, et al. Intraoperative glucose infusion and blood lactate: endocrine and metabolic relationships during abdominal aortic surgery. *Anesthesiology* 1989;71:355–361.

Chapter 46

Enteral Tube Feeding

References

Reviews

1. Bistrian BR, McCowen KC. Nutritional and metabolic support in the adult intensive care unit: key controversies. *Crit Care Med* 2006;34:1525–1531.
2. De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. *Crit Care Med* 2005;33:1125–1135.
3. Wischmeyer PE. The glutamine story: where are we now? *Curr Opin Crit Care* 2006;12:142–148.
- Guidelines
4. Stroud M, Duncan H, Nightingale J. Guidelines for enteral feeding in adult hospital patients. *Gut* 2003;52(suppl 7):vii1–vii12.
5. Kreymann KG, Berger MM, Deutz NE, et al. ESPEN Guidelines on enteral nutrition: intensive care. *Clin Nutr* 2006;25:210–223.
6. Lochs H, Allison SP, Meier R, et al. Introductory to the ESPEN guidelines on enteral nutrition: terminology, definitions and general topics. *Clin Nutr* 2006;25:180–186.

Trophism

7. Alpers DH. Enteral feeding and gut atrophy. *Curr Opin Clin Nutr Metab Care* 2002;5:679–683.
8. Deitch EA, Winterton J, Li M, et al. The gut as a portal of entry for bacteremia: role of protein malnutrition. *Ann Surg* 1987;205:681–692.
9. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host–pathogen interactions within the intestine: gut-derived sepsis redefined. *Crit Care Med* 2003;31:598–607.

10. Herskowitz K, Souba WW. Intestinal glutamine metabolism during critical illness: a surgical perspective. *Nutrition* 1990;6:199–206.
11. Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. *Best Pract Res Clin Gastroenterol* 2003;17:397–425.
12. Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. *J Parenter Enteral Nutr* 2003;27:355–373.
13. Meier R, Ockenga J, Pertkiewicz M, et al. ESPEN guidelines on enteral nutrition: pancreas. *Clin Nutr* 2006;25:275–284.

Feeding Tubes

14. Dotson RG, Robinson RG, Pingleton SK. Gastroesophageal reflux with nasogastric tubes: effect of nasogastric tube size. *Am J Respir Crit Care Med* 1994;149:1659–1662.
 15. Metheny NA, Clouse RE, Clark JM, et al. pH testing of feeding-tube aspirates to determine placement. *Nutr Clin Pract* 1994;9:185–190.
 16. Baskin WN. Acute complications associated with bedside placement of feeding tubes. *Nutr Clin Pract* 2006;21:40–55.
 17. Kolbitsch C, Pomaroli A, Lorenz I, et al. Pneumothorax following nasogastric feeding tube insertion in a tracheostomized patient after bilateral lung transplantation. *Intensive Care Med* 1997;23:440–442.
 18. Fisman DN, Ward ME. Intrapleural placement of a nasogastric tube: an unusual complication of nasotracheal intubation. *Can J Anaesth* 1996;43:1252–1256.
 19. Jabbar A, McClave SA. Pre-pyloric versus post-pyloric feeding. *Clin Nutr* 2005;24:719–726.
 20. Strong RM, Condon SC, Solinger MR, et al. Equal aspiration rates from postpylorus and intragastric-placed small-bore nasoenteric feeding tubes: a randomized, prospective study. *J Parenter Enteral Nutr* 1992;16:59–63.
- #### Feeding Formulas
21. (NIH/NLM) MP. Enteral Nutrition Formulas (Systemic). 2006 Available at: <http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202673.html> (accessed on June 6, 2006).
 22. Novartis Medical Nutrition. Product Reference Guide. 2006 Available at: http://www.novartisnutrition.com/pdfs/us/presentations/Source_Chart_04.16400.pdf (accessed on June 7, 2006).
 23. Malone A. Enteral formula selection: a review of selected product categories. *Pract Gastroenterol* 2005;June:44–74.
 24. Malone AM. The use of specialized enteral formulas in pulmonary disease. *Nutr Clin Pract* 2004;19:557–562.
 25. Gadek JE, DeMichele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome: Enteral Nutrition in ARDS Study Group. *Crit Care Med* 1999;27:1409–1420.
 26. Zaloga GP, Siddiqui R, Terry C, et al. Arginine: mediator or modulator of sepsis? *Nutr Clin Pract* 2004;19:201–215.
 27. Heyland DK, Dhaliwal R, Suchner U, et al. Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. *Intensive Care Med* 2005;31:327–337.

28. Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. *JAMA* 2001;286:944-953.

Additives

29. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? *Nutr Rev* 1990;48:297-309.

30. Swails WS, Bell SJ, Borlase BC, et al. Glutamine content of whole proteins: implications for enteral formulas. *Nutr Clin Pract* 1992;7:77-80.

31. Alitra Q. Ross Medical Nutritional Products Pocket Guide. 2005 Ross Laboratories Available at: http://www.ross.com/images/library/Ross_MN_Products_Pocket_Guide.pdf (accessed on June 9, 2006).

32. Garcia-de-Lorenzo A, Zarazaga A, Garcia-Luna PP, et al. Clinical evidence for enteral nutritional support with glutamine: a systematic review. *Nutrition* 2003;19:809-811.

33. Ziegler TR, Benfell K, Smith RJ, et al. Safety and metabolic effects of L-glutamine administration in humans. *J Parenter Enteral Nutr* 1990;14:137S-146S.

34. Palacio JC, Rombeau JL. Dietary fiber: a brief review and potential application to enteral nutrition. *Nutr Clin Pract* 1990;5:99-106.

35. Homann HH, Kemen M, Fuessenich C, et al. Reduction in diarrhea incidence by soluble fiber in patients receiving total or supplemental enteral nutrition. *J Parenter Enteral Nutr* 1994;18:486-490.

36. Spapen H, Diltoer M, Van Malderen C, et al. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. *Clin Nutr* 2001;20:301-305.

37. Frankenfield DC, Beyer PL. Soy-polysaccharide fiber: effect on diarrhea in tube-fed, head-injured patients. *Am J Clin Nutr* 1989;50:533-538.

38. Alexander WF, Spindel E, Harty RF, et al. The usefulness of branched chain amino acids in patients with acute or chronic hepatic encephalopathy. *Am J Gastroenterol* 1989;84:91-96.

39. James JH. Branched chain amino acids in hepatic encephalopathy. *Am J Surg* 2002;183:424-429.

40. Rebouche CJ. Carnitine. In: Shils ME, et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006:537-544.

41. Kazmi WH, Obrador GT, Sternberg M, et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. *Am J Nephrol* 2005;25:106-115.

42. Karlic H, Lohninger A. Supplementation of L-carnitine in athletes: does it make sense? *Nutrition* (Burbank, CA) 2004;20:709-715.

Feeding Regimen

43. Rees RG, Keohane PP, Grimble GK, et al. Elemental diet administered nasogastrically without starter regimens to patients with inflammatory bowel disease. *J Parenter Enteral Nutr* 1986;10:258-262.

44. Mizock BA. Avoiding common errors in nutritional management. *J Crit Illness* 1993;10:1116-1127.

Complications

45. Marcuard SP, Perkins AM. Clogging of feeding tubes. *J Parenter Enteral Nutr* 1988;12:403-405.

46. Benson DW, Griggs BA, Hamilton F, et al. Clogging of feeding tubes: a randomized trial of a newly designed tube. *Nutr Clin Pract* 1990;5:107-110.

47. Marcuard SP, Stegall KS. Unclogging feeding tubes with pancreatic enzyme. *J Parenter Enteral Nutr* 1990;14:198-200.

48. Metheny N. Minimizing respiratory complications of nasoenteric tube feedings: state of the science. *Heart Lung* 1993;22:213-223.

49. Metheny NA. Risk factors for aspiration. *J Parenter Enteral Nutr* 2002;26: S26-31.

50. Castel H, Tiengou LE, Besancon I, et al. What is the risk of nocturnal supine enteral nutrition? *Clin Nutr* 2005;24:1014-1018.

51. Potts RG, Zaroukian MH, Guerrero PA, et al. Comparison of blue dye visualization and glucose oxidase test strip methods for detecting pulmonary aspiration of enteral feedings in intubated adults. *Chest* 1993;103:117-121.
52. Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: feeding formula not necessarily the cause. *Am J Med* 1990;88:91-93.
53. Eisenberg PG. Causes of diarrhea in tube-fed patients: a comprehensive approach to diagnosis and management. *Nutr Clin Pract* 1993;8:119-123.
54. Cheng EY, Hennen CR, Nimphius N. Unsuspected source of diarrhea in an ICU patient. *Clin Intensive Care* 1992;3:33-36.
- Jejunostomy Feedings
55. Sagar PM, Kruegener G, MacFie J. Nasogastric intubation and elective abdominal surgery. *Br J Surg* 1992;79:1127-1131.
56. Nance ML, Gorman RC, Morris JB, et al. Techniques for long-term jejunal access. *Contemp Surg* 1995;46:21-25.
57. Collier P, Kudsk KA, Glezer J, et al. Fiber-containing formula and needle catheter jejunostomies: a clinical evaluation. *Nutr Clin Pract* 1994;9:101-103.
58. Antinori CH, Andrew C, Villanueva DT, et al. A technique for converting a needle-catheter jejunostomy into a standard jejunostomy. *Am J Surg* 1992;164:68-69.

Chapter 47

Parenteral Nutrition

References

Guidelines & Reviews

1. Dudrick SJ. Early developments and clinical applications of total parenteral nutrition. *J Parenter Enteral Nutr* 2003;27:291-299.
2. Driscoll DF. Compounding TPN admixtures: then and now. *J Parenter Enteral Nutr* 2003;27:433-438.
3. Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. *J Parenter Enteral Nutr* 2004;28:S39-70.
4. Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. *J Parenter Enteral Nutr* 2003;27:355-373.
5. American Gastroenterological Association. Medical position statement: parenteral nutrition. *Gastroenterology* 2001;121:966-969.
6. Zaloga GP. Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes. *Lancet* 2006;367:1101-1111.

Intravenous Nutrient Solutions

7. Borgsdorf LR, Cada DJ, Cirigliano M, et al. Drug facts and comparisons. 60th ed. St. Louis, MO: Wolters Kluwer, 2006.
8. Andris DA, Krzywda EA. Nutrition support in specific diseases: back to basics. *Nutr Clin Pract* 1994;9:28-32.
9. Souba WW, Klimberg VS, Plumley DA, et al. The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection. *J Surg Res* 1990;48:383-391.
10. De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. *Crit Care Med* 2005;33:1125-1135.

11. Wischmeyer PE. The glutamine story: where are we now? *Curr Opin Crit Care* 2006;12:142-148.
12. Dechelotte P, Hasselmann M, Cynober L, et al. L-Alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. *Crit Care Med* 2006;34:598-604.
13. Fuentes-Orozco C, Anaya-Prado R, Gonzalez-Ojeda A, et al. L-Alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* 2004;23:13-21.
14. Warshawsky KY. Intravenous fat emulsions in clinical practice. *Nutr Clin Pract* 1992;7:187-196.
15. Carpentier YA, Dupont IE. Advances in intravenous lipid emulsions. *World J Surg* 2000;24:1493-1497.
16. Helphingstine CJ, Bistrian BR. New Food and Drug Administration requirements for inclusion of vitamin K in adult parenteral multivitamins. *J Parenter Enteral Nutr* 2003;27:220-224.
17. Brown RO, Minard G. Parenteral feeding. In: Shils ME, et al., eds. *Modern nutrition in health and disease*. 10th ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2006:1567-1597.
- Complications
18. Phelps SJ, Brown RO, Helms RA, et al. Toxicities of parenteral nutrition in the critically ill patient. *Crit Care Clin* 1991;7:725-753.
19. Perry DA, Markin RS, Rose SG, et al. Changes in laboratory values in patients receiving total parenteral nutrition. *Lab Med* 1990;21:97-102.
20. Padberg FT Jr, Ruggiero J, Blackburn GL, et al. Central venous catheterization for parenteral nutrition. *Ann Surg* 1981;193:264-270.
21. Trissel LA. *Handbook on injectable drugs*. 13th ed. Bethesda, MD: American Society Health System Pharmacists, 2005.
22. Freund HR. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. *Nutrition* 1991;7:1-5.
23. Talpers SS, Romberger DJ, Bunce SB, et al. Nutritionally associated increased carbon dioxide production: excess total calories vs high proportion of carbohydrate calories. *Chest* 1992;102:551-555.
24. Suchner U, Katz DP, Furst P, et al. Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. *Crit Care Med* 2001;29:1569-1574.
25. Battistella FD, Widergren JT, Anderson JT, et al. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. *J Trauma* 1997;43:52-58.
- Peripheral Parenteral Nutrition
26. Culebras JM, Martin-Pena G, Garcia-de-Lorenzo A, et al. Practical aspects of peripheral parenteral nutrition. *Curr Opin Clin Nutr Metab Care* 2004;7:303-307.
27. Anderson AD, Palmer D, MacFie J. Peripheral parenteral nutrition. *Br J Surg* 2003;90:1048-1054.

Chapter 48

Adrenal and Thyroid Dysfunction

References

Reviews: Adrenal Dysfunction

1. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003;348:727-734.
2. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. *Chest* 2002;122:1784-1796.
3. Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. *Crit Care* 2004;8:122-129.
4. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. *JAMA* 2000;283:1038-1045.

Adrenal Insufficiency

5. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. *N Engl J Med* 2004;350:1629-1638.
6. Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. *Crit Care Med* 2005;33:2479-2486.
7. Rothwell PM, Udawadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. *Lancet* 1991;337:582-583.
8. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. *Am J Med* 1995;98:266-271.
9. Dorin RI, Kearns PJ. High output circulatory failure in acute adrenal insufficiency. *Crit Care Med* 1988;16:296-297.
10. Morel J, Venet C, Donati Y, et al. Adrenal axis function does not appear to be associated with hemodynamic improvement in septic shock patients systematically receiving glucocorticoid therapy. *Intensive Care Med* 2006;32:1184-1190.

11. Umpierrez GE. Euthyroid sick syndrome. *South Med J* 2002;95:506-513.

Evaluation of Thyroid Function

12. Peeters RP, Debaveye Y, Fliers E, et al. Changes within the thyroid axis during critical illness. *Crit Care Clin* 2006;22:41-55.
13. Dayan CM. Interpretation of thyroid function tests. *Lancet* 2001;357:619-624.
14. Burman KD, Wartofsky L. Thyroid function in the intensive care unit setting. *Crit Care Clin* 2001;17:43-57.
15. Fliers E, Alkemade A, Wiersinga WM. The hypothalamic-pituitary-thyroid axis in critical illness. *Best Pract Res Clin Endocrinol Metab* 2001;15:453-464.

Hyperthyroidism

16. Surks MI, Sievert R. Drugs and thyroid function. *N Engl J Med* 1995;333:1688-1694.
 17. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. *Am J Med* 1991; 91:507-511.
 18. Klein I. Thyroid hormone and the cardiovascular system. *Am J Med* 1990; 88:631-637.
 19. Franklyn JA. The management of hyperthyroidism. *N Engl J Med* 1994;330: 1731-1738.
 20. Migneco A, Ojetti V, Testa A, et al. Management of thyrotoxic crisis. *Eur Rev Med Pharmacol Sci* 2005;9:69-74.
 21. Cooper DS. Hyperthyroidism. *Lancet* 2003;362:459-468.
 22. Ehrmann DA, Sarne DH. Early identification of thyroid storm and myxedema coma. *Crit Illness* 1988;3:111-118.
- ## Hypothyroidism
23. Roberts CG, Ladenson PW. Hypothyroidism. *Lancet* 2004;363:793-803.
 24. Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. *Am J Med* 1990;88:638-641.
 25. Lafayette RA, Costa ME, King AJ. Increased serum creatinine in the absence of renal failure in profound hypothyroidism. *Am J Med* 1994;96:298-299.
 26. Myers L, Hays J. Myxedema coma. *Crit Care Clin* 1991;7:43-56.
 27. Toft AD. Thyroxine therapy. *N Engl J Med* 1994;331:174-180.
 28. McCulloch W, Price P, Hinds CJ, et al. Effects of low dose oral triiodothyronine in myxoedema coma. *Intensive Care Med* 1985;11:259-262.

Chapter 49

Analgesia and Sedation

References

Clinical Practice Guidelines

1. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. *Crit Care Med* 2002;30:119-141. (Available at <http://www.sccm.org.pdf.sedatives.pdf> . Accessed 4/2006.)

Reviews

2. Murray MJ, Plevak DJ. Analgesia in the critically ill patient. *New Horizons* 1994;2:56-63.
 3. Young CC, Prielipp RC. Benzodiazepines in the intensive care unit. *Crit Care Clin* 2001;17:843-862.
 4. Angelini G, Ketzler JT, Coursin DB. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. *Crit Care Clin* 2001;17:863-880.
 5. Watling SM, Dasta JF, Seidl EC. Sedatives, analgesics, and paralytics in the ICU. *Ann Pharmacother* 1997;31:148-153.
- ##### The Pain Experience
6. Dasta JF, Fuhrman TM, McCandles C. Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit. *Crit Care Med* 1994;22:974-980.
 7. Paiement B, Boulanger M, Jones CW, et al. Intubation and other experiences in cardiac surgery: the consumer's views. *Can Anaesth Soc J* 1979;26:173-180.

8. Melzack R. The tragedy of needless pain. *Sci Am* 1990;262:27-33.
9. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. *Lancet* 1993;341:1075-1076.
10. Hamill-Ruth RJ, Marohn ML. Evaluation of pain in the critically ill patient. *Crit Care Clin* 1999;15:35-54.

Opioid Analgesia

11. Pasternak GW. Pharmacological mechanisms of opioid analgesics. *Clin Neuropharmacol* 1993;16:1-18.
12. Soliman HM, Melot C, Vincent JL. Sedative and analgesic practice in the intensive care unit: the results of a European survey. *Br J Anaesth* 2001;87: 186-192.
13. Veselis RA, Reinsel RA, Feshchenko VA, et al. The comparative amnestic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations. *Anesthesiology* 1997;87:749-764.
14. White PF. Use of patient-controlled analgesia for management of acute pain. *JAMA* 1988;259:243-247.
15. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults. 4th ed. Philadelphia: American College of Physicians, 1999.
16. Quigley C. A systematic review of hydromorphone in acute and chronic pain. *J Pain Symptom Manage* 2003;25:169-178.
17. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. *Clin Exp Pharmacol Physiol* 2000;27:524-528.
18. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. *Anesthesiology* 1982;56:93-96.
19. Etches RC. Respiratory depression associated with patient-controlled analgesia: a review of eight cases. *Can J Anaesth* 1994;41:125-132.
20. Liu S, Carpenter RL, Neal JM. Epidural anesthesia and analgesia: their role in postoperative outcome. *Anesthesiology* 1995;82:1474-1506.
21. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *Br Med J* 2000;321:1493.
22. Chaney MA. Side effects of intrathecal and epidural opioids. *Can J Anaesth* 1995;42:891-903.
23. Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. *Drug Safety* 1998;19:173-189.
24. Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. *Drug Safety* 1992;7:200-213.
25. Weil JV, McCullough RE, Kline JS, et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. *N Engl J Med* 1975; 292:1103-1106.
26. Bailey PL. The use of opioids in anesthesia is not especially associated with nor predictive of postoperative hypoxemia. *Anesthesiology* 1992;77:1235.
27. Tomicheck RC, Rosow CE, Philbin DM, et al. Diazepam-fentanyl interaction: hemodynamic and hormonal effects in coronary artery surgery. *Anesth Analg* 1983;62:881-884.

28. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. *J Pain Symptom Manage* 2002;24:71-90.

29. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. *Am J Ther* 2002;9:53-68.

30. Lee F, Cundiff D. Meperidine vs morphine in pancreatitis and cholecystitis. *Arch Intern Med* 1998;158:2399.

31. Krimmer H, Bullingham RE, Lloyd J, et al. Effects on biliary tract pressure in humans of intravenous ketorolac tromethamine compared with morphine and placebo. *Anesth Analg* 1992;75:204-207.

32. Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. *Drugs* 1997;53:139-188.

33. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. *Drugs* 1990;39:86-109.

34. Reinhart DI. Minimising the adverse effects of ketorolac. *Drug Safety* 2000; 22:487-497.

35. Ready LB, Brown CR, Stahlgren LH, et al. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain: a double-blind, placebo-controlled, multicenter study. *Anesthesiology* 1994;80: 1277-1286.

36. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. *JAMA* 1996;275:376-382.

Anxiety in the ICU

37. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). *JAMA* 2001;286:2703-2710.

38. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. *Crit Care Med* 1999; 27:2609-2615.

39. De Jonghe B, Cook D, Appere-De-Vecchi C, et al. Using and understanding sedation scoring systems: a systematic review. *Intensive Care Med* 2000;26: 275-285.

40. Ramsay MA, Savege TM, Simpson BR, et al. Controlled sedation with alphaxalone-alphadolone. *Br Med J* 1974;2:656-659.

41. Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. *Crit Care Med* 1999;27:1325-1329.

42. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003;289:2983-2991.

43. Fragen RJ. Pharmacokinetics and pharmacodynamics of midazolam given via continuous intravenous infusion in intensive care units. *Clin Ther* 1997; 19:405-419.

Sedative Agents

44. Reves JG, Fragen RJ, Vinik HR, et al. Midazolam: pharmacology and uses. *Anesthesiology* 1985;62:310–324.
45. Barr J, Zomorodi K, Bertaccini EJ, et al. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. *Anesthesiology* 2001;95:286–298.
46. Ariano RE, Kassum DA, Aronson KJ. Comparison of sedative recovery time after midazolam versus diazepam administration. *Crit Care Med* 1994;22: 1492–1496.
47. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clin Pharmacokinet* 2000;38:41–57.
48. Hoegholm A, Steptoe P, Fogh B, et al. Benzodiazepine antagonism by aminophylline. *Acta Anaesthesiol Scand* 1989;33:164–166.
49. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. *Crit Care Med* 1998;26: 947–956.
50. Gaudreault P, Guay J, Thivierge RL, et al. Benzodiazepine poisoning: clinical and pharmacological considerations and treatment. *Drug Safety* 1991;6:247–265.
51. Moss JH. Sedative and hypnotic withdrawal states in hospitalised patients. *Lancet* 1991;338:575.
52. Saito M, Terao Y, Fukusaki M, et al. Sequential use of midazolam and propofol for long-term sedation in postoperative mechanically ventilated patients. *Anesth Analg* 2003;96:834–838.
53. McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. *CNS Drugs* 2003;17:235–272.
54. Brown LA, Levin GM. Role of propofol in refractory status epilepticus. *Ann Pharmacother* 1998;32:1053–1059.
55. McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. *Crit Care Med* 2000;28:1781–1784.
56. Shafer SL. Shock values. *Anesthesiology* 2004;101:567–568.
57. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. *Pharmacotherapy* 2005;25:8S–18S.
58. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. *N Engl J Med* 1995;333:147–154.
59. Bray RJ. Propofol infusion syndrome in children. *Paediatr Anaesth* 1998;8: 491–499.
60. Kang TM. Propofol infusion syndrome in critically ill patients. *Ann Pharmacother* 2002;36:1453–1456.
61. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. *Drugs* 2000;59:263–268.

62. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. *Crit Care* 2000;4:302–308.

Haloperidol

63. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. *Crit Care Med* 1994;22:433–440.

64. Sanders KM, Minnema AM, Murray GB. Low incidence of extrapyramidal symptoms in the treatment of delirium with intravenous haloperidol and lorazepam in the intensive care unit. *J Intensive Care Med* 1989;4:201–204.

65. Sing RF, Branas CC, Marino PL. Neuroleptic malignant syndrome in the intensive care unit. *J Am Osteopath Assoc* 1993;93:615–618.

66. Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. *Am J Cardiol* 1998;81:238–240.

Interruption of Sedative Infusions

67. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000;342:1471–1477.

Chapter 50

Disorders of Mentation

References

Introduction

1. Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital length of stay. *Intensive Care Med* 2001;27:1892–1900.

2. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *JAMA* 2004;291: 1753–1762.

Reviews

3. Inouye SK. Delirium in older persons. *N Engl J Med* 2006;354:1157–1165.

4. Stevens RD, Bhardwaj A. Approach to the comatose patient. *Crit Care Med* 2006;34:31–41.

5. Wijdicks EFM. Brain death. Oxford: Oxford University Press, 2001.

6. Wijdicks EFM. Neurologic complications of critical illness. 2nd ed. New York: Oxford University Press, 2001.

7. Plum F, Posner JB. The diagnosis of stupor and coma. 3rd ed. Philadelphia: FA Davis, 1982.

Disorders of Consciousness

8. The Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state (Part 1). *N Engl J Med* 1994;330:1499–1508.

9. Leon-Carrion J, van Eeckhout P, Dominguez-Morales M del R. The locked-in syndrome: a syndrome looking for a therapy. *Brain Injury* 2002;16:555–569.

10. The Quality Standards Subcommittee of the American Academy of Neurology. Practice parameters for determining brain death in adults (summary statement). *Neurology* 1995;45:1012–1014.

11. Brown TM, Boyle MF. Delirium. *BMJ* 2002;325:644–647.

12. Papadopoulos MC, Davies DC, Moss RF, et al. Pathophysiology of septic encephalopathy: a review. *Crit Care Med* 2000;28:3019–3024.

13. Bleck TP, Smith MC, Pierre-Louis SJ, et al. Neurologic complications of critical medical illnesses. *Crit Care Med* 1993;21:98–103.

14. Sprung CL, Cerra FB, Freund HR, et al. Amino acid alterations and encephalopathy in the sepsis syndrome. *Crit Care Med* 1991;19:753–757.

15. Sari A, Yamashita S, Ohosita S, et al. Cerebrovascular reactivity to CO₂ in patients with hepatic or septic encephalopathy. *Resuscitation* 1990;19:125–134.

Delirium

16. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001;29:1370–1379.

17. Webster R, Holroyd S. Prevalence of psychotic symptoms in delirium. *Psychosomatics* 2000;41:519–522.

18. McGuire BE, Basten CJ, Ryan CJ, et al. Intensive care unit syndrome: a dangerous misnomer. *Arch Intern Med* 2000;160:906–909.

19. Inouye SK. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. *Am J Med* 1994;97:278–288.

20. Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: a systematic review. *J Am Geriatr Soc* 2002;50:1723–1732.

21. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. *N Engl J Med* 2003;348:1786–1795.

22. Hoffman RS. An effective strategy for managing cocaine-induced agitated delirium: which therapies improve survival? Which are counterproductive? *J Crit Illness* 1994;9:139–149.

Coma

23. Hamel MB, Goldman L, Teno J, et al. Identification of comatose patients at high risk for death or severe disability. *JAMA* 1995;273:1842–1848.

24. Bateman DE. Neurological assessment of coma. *J Neurol Neurosurg Psychiatry* 2001;71:i13–17.

25. Goetting MG, Contreras E. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils. *Ann Emerg Med* 1991;20: 55–57.

26. Ong GL, Bruning HA. Dilated fixed pupils due to administration of high doses of dopamine hydrochloride. *Crit Care Med* 1981;9:658–659.

27. Gray AT, Krejci ST, Larson MD. Neuromuscular blocking drugs do not alter the pupillary light reflex of anesthetized humans. *Arch Neurol* 1997;54:579–584.

28. Edgren E, Hedstrand U, Kelsey S, et al. Assessment of neurological prognosis in comatose survivors of cardiac arrest: BRCT I Study Group. *Lancet* 1994;343:1055–1059.

29. Zandbergen EG, de Haan RJ, Koelman JH, et al. Prediction of poor outcome in anoxic-ischemic coma. *J Clin Neurophysiol* 2000;17:498–501.

30. Kunze K. Metabolic encephalopathies. *J Neurol* 2002;249:1150–1159.
31. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. *Lancet* 1974;2:81–84.
32. Teasdale G, Jennett B. Assessment and prognosis of coma after head injury. *Acta Neurochir (Wien)* 1976;34:45–55.
33. Sacco RL, VanGool R, Mohr JP, et al. Nontraumatic coma: Glasgow coma score and coma etiology as predictors of 2-week outcome. *Arch Neurol* 1990; 47:1181–1184.
34. Sternbach GL. The Glasgow coma scale. *J Emerg Med* 2000;19:67–71.
35. Booth CM, Boone RH, Tomlinson G, et al. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. *JAMA* 2004;291:870–879.
- Brain Death**
36. Smith AJ, Walker AE. Cerebral blood flow and brain metabolism as indicators of cerebral death: a review. *Johns Hopkins Med J* 1973;133:107–119.
37. Wijdicks EF. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. *Neurology* 2002;58:20–25.
38. Dominguez-Roldan JM, Barrera-Chacon JM, Murillo-Cabezas F, et al. Clinical factors influencing the increment of blood carbon dioxide during the apnea test for the diagnosis of brain death. *Transplant Proc* 1999;31:2599–2600.
39. Goudreau JL, Wijdicks EF, Emery SF. Complications during apnea testing in the determination of brain death: predisposing factors. *Neurology* 2000; 55:1045–1048.
40. Ropper AH. Unusual spontaneous movements in brain-dead patients. *Neurology* 1984;34:1089–1092.
41. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. *N Engl J Med* 2004;351:2730–2739.
42. Pennefather SH, Bullock RE, Mantle D, et al. Use of low dose arginine vasopressin to support brain-dead organ donors. *Transplantation* 1995;59:58–62.
43. Detterbeck FC, Mill MR. Organ donation and the management of the multiple organ donor. *Contemp Surg* 1993;42:281–285.
44. Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. *Lancet* 1998;352: 1178–1181.
45. Powner DJ, Hendrich A, Lagler RG, et al. Hormonal changes in brain dead patients. *Crit Care Med* 1990;18:702–708.
46. Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? *Transplantation* 1992;54:851–857.
47. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. *Transplantation* 2003;75:1336–1341.
48. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. *Transplantation* 2003;75:482–487.
49. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. *Palliative Med* 2002;16:297–303.

Chapter 51

Disorders of Movement

References

Seizures

1. Bleck TP, Smith MC, Pierre-Louis SJ, et al. Neurologic complications of critical medical illnesses. *Crit Care Med* 1993;21:98-103.

2. Wijdicks EF, Sharbrough FW. New-onset seizures in critically ill patients. *Neurology* 1993;43:1042-1044.

3. Varelas PN, Mirski MA. Seizures in the adult intensive care unit. *J Neurosurg Anesthesiol* 2001;13:163-175.

4. Delanty N, Vaughan CJ, French JA. Medical causes of seizures. *Lancet* 1998;352:383-390.

5. Chabolla DR. Characteristics of the epilepsies. *Mayo Clin Proc* 2002;77:981-990.

Status Epilepticus

6. Marik PE, Varon J. The management of status epilepticus. *Chest* 2004;126:582-591.

7. Manno EM. New management strategies in the treatment of status epilepticus. *Mayo Clin Proc* 2003;78:508-518.

Chapter 52

Stroke and Related Disorders

References

Reviews

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics: 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2006;113:85-151.

2. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. *N Engl J Med* 2000;343:710-722.

3. Warlow C, Sudlow C, Dennis M, et al. Stroke. *Lancet* 2003;362:1211-1224.

4. Goldstein LB, Simel DL. Is this patient having a stroke? *JAMA* 2005;293:2391-2402.

5. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke* 1990;21:637-676.

Guidelines

6. Adams HP, Jr., Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. *Stroke* 2003;34:1056-1083.

7. Adams H, Adams R, Del Zoppo G, et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. *Stroke* 2005;36:916-923.

8. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006;37:577-617.

9. Culebras A, Kase CS, Masdeu JC, et al. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke: a report of the Stroke Council, American Heart Association. *Stroke* 1997;28:1480-1497.
10. Kizer JR, Devereux RB. Clinical practice: patent foramen ovale in young adults with unexplained stroke. *N Engl J Med* 2005;353:2361-2372.
11. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1999;30:905-915.
12. Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1994;25:2315-2328.
13. Bederson JB, Awad IA, Wiebers DO, et al. Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke* 2000;31:2742-2750.
14. Albers GW, Hart RG, Lutsep HL, et al. AHA Scientific Statement: supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. *Stroke* 1999;30:2502-2511.
15. Ovbiagele B, Kidwell CS, Saver JL. Epidemiological impact in the United States of a tissue-based definition of transient ischemic attack. *Stroke* 2003; 34:919-924.
- Evaluation
16. Saver JL. Time is brain-quantified. *Stroke* 2006;37:263-266.
17. Hand PJ, Kwan J, Lindley RI, et al. Distinguishing between stroke and mimic at the bedside: the brain attack study. *Stroke* 2006;37:769-775.
18. Goldstein LB, Matchar DB. The rational clinical examination: clinical assessment of stroke. *JAMA* 1994;271:1114-1120.
19. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Circulation* 1994;90:1588-1601.
20. Bamford J. Clinical examination in diagnosis and subclassification of stroke. *Lancet* 1992;339:400-402.
21. Atchison JW, Pellegrino M, Herbers P, et al. Hepatic encephalopathy mimicking stroke: a case report. *Am J Phys Med Rehabil* 1992;71:114-118.
22. Palmer CA. Neurologic manifestations of renal disease. *Neurol Clin* 2002;20: 23-34.
23. Maher J, Young GB. Septic encephalopathy. *Intensive Care Med* 1993;8:177-187.
24. Georgilis K, Plomaritoglou A, Dafni U, et al. Aetiology of fever in patients with acute stroke. *J Intern Med* 1999;246:203-209.
25. Boysen G, Christensen H. Stroke severity determines body temperature in acute stroke. *Stroke* 2001;32:413-417.
26. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. *Lancet* 1996; 347:422-425.

27. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. *Stroke* 2000;31:410-414.
28. Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. *Arch Neurol* 2000;57:1617-1622.
29. Graves VB, Partington VB. Imaging evaluation of acute neurologic disease. In: Goodman LR Putman CE, eds. *Critical care imaging*. 3rd ed. Philadelphia: WB Saunders, 1993:391-409.
- Thrombolytic Therapy
30. Gerber TC, Fasseas P, Lennon RJ, et al. Clinical safety of magnetic resonance imaging early after coronary artery stent placement. *J Am Coll Cardiol* 2003; 42:1295-1298.
31. NINDS. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med* 1995;333:1581-1587.
32. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year: National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. *N Engl J Med* 1999;340:1781-1787.
33. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke* 2005;36:1232-1240.
34. Caplan LR. Thrombolysis 2004: the good, the bad, and the ugly. *Rev Neurol Dis* 2004;1:16-26.
- Antithrombotic Therapy
35. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. *Lancet* 1997;349:1641-1649.
36. The International Stroke Trial (IST). A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. *Lancet* 1997;349: 1569-1581.
- Medical Management
37. Rothrock JF, Hart RG. Antithrombotic therapy in cerebrovascular disease. *Ann Intern Med* 1991;115:885-895.
38. Mistri AK, Robinson TG, Potter JF. Pressor therapy in acute ischemic stroke: systematic review. *Stroke* 2006;37:1565-1571.
39. Semplicini A, Maresca A, Boscolo G, et al. Hypertension in acute ischemic stroke: a compensatory mechanism or an additional damaging factor? *Arch Intern Med* 2003;163:211-216.
40. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. *Neurology* 2002;59:669-674.
41. Bruno A, Williams LS, Kent TA. How important is hyperglycemia during acute brain infarction? *Neurologist* 2004;10:195-200.
- Subarachnoid Hemorrhage
42. Dippel DW, van Breda EJ, van Gemert HM, et al. Effect of paracetamol (acetaminophen) on body temperature in acute ischemic stroke: a double-blind, randomized phase II clinical trial. *Stroke* 2001;32:1607-1612.
43. Schievink WI. Intracranial aneurysms. *N Engl J Med* 1997;336:28-40.
44. Suarez JL, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. *N Engl J Med* 2006;354:387-396.
45. Naval NS, Stevens RD, Mirski MA, et al. Controversies in the management of aneurysmal subarachnoid hemorrhage. *Crit Care Med* 2006;34:511-524.

46. Wijdicks EF, Kallmes DF, Manno EM, et al. Subarachnoid hemorrhage: neurointensive care and aneurysm repair. *Mayo Clin Proc* 2005;80:550-559.
47. Dinger MN, Zazulia AR. Hyponatremia in neurologic patients: consequences and approaches to treatment. *Neurologist* 2006;12:117-126.
48. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. *Crit Care Med* 2006;34: 617-623.
49. Deibert E, Barzilai B, Braverman AC, et al. Clinical significance of elevated troponin I levels in patients with nontraumatic subarachnoid hemorrhage. *J Neurosurg* 2003;98:741-746.
50. Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. *Lancet* 2002;360:1267-1274.
51. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. *N Engl J Med* 1983;308:619-624.
52. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: results of a multicenter double-blind placebo-controlled trial. *J Neurosurg* 1988;68:505-517.
53. Barker FG 2nd, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a meta-analysis. *J Neurosurg* 1996;84:405-414.

Chapter 53

Pharmaceutical Toxins & Antidotes

References

Introduction

1. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. *Pharmacotherapy* 2006;26:601-608.
2. Trunet P, Borda IT, Rouget AV, et al. The role of drug-induced illness in admissions to an intensive care unit. *Intensive Care Med* 1986;12:43-46.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; 279:1200-1205.
4. Dasta JF. Drug prescribing issues in the intensive care unit: finding answers to common questions. *Crit Care Med* 1994;22:909-912.

Acetaminophen

5. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. *Am J Emerg Med* 2005;23:589-666.
6. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *Hepatology (Baltimore)* 2005;42:1364-1372.
7. Schiody FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. *N Engl J Med* 1997;337:1112-1117.
8. Hendrickson RG, Bizovi KE. Acetaminophen. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006:523-543.

9. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. *J Toxicol Clin Toxicol* 2002;40:3-20.

10. Anker AL, Smilkstein MJ. Acetaminophen: concepts and controversies. *Emerg Med Clin North Am* 1994;12:335-349.

N-acetylcysteine

11. Rumack BH, Peterson RC, Koch GG, et al. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. *Arch Intern Med* 1981; 141:380-385.

12. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. *Clin Pharmacokinet* 1991;20:123-134.

13. Cumberland Pharmaceuticals. Acetadote Package Insert. 2006.

14. Janes J, Routledge PA. Recent developments in the management of paracetamol (acetaminophen) poisoning. *Drug Saf* 1992;7:170-177.

15. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985). *N Engl J Med* 1988;319:1557-1562.

16. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. *Lancet* 1990;335:1572-1573.

17. Howland MA. N-Acetylcysteine. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006: 544-549.

18. Buckley NA, Whyte IM, O'Connell DL, et al. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? *J Toxicol Clin Toxicol* 1999;37:759-767.

19. Sunman W, Hughes AD, Sever PS. Anaphylactoid response to intravenous acetylcysteine. *Lancet* 1992;339:1231-1232.

20. Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. *Emerg Med J* 2002;19:594-595.

21. Miller LF, Rumack BH. Clinical safety of high oral doses of acetylcysteine. *Semin Oncol* 1983;10:76-85.

22. Spiller HA, Krenzelok EP, Grande GA, et al. A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose. *Ann Emerg Med* 1994;23:519-523.

Benzodiazepines

23. Lee DC. Sedative-hypnotics. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006:1098-1111.

24. Dasta JF, Fuhrman TM, McCandles C. Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit. *Crit Care Med* 1994;22:974-980.

Flumazenil

25. Roche Laboratories. Romazicon (flumazenil) package insert. 2004.

26. Howland MA. Flumazenil. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006:1112-1117.

27. Gross JB, Weller RS, Conard P. Flumazenil antagonism of midazolam-induced ventilatory depression. *Anesthesiology* 1991;75:179-185.

28. Shalansky SJ, Naumann TL, Englander FA. Effect of flumazenil on benzodiazepine-induced respiratory depression. *Clin Pharmacol* 1993;12:483-487.

29. Grimm G, Ferenci P, Katzenschlager R, et al. Improvement of hepatic encephalopathy treated with flumazenil. *Lancet* 1988;2:1392-1394.

30. Martens F, Koppel C, Ibe K, et al. Clinical experience with the benzodiazepine antagonist flumazenil in suspected benzodiazepine or ethanol poisoning. *J Toxicol Clin Toxicol* 1990;28:341-356.

31. Bodenham A, Park GR. Reversal of prolonged sedation using flumazenil in critically ill patients. *Anaesthesia* 1989;44:603-605.

32. Doyon S, Roberts JR. Reappraisal of the "coma cocktail": dextrose, flumazenil, naloxone, and thiamine. *Emerg Med Clin North Am* 1994;12:301-316.

33. Chern TL, Hu SC, Lee CH, et al. Diagnostic and therapeutic utility of flumazenil in comatose patients with drug overdose. *Am J Emerg Med* 1993;11: 122-124.

34. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. *Ann Pharmacother* 1994;28:1347-1349.

35. Pepperman ML. Double-blind study of the reversal of midazolam-induced sedation in the intensive care unit with flumazenil (Ro 15-1788): effect on weaning from ventilation. *Anaesth Intensive Care* 1990;18:38-44.

β -Receptor Antagonists

36. Newton CR, Delgado JH, Gomez HF. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. *Semin Respir Crit Care Med* 2002;23:19-25.

37. Kerns W, 2nd, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. *Emerg Med Clin North Am* 1994;12:365-390.

38. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. *Ann Emerg Med* 1984;13:1123-1131.

39. Henry JA, Cassidy SL. Membrane stabilising activity: a major cause of fatal poisoning. *Lancet* 1986;1:1414-1417.

40. Lane AS, Woodward AC, Goldman MR. Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump. *Ann Emerg Med* 1987;16:1381-1383.

41. Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. *J Toxicol Clin Toxicol* 1996;34:273-278.

42. Brubacher J. β -Adrenergic antagonists. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006: 924-941.

43. Howland MA. Glucagon. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al., eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006:942-945.

44. Chernow B, Zaloga GP, Malcolm D, et al. Glucagon's chronotropic action is calcium dependent. *J Pharmacol Exp Ther* 1987;241:833-837.

Calcium Antagonists

45. DeRoos F. Calcium Channel Blockers. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al. eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006: 911-923.

46. Lucchesi BR. Role of calcium on excitation-contraction coupling in cardiac and vascular smooth muscle. *Circulation* 1989;80:IV1-IV13.

47. Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. *Ann Emerg Med* 1993;22: 196-200.

48. Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. *Ann Emerg Med* 1990;19:649-653.

49. Jameson SJ, Hargarten SW. Calcium pretreatment to prevent verapamil-induced hypotension in patients with SVT. *Ann Emerg Med* 1992;21:68.

Opioids

50. Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. *Hum Exp Toxicol* 1994;13:161-166.
51. Evans RS, Pestotnik SL, Classen DC, et al. Preventing adverse drug events in hospitalized patients. *Ann Pharmacother* 1994;28:523-527.
52. Handal KA, Schauben JL, Salamone FR, et al. *Ann Emerg Med* 1983;12:438-445.
53. Howland MA. Opioid antagonists. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al. eds. *Goldfrank's toxicologic emergencies*. 8th ed. New York: McGraw-Hill, 2006:614-619.
54. Naloxone hydrochloride. In: McEvoy GK, Litvak K, eds. *AHFS Drug Information*. Bethesda, MD: American Society of Hospital Systems Pharmacists, 1995:1418-1420.
55. Tandberg D, Abercrombie D. Treatment of heroin overdose with endotracheal naloxone. *Ann Emerg Med* 1982;11:443-445.

56. Maio RF, Gaukel B, Freeman B. Intralingual naloxone injection for narcotic-induced respiratory depression. *Ann Emerg Med* 1987;16:572-573.

57. Salvucci AA Jr, Eckstein M, Iscovich AL. Submental injection of naloxone. *Ann Emerg Med* 1995;25:719-720.

58. Goldfrank L, Weisman RS, Errick JK, et al. A dosing nomogram for continuous infusion intravenous naloxone. *Ann Emerg Med* 1986;15:566-570.

59. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. *Ann Emerg Med* 1991;20:246-252.